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Olfactory ensheathing cells (OECs) are glial cells that are an attractive candidate 
for neural repair after spinal cord injury and for remyelination of axons in diseases such 
as multiple sclerosis. OECs appear to migrate within the adult mammalian central 
nervous system (CNS) in animal models of spinal cord injury, but until recently there 
has been no systematic examination of the factors inducing or guiding this migration. 
Previous work in our lab (V.Skihar) implicated microglial reactivity in the generation of 
a migratory signal(s) inducing OECs to migrate towards an ethidium bromide-induced 
focal demyelination in the adult rat spinal cord. The long-term objective of this research 
project was to test the hypothesis that reactive microglial provide a migratory signal(s) 
driving the migration of OECs within the spinal cord of adult rats. 
The first set of experiments determined the time-frame in which Wallerian 
degeneration (WD) induced microglial reactivity occurs in the right dorsal corticospinal 
tract (dCST) of adult rats at the level of T11 following aspiration of the contralateral 
sensorimotor cortex. This timing data from this study demonstrated a prominent 
microglial activation in the right dCST of T11 eight weeks after sensorimotor cortex 
injury indicating the microglial response to WD of dCST axons was very slow to appear. 
The second set of experiments determined whether OECs were induced to migrate in 
response to WD-induced microglial reactivity in the dCST, which based on the first set 
of experiments was known to occur within 8 weeks of lesioning the left sensorimotor 
cortex. This second set of experiments also examined the migratory path taken by OECs 
with respect to the location of reactive microglia (i.e. inside vs outside the right dCST). 
For these experiments, the left sensorimotor cortex was damaged 8 weeks prior to 
grafting the OECs at T12.  
The next group of experiments examined the contribution of TNF-α induced 
microglial reactivity to generation of a migratory signal.  First we identified 
concentrations of TNF-α that when injected into the DF of the T11 spinal cord segment 
of an adult rat induced microglial reactivity either along at least a 5 mm distance from 
the injection site or confined to the immediate vicinity of the injection site. The result of 
this experiment identified a concentration of 1 ng/µl and 0.01 ng/µl TNF-α as 
appropriate concentrations to induce the appropriate amount of microglial reactivity, 
 iii 
respectively. The final set of experiments used these two concentrations to determine 
whether TNF-α induced microglial reactivity that is initiated 5 mm rostral to a DiI+ve 
OEC graft generates a migratory signal(s) inducing OECs to migrate towards the rostral 
part of T11 and whether the migratory signal(s) was present only if the microglial 
reactivity extended the full 5 mm distance between the TNF-α injection and the OEC 
graft.  
The major findings were: i) there was a significantly higher density of DiI+ve 
OECs within the right dCST of rats in which there was WD-induced microglial 
reactivity as compared to the right dCST of rats in which there was no microglial 
reactivity; ii) the migratory path taken by DiI+ve OECs was preferentially within areas 
containing reactive microglia (i.e. dCST) and towards the site of TNF-α induced 
microglial reactivity (i.e. rostral to cell graft as opposed to caudal); iii) significantly 
more DiI+ve OECs migrated towards the site of a TNF-α injection when the microglia 
were reactive along the entire length of the migratory path between the cytokine 
injection and cell graft; and iv) minocycline treatment both dampened microglial 
reactivity and significantly reduced the number of migrating DiI+ve OECs. The major 
conclusions are that the migration of OECs within the adult rat spinal cord occurs in 
response to migratory signal(s) arising as a result of microglial activation and that this 
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CHAPTER 1.0      INTRODUCTION  
1.1  Primary Olfactory System  
The primary olfactory pathway consists of olfactory receptor neurons in the nasal 
cavity whose unmyelinated axons project through the cribriform plate into the central 
nervous system (CNS) to synapse with mitral and tufted cells in the olfactory bulb (OB) 
(Barber and Lindsay, 1982). The olfactory receptor neurons have the ability to regenerate 
throughout life both in response to injury and as part of normal turnover (Calof and 
Chikaraiashi, 1989; Graziadei and Monti Graziadei, 1980; Tennent and Chuah, 1996). 
The growing axons of new olfactory receptor neurons form synaptic contacts with 
neurons of the olfactory bulb, with this regenerative cycle repeating itself every  30 to 60 
days in rodents (reviewed in Farbman, 1990). This extraordinary ability of the olfactory 
receptor neurons to be regenerated in adult mammals has attracted the interest of many 
scientists interested in investigating the underlying mechanisms.  In particular, attention 
has been directed towards the possible role of olfactory ensheathing cells (OECs), which 
are the glial cells that ensheath the olfactory axons (Doucette, 1983) and that may 
promote olfactory axonal elongation towards the OB (Tennet and Chuah, 1996).  
 
1.2 Olfactory Ensheathing Cells (OECs) 
Along the primary olfactory pathway, OECs are nonmyelinating glial cells that 
provide ensheathment for the small (0.1-0.5 µm in diameter in mammals) olfactory axons 
along their entire length, grouping them into fascicles of variable size in both the lamina 
propria and the olfactory nerve fiber layer (ONL) of the OB (Doucette et al., 1983; 1984). 
During embryonic development, OECs are thought to migrate ahead of the growing 
axons and are thought to guide and support this axonal growth both in the peripheral 
nervous system (PNS) and CNS portions of the primary olfactory pathway (Calof and 
Chikaraiashi, 1989; Doucette, 1983; Graziadei and Monti Graziadei, 1980; Tennet and 
Chuah, 1996).   
In addition to the growth promoting properties that OECs appear to possess, an 
exceptional characteristic feature of the OEC is its highly malleable phenotype (Gong et 
al., 1994). OECs express a mixture of astrocyte-specific and Schwann cell-specific 
phenotypic features (Barber and Lindsay, 1982; Doucette 1984, 1990; Gong et al., 1994) 
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and perform the role of both astrocytes and Schwann cells (Doucette, 1990, 1993a; 
Doucette and Devon, 1993). In spite of these similarities OECs are referred to as a new 
class of glial cells (Barnett et al., 1993; Doucette and Devon, 1993). In recent years, in 
vivo (Lakatos et al., 2003) and in vitro (Lakatos et al., 2000) studies demonstrated clear 
differences between Schwann cells and OECs in terms of cellular interaction with 
astrocytes, thus reinforcing the notion of OECs as a distinct class of glia. Lakatos and 
coworkers (2003) showed that Schwann cell transplantation resulted in a greater area of 
increased glial fibrillary acidic protein (GFAP) expression compared to that associated 
with OEC transplantation in rat spinal cord. This was accompanied by a greater increase 
in the expression of axon growth inhibitory chrondroitin sulfate proteoglycans (CSPGs) 
following Schwann cell transplantation compared to OEC transplantation. In fact 
transplanted cells can exert an effect on the host tissue that will influence the extent to 
which regenerating axons can grow beyond the transplanted area and reenter the host 
environment.  
Similar to Schwann cells in peripheral nerves; olfactory fascicles in the PNS are 
enclosed within a basal lamina that separates OECs from the surrounding connective 
tissue. However, in the OB OECs are only apposed to a basal lamina where they 
contribute to the formation of the glia limitans. Compared to other PNS-CNS transitional 
zones, the plasma membranes of ensheathing cells and astrocytes are not separated by a 
basal lamina (Barber and Lindsay, 1982; Doucette, 1991), because the OECs assist in 
forming the glia limitans, which elsewhere in the CNS is formed exclusively by 
astrocytes. OECs also form end-feet at blood vessels in a manner comparable to 
astrocytes (Doucette, 1984, 1990, 1991). The comparison is based exclusively on 
morphology and it is not clear whether OECs are functioning the same as astrocytes.  
OECs are located within the lamina propria of the olfactory mucosa and in the 
first two layers of the OB (Doucette, 1993). It is well known that the olfactory epithelium 
originates from the olfactory placodes, which appear in the rostrolateral region of the 
embryonic head (Costanzo and Graziadei, 1983; Farbman and Squinto, 1985; Valverde et 
al., 1992).  However, the OB originates from the rostral end of the cerebral vesicle 
(Doucette, 1989).  Thus, OECs reside within two sets of tissues that arise in the embryo 
from components of the PNS and CNS, respectively, even though they are most likely 
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derived during embryonic development from the peripheral structure, namely the 
olfactory placode (Doucette, 1993b) OECs do not express the antigenic epitope 
recognized by the A4 monoclonal antibody (Miller et al., 1984), which immunostains all 
cells of neural tube origin.  
 
1.2.1  Phenotype of OECs 
  OECs display several very distinct phenotypic features that are dependent on their 
immediate environment. These cells normally possess a mixture of astrocyte- and 
Schwann cell-specific phenotypic features in vivo (see Section 1.2).  OECs can be 
distinguished from other cells migrating away from the olfactory placodes by their dark 
appearance, mode of association with axons, and their ultrastructural features (Doucette, 
1989; Valverde and Lopez-Mascaraque, 1991). OECs contain a lobulated electron dense 
nucleus with irregular chromatin under the nuclear envelope and one or two nucleoli 
(Valverde et al., 1992).  
There are several phenotypic markers known to be expressed by OECs. It was 
shown that OECs can be immunostained with antibodies to platelet-derived growth factor 
(PDGF) (Kott et al., 1994), neuropeptide Y (Ubink et al., 1994), and also with protein 
S100 (Gong et al., 1994), which is associated with growth and survival of cells in other 
systems (Van Eldik et al., 1991). In addition, OECs express low affinity nerve growth 
factor receptor (p75) (Barnett and Hutchins, 1993; Gong et al., 1994; Miwa et al., 1993; 
Turner and Perez-Polo, 1993, 1994; Vickland et al., 1991). Several studies showed that 
axotomy up-regulates the expression of p75 by OECs in the adult olfactory nerve (Gong 
et al., 1994; Miwa et al., 1993; Turner and Perez-Polo, 1993, 1994). 
OECs also express membrane-associated molecules known to be involved in cell 
adhesion and axonal growth (Kleitmsn et al., 1988), such as L1 ( Miragall et al., 1988), 
laminin (Doucette, 1996; Kafitz and Greer, 1997) and polysialic acid containing molecule 
(PSA-N-CAM) and adult forms of the neural cell adhesion molecule (N-CAM) ( Miragall 
et al., 1988). L1, laminin and PSA-N-CAM are all expressed by OECs throughout 
development (Miragall et al., 1988). The O4 monoclonal antibody, which recognizes an 
antigenic epitope expressed on the surface of progenitor cells in the oligodendrocyte type 
2 - astrocyte (O-2A) lineage as well as Schwann cells, also recognizes an epitope on the 
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surface of OECs at all development stages (Barnett and Hutchins, 1993; Franceschini and 
Barnett, 1996). However, OECs are HNK-1-ve and galactocerbroside-ve (Gal-C-ve), 
which are two markers expressed by oligodendrocytes (Jessen and Mirsky, 1991; 
McGary et al., 1983). In spite of OECs expressing cytoplasmic and membrane associated 
molecules in common with other known glial cell populations, the antigenic phenotype of 
OECs does not completely match any of these other glial cell types. Recent proteomic 
studies have revealed that OECs, but not Schwann cells, express calponin (Boyd et al., 
2005) and smooth muscle alpha actin (SMA) (Jahed et al., 2007), thus demonstrating that 
these cells have a phenotype that is distinct from Schwann cells.  
The first evidence of the myelinating capacity of OECs was demonstrated by 
Devon and Doucette (1992). They showed, at the light and electron microscopic level, 
that embryonic OECs co-cultured with dorsal root ganglion (DRG) neurons associated 
with both myelinated and unmyelinated axons in a manner virtually identical to the 
ensheathment normally provided by Schwann cells of the PNS. The authors explicitly 
stated that the myelinating cells are not contaminating Schwann cells since the negative 
controls were pure neuronal cultures that contained no glial cells and showed no 
ultrastructural evidence of myelination. In addition, it was observed that OECs expressed 
certain myelin-associated proteins under various culture conditions. O4+ve OECs isolated 
from neonatal rat OB were found to only weakly express the peripheral myelin protein P0 
and Gal-C (Barnett et al., 1993). Noncompact myelin protein 2',3'-cyclic nucleotide 3'-
phosphodiesterase (CNPase) was also reported to be weakly expressed by bipolar and/or 
multipolar OECs obtained from the adult OB (Santos-Silva and Cavalcante, 2001). 
However, Pixley (1996) failed to detect the CNPase in bipolar cells in explant cultures 
from neonatal OBs. A similar controversy exists over the expression of myelin basic 
protein (MBP) by OECs. In neuron-free cultures, neither unpurified embryonic OECs 
(Devon and Doucette, 1995) nor purified neonatal OECs (Barnett et al., 1993) expressed 
MBP in vitro even after intracellular up-regulation of cyclic adenosine monophosphate 
(cAMP), a strong stimulus for induction of MBP synthesis by Schwann cells (Devon and 
Doucette, 1995). In contrast, OECs isolated from the adult rat OB and purified on the 
basis of their expression of the p75 neurotrophin receptor (p75) displayed robust MBP 
immunoreactivity (Ramon-Cueto and Nieto- Sampedro, 1992).  
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1.2.2  Protocols for generating OEC cell cultures 
Within the past decade, numerous studies have supported the idea that OECs are 
effective in promoting neural repair in several different animal models of CNS injury 
(Boyd et al., 2004; Chuah et al., 2004). The main aim of these experiments was to 
facilitate and support axonal growth across the lesion and into the tissue on the distal side 
through manipulation of the cellular environment of the lesion site in the brain or spinal 
cord.  The OECs used in these cell grafting experiments were obtained from cell cultures 
set up using tissue from either the OB or lamina propria (LP); i.e. from either the CNS 
(Boyd et al., 2004, Chuah et al., 2004) or PNS (Au and Roskam., 2003) component of the 
primary olfactory pathway.  
The two main tissue sources that have been used to initiate cell cultures of OECs 
are the PNS (i.e. lamina propria) and CNS (i.e. nerve fiber layer of OB) portions of the 
primary olfactory pathway. Since at day 18 of embryonic development all of the glial 
cells in the ONL of the rat OB are OECs (Doucette, 1989) no further purification steps 
are required when using this tissue for setting up OEC cultures, which is the main  benefit 
of using embryonic tissue. However, the cell cultures obtained from the ONL of newborn 
and adult animals are usually contaminated with other cells (oligodendrocytes, astrocytes, 
and possibly even leptomeningeal Schwann cells); thus, further techniques such as 
immunopanning protocols using antibodies to p75 (Ramon-Cueto and Nieto-Sampedro, 
1994; Takami et al., 2002) or using a cell sorter to choose O4+ve/Gal-C-ve cells (Pascual 
et al., 2002) are required to enrich the cell cultures for OECs. Barnett et al. (1993) used 
the O4 monoclonal antibody as a marker to recognize OECs since it was obsereved OECs 
in vivo in the OB are O4+ve. However, the O4 monoclonal antibody also immunostains 
Schwann cells, oligodendrocytes, and O-2A progenitors.  
Establishing an OEC line is also another way to acquire OECs for transplantation. 
Goodman et al. (1993) successfully generated a p75 NGFR+ve OEC clonal cell line from 
Sprague-Dawley rat pups using the SV40 large T antigen. An advantage of engineering 
cell lines is to prevent cell contamination and provide a long constant supply of a purified 
cell population. However, more research needs to be done before any clinical approach is 
used to ensure the safety of the cell lines from developing tumors or from causing any 
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other disorders as a result of uncontrolled cellular growth after grafting. A majority of 
studies have used unpurified cell cultures of OECs. Mixtures of OECs with other cells, 
(i.e. meningeal cells) were used by Li et al., (1997, 1998) and Lakatos et al (2003) in their 
experiments. Recently, researchers used additional growth factors (i.e. bovine pituitary 
extract) in order to increase the number of OECs in cell cultures and/or after OEC 
transplantation (Chuan and Teague, 1999). In the absence of specific markers for OECs, 
these cells need to be prelabelled before grafting. There are several cell labeling 
techniques that have been used to prelabel OECs. Hoechst  dye, a nuclear fluorochrome 
bisbenzimide (Imaizumi et al., 2000; Lu et al., 2002 ; Ramon-Cueto et al., 1998, 2000), 
DiI (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate), which is 
another fluorescent dye (Basiri and Doucette, 2007), and Cell-Tracker probes (Li et al., 
1997) have all been used to label OECs before transplantation in different animal models. 
The disadvantage of using a fluorescent labeling dye might be its leakage to surrounding 
cells. Although there is no evidence of these dyes being transferred directly to 
surrounding cells, there is a possibility of phagocytosis of dying OECs at the implantation 
site by microglia, macrophages or astrocytes. Thus, false positives have been reported 
when Hoechst dye was used to prelabel OECs prior to transplantation (Ruitenberg et al., 
2002), which may lead to overestimation of the survival and migration of Hoechst-
prelabelled transplanted cells. 
Molecular biological techniques for labeling OECs include adenoviral-mediated 
(Ruitenberg et al., 2002, 2003) or retroviral-mediated (Boyd et al., 2004; Lakatos et al., 
2003) expression of LacZ or of the use of adenoviral vectors to induce expression of 
green fluorescent protein (GFP) (Li et al., 2003). These techniques have demonstrated at 
both the light and electron microscopic levels that implanted OECs can survive after 
grafting into a CNS lesion (Boyd et al., 2004, Lakatos et al., 2003; Li et al., 2003; 
Ruitenberg et al., 2002, 2003). The use of LacZ transfected OECs has provided 
information on the characterization of the interaction of these cells with their host 
environment at both the light and electron microscopic level. Boyd et al. (2004) 
demonstrated that the LacZ-expressing OECs had no direct contact with CNS axons that 
regenerated into a cystic cavity following spinal cord contusion and thus did not form 
myelin sheaths, but axon remyelination was a prominent feature due to the invasion of 
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the lesion by Schwann cells (Boyd et al., 2004). A proteomic comparison of OECs and 
Schwann cells by Boyd et al. (2005) revealed that OECs but not Schwann cells expressed 
calponin. A more recent study demonstrated the expression of smooth muscle actin 
(SMA) by OECs (Jahad et al., 2007). These two biomarkers will be most helpful in 
clarifying the fate of OECs following spinal cord implantation. Intracellular and cell 
surface receptor molecules expressed by OECs are summarized in Table 1.1. 
 
1.2.3 Therapeutic potential of OECs for neural repair 
The ultimate goal of grafting OECs into areas of CNS injury is to develop a 
therapeutic protocol that can be used to restore functional ability to patients with 
neurological injury. The first test of the therapeutic potential of OEC transplants in an 
animal model of neural injury was reported by Ramon-Cueto and Nieto-Sampedro 
(1994). In their experiment, the grafted OECs, which were obtained from the ONL of 
adult rats, promoted the regeneration of transected dorsal root axons. The grafted OECs 
accompanied the axons as they grew past the glial scar and into the dorsal horn.  Li et al. 
(1997, 1998)  showed that OEC transplants could promote the regeneration of spinal cord 
axons and restore behavior, and others have similarly observed improvement in 
coordinated locomotion, weight-bearing, touch, and proprioceptive functions following 
this treatment (Ramon-Cueto et al., 2000). Lu et al. (2002) also reported that OECs 
promoted axonal regeneration after delayed transplantation of up to four weeks after SCI.  
In addition to supporting axonal regeneration, OECs may be able to remyelinate spinal 
cord axons (Franklin et al., 1996b), thereby restoring action potential conduction 
(Imaizumi et al., 1998), although whether this occurs after grafting has been questioned 
(Boyd et al., 2004). In another CNS injury model, the cholinergic fibers of the 
fimbria/fornix pathway were destroyed by aspiration and then an OEC-containing 
collagen gel was placed into the cavity formed by the lesion. The data demonstrated that 
OECs promoted cholinergic fiber ingrowth into the lesion (Smale et al., 1996).  Li et al. 
(1997, 1998) and Nash et al. (2002) lesioned the corticospinal tract in adult rats and 
showed that OEC grafts promoted the growth of corticospinal fibers.  Ramon-Cueto et al. 
(1998) removed an entire spinal cord segment before grafting OECs into the proximal  
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Table 1.1    Molecules Expressed by OEC 
 
Antigen In vitro In vivo References 
S100 + OB, ON Astic et al., (1998); Franceschini  and 
Barnett(1996); Baber andLindsay  
(1982); Gong  et al., (1994) 
GFAP + OB, ON Astic et al., (1998);Franceschini and 
Barnett (1996); Barber and Lindsay  
(1982) 
 
P75 + OB, ON Barnett et al., 2000; Nash et al., (2002) 
 Ramon-Cueto et al (1998, 2000) 
 
O4 + OB, ON Barnett et al., (1993); Franceschini  
and Barnett (1996) 
Neuropeptide Y n.d OB, ON Ubink et al., (1994) 
Nestin + n.d Ubink et al., 1994;  
Sonigra et al., (1999) 
Calponin + OB,  ON Boyd et al., 2006 
SMA  + OB, ON Jahed et al., 2007 
 
n.d= not determined; OB= Olfactory bulb; ON= olfactory nerve 
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and distal stumps of the transected cord and demonstrated significant long-distance 
regrowth of the damaged fibers with some axons appearing to have grown as far as 12-14 
spinal cord segments. 
Whether OECs have the ability to myelinate axons in vivo has received support in 
some research reports. Franklin et al. (1996) used an O4+ve clonal OEC cell line that was 
generated from the OB of rat pups and showed these cells would remyelinate spinal cord 
axons after transplantation into an ethidium bromide/X-irradiated demyelinated area of 
the adult rat spinal cord. Exposing the damaged spinal cord to high doses of X-irradiation 
causes a significant delay in the endogenous remyelination process. This animal model of 
CNS demyelination provides a microenvironment in which to test the remyelinating 
ability of transplanted cells. An idea that should be considered when using this animal 
model is the possibility that Schwann cells could migrate into the demyelinated zone and 
form peripheral myelin-like sheaths around the CNS axons.  In the absence of a cell graft, 
a significant delay of more than eight weeks has been reported in the endogenous 
remyelination (Franklin et al., 1996; Imaizumi et al., 1998). However, implanted cells 
may provide an additional incentive (e.g. migratory signals) for Schwann cell migration 
into the demyelinated area, either via release of paracrine chemotactic factors or by 
providing a permissive substrate for Schwann cell migration into the CNS.  
In a recent study, Akiyama et al. (2004) isolated OECs expressing the alkaline 
phosphatase gene from transgenic adult rats and transplanted these cells into the 
demyelinated dorsal columns of immunosuppressed rats. The authors described 
peripheral-type myelination in the dorsal columns after implantation of these transgenic 
OECs, but this pattern of alkaline phosphatase reactivity was diffuse, thus making it 
difficult to distinguish between axons that were myelinated by the transplanted OECs and 
axons that were myelinated by host Schwann cells. Subsequent investigation by Sasaki et 
al. (2004) addressed this concern by using OECs isolated from the ONL of the OB of 
adult transgenic Sprague-Dawley rats in which the OECs constitutively expressed GFP. 
The OECs were transplanted immediately after transection of the dorsal funiculus. The 
advantage of this strategy is that GFP could be detected immunohistochemically for 
ultrastructural identification of labeled cells. The results of this study showed that part of 
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the axons that displayed compact myelin were myelinated by GFP+ve cells (Sasaki et al., 
2004). 
However, in an in vitro study by Plant et al., (2002), using the technique of 
Ramon-Cueto and Nieto-Sampedro (1992) for generating OEC cultures, the myelinating 
ability of OECs were not verified as these cells failed to myelinate neurites when the cells 
were cocultured with DRG neurons. Boyd et al. (2004) used embryonic rat LacZ-
expressing OECs for identification of the cells at the ultrastructural level. These LacZ-
expressing OECs were grafted one week following a mild clip compression injury at the 
T10 spinal cord level. Evaluation of the injury and grafting site three weeks after cell 
transplantation revealed no LacZ-expressing OECs associated with either unmyelinated 
or myelinated axons. Instead, these LacZ-expressing OECs formed unique tunnel-like 
structures in the damaged spinal cord. Unlabeled cells were observed within these 
tunnels, and it was these cells that associated with single myelinated axons or with 
multiple unmyelinated axons. These unlabeled cells were morphologically identical to 
Schwann cells at the ultrastructural level, having small ovoid nuclei and a continuous 
basal lamina encircling a single cell and its associated axons. Thus, these cells within the 
tunnels created by the implanted LacZ-expressing OECs likely represent a population of 
host Schwann cells that had migrated into the cystic cavity. The number of axon-
Schwann cell units inside the tunnels created by implanted OECs ranged from one to 
several dozen. Therefore, the myelination phenotype of OECs in vivo is still under 
debate. 
OECs are also a potential source of a number of growth factors that could 
contribute to promotion of neuronal survival after transplantation (Ramon-Cueto and 
Avila, 1998). OECs express nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), and neutrophin 4/5, but there is no evidence they produce neurotrophin 3 
(NT3) or ciliary neurotrophic factor (CNTF) (Boruch et al., 2001, Woodhall, et al., 2001). 
OECs also express glial cell line-derived neurotrophic factor (GDNF) and neurturin. 
OECs express the trkB and p75 low affinity NGF receptors and thus the BDNF they 
produce may have an autocrine action on the cells. In addition, OECs produce platelet-
derived growth factor (PDGF) (Kott et al., 1994), neuropeptide Y (Ubink et al., 1994), 
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and S100 (Franceschini and Barnett, 1996), all of which are known to promote neuronal 
survival.  
Upon survival, injured neurons should enter the regenerative mode and extend 
their axons, overcoming the inhibitory environment. OECs could favor axonal elongation 
by directly acting on axons through the expression of adhesion molecules, or indirectly 
by neutralizing the effects of the negative signals. OECs support neurite outgrowth from 
embryonic and adult neurons in culture (Kafitz and Greer, 1999; Ramon-Cueto et al., 
1993; Sonigra et al., 1999). Neurites grew randomly with no particular orientation when 
the neurons were co-cultured with either astrocytes or fibroblasts; in contrast, neurons co-
cultured with OECs oriented their neurites in parallel with the orientation of the OECs. In 
this study, the OECs had an elongated morphology, the neurite were aligned along the 
length of the cells, and the OECs ensheathed the neurites (Ramon-Cueto et al., 1993; 
Sonigra et al., 1999). In addition, OECs were found to be a better and more effective 
substrate for neurite elongation than Schwann cells (Sonigra et al., 1999). The expression 
of adhesion molecules on the surface of OECs could be responsible for this promotion of 
axonal elongation. These cells express molecules known to be involved in neurite 
extension such as L1, laminin, neural cell adhesion molecules (N-CAM), embryonic 
polysialic acid containing N-CAM (PSA-N-CAM), and fibronectin (Barnett et al., 2000, 
Doucette, 1996, Franceschini and Barnett, 1996, Kafitz and Greer, 1999; Pixley, 1992; 
Ramon-Cueto, and Nieto Sampedro 1992). OECs from the olfactory mucosa and OB also 
express the transmembrane adhesion molecule neuroglin 3 throughout life, and this 
expression is related to neuron-glia and glia-glia interaction (Gilbert et al., 2001). Similar 
to the tissue culture situation, after transplantation into injured spinal cords, OECs may 
be a good substrate for axonal elongation, and thus stimulate the growth of injured fibers. 
The expression of adhesion molecules by OECs could be, in part, responsible for this 
promotion of axonal regeneration.  
In addition, OECs could also act as isolators, ensheathing regenerating fibers and 
preventing their exposure to chemorepellent molecules, as they do in the OB (Pasterkamp 
et al., 1998). Furthermore, OECs might be, somehow, changing the response of glial cells 
to damage and counteracting the effect of the growth inhibitors released at the lesion site. 
Strikingly, recent studies reported that in contrast to other cell types, OECs did not induce 
 12 
changes in astrocytes associated with a reactive phenotype (Franklin and Barnett, 2000, 
Lakatos et al., 2000). The size and shape of astrocytes and the expression of CSPGs by 
these cells were not altered by contact with OECs.  
One important consideration is that OECs have the potential to be directly 
harvested from the patient and then transplanted back into the same individual. Thus, the 
clinical issues of tissue rejection and immune suppression therapy can be avoided. The 
future of OEC research will require recording the properties and mechanisms by which 
OECs enhance regeneration and will require finding a reliable human source of these 
cells. The function of OECs and how they interact with axons includes their role in 
demyelinating situations, including spinal cord injury (SCI) and various types of 
demyelinating diseases. Although OECs do not normally myelinate axons in the olfactory 
system, they offer promise in the field of demyelinating diseases (Franklin, 2003). 
Franklin (2003) points out that OECs remyelinate more efficiently in combination with 
meningeal cells. The exact population of olfactory cells - whether pure or heterogeneous, 
neonatal or adult - that remyelinates axons needs to be defined, so that ultimately the 
most appropriate cell treatment can be applied to injury situations.  
It was hypothesized that the presence of OECS would create a more favorable and 
supportive environment for axonal growth (Doucette, 1990, 1995; Franklin and Barnett, 
1997; Ramon-Cueto and Valverde, 1995).  OECs could freely migrate into white matter, 
gray matter, connective tissue, and glia to support axonal regeneration over long 
distances in the spinal cord (Ramon-Cueto et al., 1998), and this was an improvement 
over Schwann transplants.  Schwann cells are also considered to be high-quality 
promoters of axonal growth (Ard et al., 1987, Bahr and Bunge, 1989). Also, under certain 
circumstances, astrocytes may promote axonal growth (Hatten et al., 1991; Smith et al., 
1986). However, the treatment of SCI is more complex and promoting axonal growth 
through the injury site is not the only problem that must be overcome (Collins and West, 
1989). It is unlikely that any glial cell type can correct all of these problems; however, it 
would be really interesting if a cell type can adopt several different roles as the need 
arises. OECs may be able to do that (Doucette and Devon, 1993) by switching their 
phenotype from an astrocyte-resembling phenotype to a myelinating Schwann cell-type 
one (Devon and Doucette, 1992, 1995). Thus, it is possible that OECs will be able to 
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combine the roles of Schwann cells and astrocytes when transplanted into a lesion cavity, 
due to their having such a phenotype (Doucette and Devon, 1993). 
 
1.3 Microglia 
1.3.1 Microglia in normal CNS 
Microglia were first described by del Rio-Hortega as a third type of CNS glial 
cell that differed from macroglia (i.e., astrocytes and oligodendrocytes) in terms of their 
phenotype and function (Kim and de Vellis, 2005; Rezaie and Male, 2002), but were 
closely similar to tissue-resident macrophages in these aspects (Kim and Vellis, 2005). It 
was estimated microglia comprise 10% of all cells in the brain parenchyma (Yokoyama 
et al., 2004). Their main role is as a first line of defense against pathological insults and 
they are considered to be a kind of sensor in the brain, because they have receptors for 
CNS signalling molecules such as adenosine triphosphate (ATP), acetycholine and 
noradrenaline and can also react to changes in their extracellular ionic milieu  
(Kreutzberg, 1996).  Microglia have at various times been described as mesodermal 
(Kitamura et al., 1984), hematomonocytic (Ashwell, 1990), or of ectodermal origin (Kaur 
et al., 2001) but the current view is that monocytes in the bloodstream enter the CNS 
during embryonic development, differentiate into the brain resident microglia, and share 
many of the cell surface antigens found on macrophages (Guillemin and Brew, 2004).  
Microglia exist in three distinct forms known as amoeboid, ramified and reactive 
microglia all of which serve different functions (Ladeby et al., 2005). In rats it has been 
shown that amoeboid microglia appear late in gestation and disappear soon after birth 
(Dalmau et al., 1997; Ling et al., 1979). These cells exhibit a round cell body, possess 
pseudopodia and thin filopodia-like processes and contain numerous lysosomes, 
indicative of a motile phagocytic phenotype (Ladeby et al., 2005). During the postnatal 
period amoeboid microglia are believed to play a role in tissue histogenesis through the 
removal of inappropriate axons (Innocenti et al., 1983) and through the promotion of 
axonal migration and growth (Polazzi & Contestabile 2002; Schwartz et al., 2006). 
Ultimately, amoeboid microglia grow long processes and transform into ramified 
microglia, which are the predominant cell type found in the adult CNS (Kaur and Ling 
1991; Ling, 1979). These amoeboid microglia differentiate into ramified microglia 
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(postnatal days 9-15 in rats) that are characterized by long cytoplasmic processes and are 
found throughout the CNS of adult mammals (Ladeby et al., 2005; Ling 1991). Although 
ramified microglia were considered to be inactive as phagocytic cells, under normal 
conditions, Booth and Thomas (1991) showed that these microglia exhibited pinocytotic 
activity.  
Microglial cytoplasmic processes make contact with neuronal cell bodies, 
astrocytes and the lamina propria of blood vessels (Nimmerjahn et al., 2005). Thus, 
microglia are ideally situated to monitor the well-being of brain cells and also to function 
in cleaning up the extracellular fluid to maintain central homeostasis (Booth and Thomas, 
1991; Fetler and Amigorena, 2005). In this respect, it has been suggested that ramified 
microglia contribute to metabolite removal and to the clearance of toxic factors released 
from injured neurons (Fetler and Amigorena, 2005). In case of CNS injury or disease 
(e.g., degenerative, infectious, or autoimmune diseases), the resident ramified microglia 
change their morphology and transform into cells having retracted cytoplasmic processes 
and enlarged cell bodies; these cells are generally referred to as “activated microglia” or 
“reactive microglia” (Kreutzberg, 1996).  The term reactive microglia will be used in this 
thesis and these cells are described in more detail in Sections 1.3.2 and 1.3.3. 
 
1.3.2 Microglial response to neural injury 
 Following CNS injury or pathogen invasion, quiescent ramified microglia 
transform into reactive microglia (Kreutzberg, 1996; Stence et al., 2001). Proliferation 
and cell migration are two main factors contributing to the accumulation of reactive 
microglia at the site of injury (Dihne et al., 2001; Giordana et al., 1994) where they play a 
neuroprotective role in phagocytosing damaged cells and cellular debris. In acute lesions, 
usually 2-3 days after insult is the time when microglial activation reaches its peak 
(Banati, 2003). Although microglial activation is unrelated to the type of injury and is a 
rapid process that begins from minutes to a few hours after injury, in later stages of 
activation the morphological transformation is related to the type of lesion. For example, 
the “bushy” phenotype of microglia is observed in areas with Wallerian and terminal 
synaptic degeneration (Jensen et al., 1994). In contrast, rod cell-shaped reactive microglia 
are found where dense dendritic degeneration is occurring (Morioka et al., 1991) and 
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hyper-ramified perineuronal microglia are found around each degenerating neuron (Streit 
et al., 1999). In the presence of extensive neuronal degeneration, and especially in the 
later phase of the degenerative process, microglia may modify into round phagocytic 
cells that are indistinguishable from blood-borne macrophages (Guillemin and Brew, 
2004).  Throughout the remainder of this thesis these reactive cells will be referred to as 
microglia/macrophages if the morphology of the cells does not allow the two cell types to 
be distinguished or if the study being referenced has not clearly indicated which cell type 
is being described.   
Reactive microglia express major histocompatibility complex (MHC) class I and 
II antigens as well as CD40, B7 and intercellular adhesion molecule-1 (ICAM-1), which 
are specific antigen presenting molecules (Benveniste et al., 2001; Finsen et al., 1993). 
Therefore, microglia are considered to be the most potent antigen presenting cell type in 
the CNS. Like macrophages, reactive microglia secrete a number of inflammatory 
mediators, which serve to organize the CNS immune response. Proinflammatory 
molecules secreted include various interleukins, monocyte chemotactic protein-1 (MCP-
1) (Kim et al., 2005), and tumor necrosis factor alpha (TNF-α) (Taylor et al., 2005). 
Besides their morphology, reactive microglia/macrophages are identified based on their 
immunostaining with Mac-1, ED1, OX18, OX42, OX6 and OX1 antibodies (Ling et al., 
1991). 
Microglial/macrophage expansion in response to neural injury or to 
neuroinflammation can occur by: (1) proliferation of ramified resident microglia, (2) by 
their migration from adjacent intact brain areas, (3) by recruitment of monocytes from the 
blood, or (4) by a combination of each of these processes (reviewed Ladeby et al., 2005). 
Microglial cells are present in all regions of the mature CNS, but are at different cell 
densities in various areas of the parenchyma (Schwartz et al., 2006).  
Following transection of the hippocampal perforant path projection, microglia 
located within the denervated outer part of the dentate molecular layer transformed into 
reactive microglia and began to display an activated morphology from 12 to 24 h after the 
axotomy (Jensen et al., 1994; Jensen et al., 1999), and they attained a typical bushy 
morphology by day 3. These morphological changes occurred in parallel to an increased 
intensity of microglial CD11b immunoreactivity (Jensen et al., 1999). At 24h after 
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perforant path transection, reactive microglia also began to accumulate at the border 
between the nondenervated inner commissural-associational zone and the denervated 
outer perforant path zone. The reactive microglia migrated into the denervated zone from 
day 1 to 3 after transection in parallel to their maximal rate of proliferation giving rise to 
a strongly increased cell density in the denervated zone (Jensen et al., 1994). The 
microglial response to perforant path transection reached maximum levels between 5 to 7 
days after lesioning, with the reactive microglia having a bushy morphology and multiple 
partly retracted, cellular processes (Jensen et al., 1994; Jensen et al., 1997). Microglial 
activation measured as the density of Mac-1+ve cells within the denervated perforant 
path zone at day 5 after transection was correlated with the severity of the neuronal 
damage, as measured by the density of the anterogradely degenerating axons (Jensen et 
al., 1997). Estimates of the fold increase in the microglial cell population in the perforant 
path-denervated dentate gyrus at 3 days after injury vary from a 3-fold increase in mice 
(Lakeby et al., 2005) to a 6-fold increase in rats (Hailer et al., 1999). These estimates 
were obtained at a time point after injury at which microglial proliferation is just 
beginning (Hailer et al., 1999) so undoubtedly they are under estimates of the magnitude 
of the final increase in cell density.  Microglial proliferation begins around postlesion 
days 2–3 and has been demonstrated by pulse labeling of mitotically active cells in 
perforant path lesioned rats using bromodeoxyuridine (Brdu) injected 1 h prior to 
sacrifice. Hailer et al. (1999) showed that 17–18% of microglia within the denervated 
zones in the dentate gyrus had incorporated Brdu at day 3 after transection, which 
decreased to 2% by day 7 and to 1% by 4 weeks (Hailer et al., 1999). 
  Microglial proliferation and expansion are under the control of several factors. 
Macrophage colony-stimulating factor (M-CSF) promotes microglial proliferation in vitro 
(Tomozawa et al., 1996) as well as in vivo (Raivich et al., 1994). In addition, upregulation 
of M-CSF receptors by reactive microglia further increases their responsivity to M-CSF 
during the acute phase 1–2 days after facial nerve axotomy at the onset of microglial 
proliferation (Raivich et al., 1998). In the osteopetrotic mice, which are deficient in M-CSF, 
there is a 30% and 39% reduction in microglial cell number per unit area in the neocortex 
and the pons, respectively (Sasaki et al., 2000). Other proinflammatory cytokines including 
interleukin- 6 (IL-6) (Klein et al., 1997), IL-1ß, and TNF-α (Kloss et al., 1997) have also 
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been shown to promote microglial proliferation and survival.  However anti-inflammatory 
cytokines such as transforming growth factor-beta (TGFβ) are strong inhibitors of 
microglial proliferation (Jones et al., 1998). 
 
1.3.3 Microglial response to neuroinflammation 
For decades, the brain has been considered an immune privileged organ (Zipp and 
Aktas, 2006). Nowadays, biochemical studies of the nervous tissue in diverse 
physiological and pathological circumstances have revealed that inflammation in the 
CNS constitutes the principal host defense to CNS injury and infection. In contrast with 
the rapid and massive invasion of leukocytes and edema that are evident in peripheral 
tissues, it is the recruitment and rapid activation of locally resident microglia that occurs 
in the CNS.  
Lipopolysaccharide, interferon-gamma (IFN-γ), HIV-related molecules, prion 
protein, ATP, and cytokines are among the best-documented activators of microglial cells 
(Nakamura, 2002). Within minutes or hours, resting ramified microglia transformed into 
motile amoeboid microglia (Kreutzberg, 1996). At the molecular level, a variety of genes 
show up-regulation, including the MHC and complement receptors (Liu and Hong, 2003) 
and the high affinity glutamate transporter-1 (GLT-1) (Lopez-Redondo et al., 2000; 
Persson et al., 2005). Finally, as a major issue in the neuroinflammatory process, 
activated microglia release a large variety of pro- and anti-inflammatory mediators, 
including cytokines, reactive oxygen species (ROS), nitric oxide (NO), prostanoids, and 
complement factors (Nakajima et al., 2001). Neuroinflammation in the CNS is a complex 
interplay of glial cells that begins with “reactive” microglial cells, which in turn activate 
astrocytes. Two major components of the reactive microglial response to CNS 
neuroinflammation are changes in cell immunophenotype including expression of MHC 
class I (OX18) (Graeber et al., 1992) and II (OX6) (Graeber et al., 1992) proteins, 
upregulation of CD11b (OX42 monoclonal antibody) (Nagai et al., 2001), CD4 (OX35 
monoclonal antibody) (Ford et al., 1995), and ED1 (ED1 monoclonal antibody) (Lee et 
al., 2006) antigenic epitopes, as well as changes in cell secretory activity (Lee et al., 
2006; Murphy et al., 1998; Puliti et al., 1999). In addition, there is consistent microglial 
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hyperplasia and hypertrophy, which have been documented in many animal models of 
acute CNS neuroinflammation (Ladeby et al., 2005).   
 
1.4 Astrocytes 
1.4.1 Astrocytes in normal CNS  
 Astrocytes are the most numerous non-neuronal cell type in the CNS that  
envelope all cellular components throughout the CNS with their fine branching processes 
(Bignami et al., 1972). Astrocytes make up around 50% of all glial cell types.  Based on 
their morphology, they can be classified into two main groups; namely, the fibrillary 
astrocytes, which are located in white matter and have long slender cytoplasmic 
processes, and the protoplasmic astrocytes, which reside in gray matter and have 
numerous short, highly branched cytoplasmic processes (Tsacopoulos and Magistretti, 
1996).  The fibrillary astrocytes have more GFAP containing intermediate filaments in 
their cytoplasm, and thus stain more intensely with antibodies to GFAP than do 
protoplasmic astrocytes (Wagner et al., 1993). However, protoplasmic astrocytes are 
relatively poor in intermediate filaments, and consequently are only weakly 
immunostained with antibodies to GFAP (Wagner et al., 1993). Astrocytes exhibit a 
strong structural interrelationship with neurons in all regions of the CNS. Those somatic 
and dendritic surfaces that are not sites of synaptic terminals are invested by sheet-like 
processes from astrocytes. Astrocytes also provide the structural boundary to the blood 
vessels (perivascular endfeet), the pia mater (glia limitans), and the border between the 
CNS and PNS in sensory and motor roots of spinal and cranial nerves (Fraher, 1992). The 
expression of gap junctions by astrocytes and the use of these junctions to communicate 
with one another emphasizes the epithelial organization of astrocytes (Giaume and 
McCarthy, 1996), which also express transporter systems for several key molecules 
(Rothstein et al., 1994; Vannucci et al., 1997) as well as a wide variety of membrane 
receptors for neurotransmitters (Kimelberg, 1995) and growth factors (Raivich and 
Kreutzberg, 1994; Rudge et al., 1994). The astrocytic network thereby forms a 
syncytium, acting to optimize neural function by maintaining homeostasis in the 
extracellular environment (Montgomery, 1994). 
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Astrocytes provide many supportive activities that are essential for neuronal 
function in the normal CNS, including homeostatic maintenance of extracellular ionic 
concentrations, as well as the clearance and release of extracellular glutamate (Mazzanti 
et al., 2001). It has recently been appreciated that astrocytes also play an important role in 
regulating neuronal function through the release of neurotrophic factors, by guiding 
neuronal development, by contributing to the metabolism of neurotransmitters, and by 
regulating extracellular pH and K+ levels (Haydon, 2000). Astrocytes also may actively 
participate in synaptic plasticity (Ullian et al. 2001). In addition, the formation and 
maintenance of the blood-brain barrier (BBB) are dependent on astrocytes in vivo; 
astrocytic perivascular endfeet are in close apposition to the basal lamina of endothelial 
cells lining the lumen of capillaries in the CNS, thus inducing the maintenance of a BBB. 
Soluble factors secreted by astrocytes appear to be involved in the maintenance of the 
BBB, possibly by inducing the formation of tight junctions between endothelial cells 
(Rubin and Staddon, 1999); thus, astrocytes contribute to both the structural and 
functional integrity of the BBB (Wolburg and Risau, 1995).  
 
1.4.2 Astrocytic response to neural injury 
Astroglia are known to play a key role in the tissue response to CNS injury 
(Fawcett and Asher, 1999; Hatten et al., 1991). In response to CNS injury, astrocytes 
proliferate, change their morphology, and increase their expression of GFAP; 
collectively, these changes are termed astrogliosis, which is an astrocytic response that is 
a common hallmark of neural injury and diseases in which neuroinflammation is a 
prominent component (reviewed in Hatten et al., 1991). Depending on the injury 
condition, astrogliosis may have beneficial effects for promotion of neuronal survival by 
the production of growth factors such as neurotrophins that support neuronal growth, or 
detrimental for neuronal functional recovery by the formation of a glial scar. After injury, 
these cells are involved in the uptake of potentially harmful substances, such as excitatory 
amino acids and K+, and also in the release of certain cytokines (Norenberg, 1994, 1996).  
The basic process of reactive astrocytosis involves astrocyte proliferation and changes in 
gene expression (Fawcett and Asher, 1999).  Nevertheless, the specific functions 
performed by reactive astrocytes are not well defined, although they are always present in 
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CNS tissue that has been damaged or that contains degenerating neurons. Some of the 
suggested functions of reactive astrocytes include contributing to the inflammatory 
response, secretion of cytotoxins that kill neurons, and forming scar tissue that inhibits 
axonal regeneration (Norenberg, 1996). Experimental investigations have demonstrated a 
heterogeneous reaction pattern of astrocytes depending on the proximity to and the type 
of injury. Lesions involving direct tissue damage and destruction of the BBB lead to an 
anisomorphic astrogliosis (Wolburg and Risau, 1995).  
The astroglial response to injury is characterized by an increase in cell numbers 
(hyperplasia), cell size, and cytoplasmic processes (hypertrophy). These changes in cell 
number and morphology of reactive astrocytes are accompanied by an increased 
expression of GFAP by the cells contributing to the formation of a gliotic scar (Ridet et 
al., 1997). Within 3-5 days after motor axon injury, reactive astrocytes begin to wall-off 
the injured area by interdigitating their cytoplasmic processes (reviewed in Eddleston and 
Mucke, 1993; Hatten et al., 1991; Norenberg, 1994; Ridet et al., 1997). These astrocytic 
responses create a dense plexus, or wall, of astrocytes. The molecular profile of reactive 
astrocytes also includes high concentrations of S100ß (Tateishi et al., 2006) and of 
growth factors such as fibroblast growth factor 2 (FGF2), NGF, CNTF, and glia-derived 
nexin, which is a protease inhibitor with neurite promoting activity (Games et al., 1999; 
Markiewicz and Lukomska, 2006). Numerous aspects of astrocytosis point to reactive 
astrocytes as cells that phenotypically revert to a primitive, fetal state, re-acquiring 
factors that are present in the developmental state that had been lost upon differentiation 
into mature astrocytes (Markiewicz and Lukomska, 2006). The proteins expressed by 
reactive astrocytes that support this view include nestin (Brook et al., 1999), microtubule 
associated protein-2 (MAP-2), and gamma-aminobutyric acid (GABA) (Geisert et al., 
1990). 
Within less than one hour after motor axon injury, there is an increased 
immunoreactivity for connexin 43, the major component of astrocytic gap junctions 
(Rohlmann et al., 1994). Within 24 hr, astrocytes expressed increased immunoreactivity 
for GFAP (Graeber and Kreutzberg, 1986; Ruan et al., 1994) and upregulated both GFAP 
mRNA and protein (Tetzlaff et al., 1988). In a longer time frame, reactive astrocytes 
develop slender, sheet-like processes covering non-synaptic areas of the neuronal 
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membrane. In parallel with the increased expression of GFAP there is also increased 
expression of the multifunctional glycoprotein clusterin (Svensson et al., 1995). Clusterin 
inhibits complement-mediated cell lysis, but is also involved in cell adhesion, lipid 
transport, and processes associated with cell survival or cell degeneration (Rosenberg and 
Silkensen, 1995). Its role in the axotomy-induced astroglial response is unknown, 
however. Astrocytes upregulate PDGF and mRNA for the B-chain of the PDGF receptor 
during the injury response (Hermanson et al., 1995). However, a proportion of these cells 
also begin to express TGFβ-1 mRNA (Acarin et al., 2000). Since astrocytes respond to 
TGFβ-1 (Acarin et al., 2000), it is possible that this molecule is involved in autocrine or 
in paracrine interactions, influencing neighboring cells including other astrocytes 
(Lindholm., et al., 1992) 
 
1.4.3 Astrocytic response to neuroinflammation 
After neuroinflammation, astrocytes release large amounts of ATP into the 
extracellular environment (Zimmermann, 1994). Such ATP release may be important in 
triggering cellular responses to trauma and ischemia by initiating and maintaining 
reactive microglia and involves striking changes in astrocyte proliferation and 
morphology (Neary et al., 1999). ATP released as part of the astrocytic response to 
neuroinflammation may contribute to the pathophysiology initiated after trauma (Neary et 
al., 2006). For example, treatment of cultured astrocytes with cytokines such as IL-1ß 
enhanced the ATP-evoked release of arachidonic acid via P2Y2 receptors and cytosolic 
phospholipase A2 (Neary et al., 1999). This enhanced release from astrocytes may 
contribute to the neuronal loss associated with the neuroinflammation caused by cerebral 
ischemia or traumatic brain injury (Stella et al., 1997). Several experimental strategies 
designed to elucidate the roles of astrocytes and their interaction with extracellular matrix 
(ECM) molecules after CNS inflammation have identified these molecules as 
contributing to the formation of an astrocytic scar as well as establishing a favorable 
environment for neuronal repair (McGraw et al., 2001). Nevertheless, it is most likely 
that to obtain long distance axonal regeneration within the injured adult CNS will require 
different repair strategies, not limited solely to the modulation of astrogliosis.  
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 Neuroinflammation as a result of brain damage causes the release of glutamate by 
neurons and astrocytes that may cause secondary excitotoxic neuronal and 
oligodendroglial progenitor cell death (Liberto et al., 2004). The level of glutamate may 
be regulated homeostatically by activated astrocytes that can remove it from the 
extracellular space and convert it to glutamine (Zelenaia et al., 2000). Therefore, the 
capacity of astrocytes to reduce extracellular levels of glutamate can dramatically impact 
the extent of neuronal and oligodendroglial damage after an insult. The expression levels 
of glutamate transporter and glutamine synthase both increase when astrocytes become 
activated (Ahlemeyer et al., 2002). GLT-1 and glutamate-aspartate transporter (GLAST) 
are two glutamate transporters that remove excess glutamate (Duan et al., 1999). 
Astrocytes in vitro that are exposed to epidermal growth factor (EGF) increase their 
expression of GLT-1 (Zelenaia et al., 2000). Likewise, the level of GLAST expression by 
astrocytes increases following treatment with FGF-2, EGF, and insulin-like growth factor 
1 (IGF-1) (Suzuki et al., 2001). Neuroinflammation also affects GLT-1 and GLAST 
expression in vivo. GLT-1 levels increased 2.5 fold above control levels three days after 
trauma produced by transplanting E18 neocortical tissue into adult rat cerebral cortex 
(Krum et al., 2002). Similarly, GLT-1 and GLAST mRNA expression were induced after 
physical trauma to astrocytes in vitro (Faden et al., 1989; Eng et al., 1997). The levels of 
the glutamate transporters also may be indirectly regulated by cytokines (Aronica et al., 
2003). In vitro studies have shown that astrocytic expression of metabotropic glutamate 
receptors (mGluRs) can be altered in response to FGF-2 and EGF (Balaz et al., 1997; 
Minoshima and Nakanishi 1999); as a consequence of the altered expression of mGluRs, 
the level of glutamate transporters on astrocytes increased (Ciccarelli et al., 1997; Bruno 
et al., 1998). Therefore increased expression of mGluRs, GLAST and GLT-1 following 
neuroinflammation better enables astrocytes to deal with the excess glutamate and 
provide some measure of neuroprotection.  
 
1.5 Cytokines 
Cytokines are polypeptides or glycoproteins with low molecular weight (<40 
KDa) that regulate a variety of cellular functions including proliferation, survival and 
maturation (Aarli, 2003; Farina & Winkelman, 2005). One major function of cytokines is 
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as chemical messengers for regulating the activity of the innate and adaptive immune 
system (Vilcek & Feldmann, 2004). The major cytokine producers in the body are T 
helper cells (Th) and macrophages (Kielian, 2006), although all cells involved in innate 
and adaptive immunity can synthesize and secrete cytokines. The activation of cytokine-
producing cells by UV light, heat-shock, hyperosmolarity, infection etc. triggers them to 
synthesize and secrete their cytokines (Dinarello, 2000).   
Cytokines generally act over short distances (paracrine signaling), for short time 
spans (from minutes to hours) (Deehan et al., 1995), and at very low concentrations (2-20 
pg/ml) (Farina & Winkelman, 2005). Cellular responses to cytokines include increasing 
or decreasing expression of membrane proteins (including cytokine receptors), cell 
proliferation, and secretion of effector molecules, free radicals, growth factors, enzymes 
etc. (Farina & Winkelman 2005; Popovich et al., 1997).  
Cytokines are pleiotropic molecules, which means that a particular cytokine can 
act on a number of different cell types rather than a single cell type. They are also 
redundant, which refers to different cytokines regulating similar cellular functions.  In 
addition, cytokines are also multifunctional since each cytokine is able to regulate a 
number of different cellular functions (Farina & Winkelman, 2005). Cytokines act by 
binding to specific membrane receptors on target cells, which then signal via second 
messengers (e.g. tyrosine kinases) inducing the cell to alter its behavior (for instance, 
gene expression) (Munoz-Fernandez & Fresno, 1998). Thus, what determines the 
response of a target cell to a specific cytokine is dependent on which signalling pathways 
are activated when the ligand binds its receptor. 
 
1.5.1 Cytokines in CNS 
 Cytokines function as powerful regulators of astrocyte and microglial function in 
the CNS (Fawcett & Asher, 1999). The numerous cytokines that can affect cellular 
functions in the CNS have two possible cellular sites of synthesis: (1) from cells of 
peripheral immune organs (e.g. spleen, lymph node), with the cytokines crossing BBB; or 
(2) from astrocytes and microglia in the CNS (Segal, 2005). The expression of most 
cytokines is tightly regulated by negative feedback and these factors are usually only 
produced in quantities sufficient to reach physiologically relevant concentrations after 
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activation of peripheral immune cells, astrocytes, or microglia in response to an induction 
signal (John et al., 2003). 
 Following brain damage or infection, peripheral immune cells, such as 
macrophages, Th cells and neutrophils, can enter the brain due to the breakdown of the 
BBB and comprise the main sources of proinflammatory cytokines such as IL-1ß, IL-6, 
TNF-α, and IFN-γ (Hopkins and Rothwell, 1995). Astrocytes and microglia can also 
synthesize and secrete some of those cytokines (IL-1ß, IL-6 and TNF-α) as part of an 
inflammatory response as well as during neural development (Benveniste et al., 1990; 
Lechan et al., 1990). Each of these proinflammatory cytokines can, in turn, induce the 
synthesis and secretion of a variety of other cytokines by CNS glia, as well as regulate by 
autocrine mechanisms their own synthesis and secretion. In situ mRNA analyses have 
shown that proinflammatory cytokine synthesis occurs not only by astrocytes and 
microglia in vitro but also by these same cells in vivo (Benveniste et al., 1990; Lechan et 
al., 1990).  
Damage to the CNS is probably the most profound activator of inflammatory 
cytokine expression (Hashizume et al., 2000). There is an increase in the concentration of 
several proinflammatory cytokines (e.g. IL-1ß, TNF-α, IL-6) in the cerebrospinal fluid 
(CSF) and in brain and spinal cord tissues after mechanical injury; for instance, by 
insertion of a microdialysis probe designed to induce mechanical trauma to the brain.  
There is also a remarkable upregulation of IL-1ß mRNA in the cerebral cortex, 
hippocampus, striatum, and thalamus after transient forebrain ischemia or infection (e.g., 
malaria, HIV, meningitis) (Hopkins and Rothwell, 1995; Merrill and Benveniste, 1996). 
The expression of IL-6 and TNF-α seem to be greatest in the hypothalamus and 
hippocampus after ischemia and infection, with lower levels of expression in the cerebral 
cortex and brainstem, and even lower but still detectable levels in other brain regions 
(Hopkins and Rothwell, 1995; Mehler and Kessle, 1997). 
Certain proinflammatory cytokines in the CNS might function early to amplify 
the disease process, such as in the experimental autoimmune encephalomyelitis (EAE) 
animal model, and then later function to attenuate the pathophysiology. It was shown that 
IL-6 increased BBB permeability, induced gliosis, upregulated proinflammatory cytokine 
and antibody production, and yet might have accounted for the survival, migration and 
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differentiation of oligodendrocyte precursors that are required for the repair of damaged 
myelin. TGF-β is chemotactic for macrophages, microglia and astrocytes and therefore 
induces infiltration and gliosis and yet it is a potent inhibitor of the functions of 
astrocytes and microglial cells when these cells are in an activated state (Merrill and 
Zimmerman., 1991).  
The major source of proinflammatory cytokines (e.g. IL-1ß, IL-6 and TNF-α) in 
the brain appears to be from activated microglia and astrocytes (Giulian et al., 1986; 
Sawada et al., 1989; Chung and Benveniste, 1990). Perivascular macrophages and brain 
endothelial cells are two additional potential sources of cytokines in CNS tissue, and each 
of these cell types have been shown to express IL-6 in response to other proinflammatory 
cytokines (Fabry et al., 1993). Proinflammatory cytokines can trigger the synthesis and 
secretion of a cascade of cytokines in the CNS, normally first acting on astrocytes and 
microglia, followed by glial-derived cytokines acting on neurons, although the initially 
produced proinflammatory cytokines may have a direct influence on neurons as well 
(Sawada et al., 1989; Chung and Benveniste, 1990). For example, TNF-α mostly induces 
IL-1ß and IL-6 expression. In contrast, growth factors such as neurotrophins are induced 
by IL-1ß, and IL-6 can block IL-1ß and TNF-α expression in target cells (Norris et al., 
1994). It is interesting that proinflammatory cytokines can regulate the production and 
release of NGF and other neurotrophic molecules by astrocytes in vitro (Spranger et al., 
1990; Sagoh et al., 1993) and by cells in the injured sciatic nerve (Lindholm et al., 1987) 
that are capable of promoting neuronal survival and repair of neural tissue. 
 
1.5.2 Proinflammatory Cytokines: Signal Transduction  
There is considerable evidence that the peripheral immune system can signal the 
CNS to elicit a response during CNS inflammation or infection (Hosoi et al., 2002). 
Proinflammatory cytokine expression such as IL-1ß, TNF-α and IL-6 is involved in 
response to a variety of animal models of CNS injury (Besedovsky et al., 1996; Hosoi et 
al., 2002).  CNS injury may upregulate specific transcription factor-dependent cytokine 
production; for example, the activity of nuclear factor kappa B (NF-kB), an 
inflammatory-induced transcription factor (Haddad, 2002). Poly (ADP-ribose) 
polymerase-1 (PARP-1) is an abundant nuclear enzyme that is activated by DNA 
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damage.  In response to proinflammatory cytokine up regulation, PARP-1 may play a key 
role in NF-kB-driven expression of inflammatory mediators by microglia and astrocytes 
during the neuroimmune response.  PARP-1 promotes the DNA binding of NF-kB in 
microglia exposed to lipopolysaccharides, IFN-λ or β-amyloid (Chiarugi and 
Moskowitz, 2003). Excessive PARP-1 activation is implicated in a variety of pathologies, 
such as cerebral ischemia and traumatic SCI (Chiarugi and Moskowitz, 2003).  
The JAK/STAT signal transduction pathway is one of the intracellular signaling 
pathways activated by cytokines and growth factors that was first studied in the 
hematopoietic system, but recent data demonstrate that pathway is also greatly utilized by 
other systems. The JAK/STAT pathway is a signaling cascade that links the activation of 
specific cell membrane receptors to nuclear gene expression (Licinio et al., 2000; Kim et 
al., 2002). Most cytokines act through cell surface receptors that have one transmembrane 
domain and transduce a signal through the JAK/STAT pathway.  Signaling through its 
receptor, IL-3 has been shown to induce the activation of JAK/STAT and MAPK 
pathways in microglial cells, thereby upregulating the expression of CD40 and MHCII 
molecules (Natarajan et al., 2004).  
 
1.5.3 Proinflamatory Cytokines: Neural Injury 
The upregulation of several families of inflammatory molecules, including 
cytokines and chemokines, is a prominent consequence of SCI (Bethea, 2000; McTigue 
et al., 1998; Jones et al., 2005). The potential sources of these molecules are intrinsic 
CNS cells, including microglia, and extrinsic leukocytes that are recruited to the site of 
damage. Breakdown of the BBB, demyelination, and axonal injury are some detrimental 
consequences of rapid upregulation of inflammatory mediators (Allan and Rothwell, 
2003). In correspondence with these undesirable actions, systemic treatment with the 
anti-inflammatory cytokine IL-10 limited the neuronal damage and improved the 
functional recovery in rats after SCI (Bethea et al., 1999). Furthermore, neutralization of 
the T cell chemoattractant CXCL10 reduced T cell infiltration and secondary 
degeneration in SCI (Gonzalez et al., 2003). Finally, depletion of peripheral macrophages 
resulted in improved hindlimb function after SCI in rats (Popovich et al., 1999). The 
temporal pattern of cytokine expression after clip compression-induced SCI in the mouse 
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revealed an elevation of IL-1ß mRNA levels by 30 minutes after injury. This rapid 
elevation of IL-1ß was transient and peaked between 90 minutes and 3 hours after injury; 
the levels had decreased to sham levels by 24 hours after injury (Rice et al., 2007). 
Molecules such as the IL-1 receptor antagonist (IL-1ra) and IL-6 were induced within the 
first 3 hours after SCI but were not readily apparent by 30 minutes after injury. TNF-α is 
a proinflammatory cytokine that has been implicated in the inflammatory reaction 
associated with SCI. The expression of TNF-α mRNA was elevated within 30 minutes of 
SCI, but the mRNA levels of cytokines such as IL-6, lymphotoxin-ß (LT-ß) and TGF-ß 
remained at normal levels at this time (Rice et al., 2007). 
In situ hybridization and immunocytochemistry have demonstrated that 
microglia/macrophages are a source of the cytokines produced early in the inflammatory 
reaction to spinal cord injury. Rice et al. (2007) have shown that cells that expressed IL-
1ß mRNA were seen around the lesion site by 3 hours after SCI in mice. These cells were 
Iba-1+ve, a microglia/macrophage marker. Not all Iba-1+ve cells, however, expressed the 
IL-1ß signal, but the cells that expressed this cytokine were all Iba-1+ve at the 3-hour 
time point. As blood-derived macrophages are known to infiltrate the parenchyma of the 
injured brain no earlier than 5 hours after traumatic brain injury (Giulian et al., 1989), 
Rice et al. (2007) hypothesized that microglia within the CNS are the main source of IL-
1ß mRNA in the acute phase after SCI in mice. However, since staining with Iba-1 
cannot discriminate between microglia and macrophages, the latter cell type cannot be 
excluded as a possible source of IL-1ß in the study by Rice et al. (2007). Recently, 
however, Pineau and Lacroix (2007) reported data from chimeric mice that had a SCI; in 
these mice, GFP-expressing hematopoietic stem cells had been transplanted 6 months 
prior to the SCI, with the transplantation occurring following bone marrow irradiation. At 
1 hour after SCI in these chimeric mice the cells expressing IL-1ß were GFP-ve, thus 
supporting the hypothesis of Rice et al. (2007) that cells other than those derived from the 
blood must be the source of inflammatory molecules early after such an injury. Within 30 
minutes of an impact injury to the rat spinal cord, the activation of NF-қB, which 
regulates the transcription of several cytokines and cytokine-responsive genes, was 
demonstrated in microglia and endothelial cells whereas neuronal expression of NF-қB 
was only evident after 24 hours (Bethea et al., 1998). After a contusion injury to the 
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mouse spinal cord, astrocytes and microglia were reported to express proinflammatory 
cytokines by 1 hour after injury (Pineau and Lacroix, 2007).  
To further dissociate infiltrating macrophages from microglia as the early cellular 
sources of IL-1ß and other inflammatory molecules after SCI, it would be ideal to have a 
model of SCI in which no leukocytic infiltration occurs. In this regard, the spinal cord 
slice culture provides at least a partial solution (Pan et al., 2002). Obtaining a slice of the 
spinal cord to grow as an organotypic slice culture is a type of transection injury, and the 
time in culture is similar to the time after injury. Over the first 1, 3, and 6 hours, neurons 
in the spinal cord became pyknotic, the processes of neurons disappeared, and the 
neuronal density declined. Microglia in the slices transformed from a ramified 
morphology typical of resting microglia and acquired shorter thicker processes that are 
indicative of activated microglia (Pan et al., 2002). There was an upregulation of IL-1ß, 
IL-6, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein 1 
alpha (MIP-1α), MIP-1ß, and MIP-2 in the slices as early as 3 hours in vitro (Rice et al., 
2007). These results demonstrated that cells intrinsic to the spinal cord are sufficient to 
mount an inflammatory response, similar to that observed following the in vivo clip 
compression SCI, and in the absence of a blood source and potential infiltration of the 
lesion by leukocytes. A likely source of inflammatory molecules in the in vitro SCI 
model are the microglia, a conclusion supported by the morphological evidence of their 
activation. There is increasing recognition of the fact that there are different functional 
states of microglia/macrophages, such that one that is performing a phagocytic role or 
generating free radicals may not be playing a role in the production of inflammatory 
cytokines. In support of this suggestion, the treatment of microglia with GDNF increased 
nitric oxide production and phagocytic activity but had no effect on the secretion of IL-1ß 
and TNF-α (Chang et al., 2006). Disrupting the function of the Kv1.3 ion channel in 
microglia attenuated their neurotoxic property but did not affect their production of nitric 
oxide (Fordyce et al., 2005). Furthermore, the production of CCL3 and the phagocytic 
function by microglia are regulated through different signaling cascades (Song et al., 
2004). Clearly, much remains to be understood of the functions of proinflammatory 
cytokines in the context of the neuroinflammation that occurs after a SCI. It is possible 
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that the type of SCI, such as contusion, transection, or ischemic damage, may 
differentially alter cytokine secretion and thus the intensity of the inflammatory reaction.  
 
1.5.4 Proinflamatory Cytokines: Neuroinflammation 
Cytokines have been implicated in oligodendrocyte cell death, axonal degeneration and 
neuronal dysfunction (Wujek et al., 2002). Proinflammatory cytokines are thought to be 
key players in the pathophysiology of MS (Lucchinetti et al., 2001).   The cerebrospinal 
fluid (CSF) from patients with the primary progressive type of MS contains soluble 
mediators that have been shown to induce axonal damage and apoptosis of neurons in 
vitro (Alcazar et al., 2000). Therefore, understanding the mechanisms of cytokine-
mediated neural injury is necessary to design therapies that promote oligodendrocyte and 
axon survival and prevent irreversible chronic disability as a consequence of CNS 
inflammation.  
On the other hand, proinflammatory cytokines may have some beneficial roles to 
play in some aspects of neuroinflammation after SCI (Franzen et al., 1998; Prewitt et al., 
1997). It was hypothesized that neuroinflammation also has an important role to play as a 
host defense mechanism after different types of SCI. In support of this hypothesis, the 
application of macrophages (Franzen et al., 1998; Rapalino et al., 1998) or microglia 
(Prewitt et al., 1997) into the lesion site after SCI promoted neural repair. Thus, the role 
of inflammation in tissue repair after SCI is complex.  In addition, proinflammatory 
cytokines within the CNS have been suggested to provide neuroprotective benefits during 
the healing process of the brain and spinal cord that depends on the activation state of the 
cytokine-producing cells (Klusman and Schwab, 1997; Schwartz and Yoles, 2006). In 
addition to proinflammatory cytokines, macrophages can secrete factors that are growth 
promoting, such as NGF and NT-3 (Elkabes et al., 1996) and thrombospondin (Chamak 
et al., 1994). Even zymosan, which triggers a robust inflammatory reaction, when placed 
in the vitreous chamber of the eye can facilitate regeneration of injured optic nerve fibers 
(Leon et al., 2000). Injection of  zymosan into a DRG prior to a crush injury of its dorsal 
root when combined with modification of the ECM in the CNS component of the 
pathway appear essential to the success of axon regeneration into the spinal cord 
(Steinmetz et al., 2005). Intense inflammatory states created just outside of the CNS 
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illustrate that in certain circumstances inflammation can facilitate axon regeneration, 
perhaps by triggering a conditioning-like effect within the neuron (Calvo et al., 2005).  
  The size, duration and location of the injury, as well as the predominant 
expression of specific cytokines and neurotrophic factors, are important determinants of 
whether neuroinflammation will be beneficial or detrimental. The time period after SCI 
may be another criterion, and there are data to support the suggestion that although the 
very early phase of neuroinflammation after SCI may be undesirable, at later times after 
injury it may have a useful role to play (Bethea, 2000). Klusman and Schwab (1997) 
noted that a mixture of IL-1ß, IL-6 and TNF-α delivered into the spinal cord 1 day after 
SCI exacerbated the injury-induced inflammatory reaction but it reduced tissue loss if the 
cytokine treatment was delivered 4 days after SCI.  Microglia are a pivotal cell type in 
the regulation of the early neuroinflammatory response after SCI and the main source of 
the different type of cytokines produced in the injured spinal cord (Lotan and Schwartz, 
1994; Schwartz and Yoles, 2006).  
 
1.6 Cellular Therapeutic Strategies for Neural Repair 
Cell-based therapeutic approaches are being considered for a number of 
neurological diseases. Remyelination and improvement in action potential conduction has 
been demonstrated following transplantation of oligodendroglial lineage cells 
(Utzchneider et al., 1994; Keirstead et al., 2005; Groves et al., 1993), Schwann cells 
(Honmou et al., 1996), OECs (Barnett et al., 2000; Kato et al., 2000; Franklin et al., 
1996; Imaizumi et al., 2000) and various types of stem cells (Akiyama et al., 2001; 
Akiyama et al., 2002, Brustle et al., 1999; Nistor et al., 2005). Given the success of cell 
transplantation to form functional myelin in animal models, myelin-forming cell 
transplantation has been suggested as a potential repair strategy for demyelinated CNS 
axons (Kocsis, 1999; Groves et al., 1993, Honmou et al., 1996).  
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1.6.1 Transplantation of Oligodendrocytes                                                                 
The studies on oligodendrocyte transplantation have great importance. Recently, 
it has become evident that axonal degeneration and/or SCI induces considerable 
oligodendrocyte apoptosis, thus reducing the number of glial cells that are able to 
remyelinate axons at the lesion site (Warden et al., 2001; Casha et al., 2001). The long 
fiber tracts situated in the white matter of the spinal cord provide an excellent model 
system for the study of migration and remyelination of grafted oligodendrocytes. Wild-
type oligodendrocytes transplanted into the hypomyelinated brain of Shiverer mice were 
able to remyelinate the axons that were left unmyelinated as a result of the Shiverer 
mutation (Lachapelle et al., 1983). It appeared likely that demyelination and 
transplantation enhanced the remyelination capability of host oligodendrocytes but the 
host cells were not able to migrate over as long distances as did the transplanted 
oligodendrocyte progenitor cells (Wolswijk and Noble, 1989). Human oligodendrocyte 
progenitor cells have been shown to myelinate axons in lysolecithin-induced 
demyelinated lesions of the adult mouse brain (Windrem et al., 2002). LacZ-expressing 
oligodendrocyte progenitor cells obtained from rat optic nerve cell cultures and 
transplanted directly into an x-irradiated EtBr lesion remyelinated approximately 90% of 
the axons by 21 days after transplantation, which indicated the transplanted LacZ-
expressiong progenitor cells were able to differentiate into myelinating oligodendrocytes 
(Groves et al., 1993).  Remyelination of axons in an x-irradiated EtBr lesion can also be 
achieved using oligodendrocyte cell lines such as the CG4 cell line (Franklin et al. 1995). 
Transplanted CG4 cells were able to migrate within x-irradiated areas of the adult rat 
spinal cord and they could enter and contribute to the repair of areas of demyelination 
remotely located with respect to the point of transplantation. However, the transplanted 
CG4 cells failed to survive and did not migrate when transplanted into the spinal cord of 
control (i.e. no x-irradiation or EtBr injection) adult rats (Franklin et al., 1996). It is likely 
that oligodendrocyte progenitor cells would be the most suitable for cell transplantation 
for the repair of CNS demyelination in diseases such as MS, but because of the 
complexity of getting sufficient numbers of these cells from a therapeutically and 
ethically viable tissue source, these cells have yet to be tested in a clinical trial.  
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1.6.2 Schwann Cell Transplantation 
Schwann cells from peripheral nerves have been used for transplantation into a 
variety of SCI models. After transection and implantation of Schwann cells, sensory and 
spinal axons whose cell bodies are located near the grafts and the site of injury grow into 
these bridging grafts and were myelinated (Xu et al., 1995). After a contusion injury and 
implantation of Schwann cells in adult rats, cavitation is reduced and spinal axons grow 
into the grafts, with many of these axons being remyelinated (Takami et al. 2002). After 
thoracic spinal cord transection in adult rats the transplantation of Schwann cells with 
concomitant delivery of neurotrophins enhances axon regeneration (Menei et al., 1998;   
Xu et al., 1995). The accessibility of Schwann cells from a patient’s peripheral nerves for 
setting up cell cultures to obtain a sufficient number of cells for grafting makes autograft 
transplantation feasible, which in turn means there would be no need for 
immunosupressive procedures if Schwann cells from this tissue source were used. 
However, it is also known that Schwann cells migrate into areas of CNS injury and 
remyelinate axons only in the absence of astrocytes from the injury site (Franklin and 
Blakemore, 1993; Woodruff and Franklin, 1999).   
 
1.6.3 OEC Transplantation  
Embryonic or adult OECs (porcine, primate and human) obtained from the OB or 
olfactory mucosa have been tested in rodent and non-human primate models of SCI or 
demyelination (Barnett et al., 2000; Kato et al., 2000; Imaizumi et al., 2000) (see section 
1.2.3). Functional recovery and/or CNS axon regeneration has been reported when OECs 
are transplanted immediately or as long as 2 months after SCI in adult rats (Li et al., 
1997; Li et al., 1998; Li et al., 2003; Lu et al., 2001; Lu et al., 2003; Ramon-Cueto et al., 
2000; Sasaki et al., 2006). After lateral cervical hemisection in adult rats, injection of 
OECs led to improvements in respiratory function and enhanced their performance on a 
climbing task (Li et al., 2003). It was suggested these OEC transplants might also have 
prevented injury-induced loss of neural tissue (Sasaki et al., 2006; Ruitenberg et al., 
2005) and also appeared to have resulted in enhancement of the remyelination after SCI 
(Sasaki et al., 2004), although whether OECs directly remyelinated these regenerated 
axons or provided an environment conducive for the ingrowth of host remyelinating 
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Schwann cells is controversial (Boyd et al., 2005). The general consensus is that OEC 
grafts facilitate neural repair, although the mechanisms through which this is 
accomplished are under debate (Boyd et al., 2005; Ramon-Cueto et al., 1998).  Important 
issues that remain to be resolved include the optimal source of cells (lamina propria 
versus OB), age of the animal for obtaining the cells (embryonic versus adult) and the 
graft strategy (for example, injection of suspensions or transfer within a cellular matrix). 
It will also be important to determine whether enriching cultures for specific phenotypes 
of OECs improves the structural and/or functional recovery (Li et al., 2003; Boyd et al., 
2005; Lakatos et al., 2003). 
 
1.6.4 Transplantation of Neuronal Stem Cells (NSCs) 
After spinal cord transection in adult rats and transplantation of neural stem cells 
(NSCs) into the lesion site, a small number of host axons regenerated into the transplant 
but their growth terminated near the host transplant border (Bregman et al., 1997; 
Jakeman et al., 1991). A small but significant degree of functional recovery was observed 
in rats (Kunkel-Bagden and Bregman 1990) and cats (Reier et al., 1992) who had 
received such grafts. Mouse clonal NSCs that were injected into the brain ventricles of 
newborn Shiverer mice have also been shown to myelinate axons and result in improved 
function in the mutant strain (Yandava et al., 1999). In the latter study, it was found that 
most of the transplanted cells migrated through the brain and differentiated into 
oligodendrocytes. The injection of NSCs derived from wild type mice and injected either 
intravenously or into the cerebral ventricles of EAE mice resulted in a remarkable 
increase in the number of oligodendrocyte progenitors within demyelinated areas as well 
as of functional recovery in the mice receiving such transplants, along with a significant 
decrease in the extent of axonal loss (Pluchino et al., 2003).  
Grafting of human NSCs into a demyelinated area of adult rat spinal cord showed 
extensive remyelination with a peripheral myelin pattern similar to that seen when 
Schwann cells remyelinate axons, characterized by large cytoplasmic and nuclear 
regions, a basal lamina, and P0 immunoreactivity; there was also an improvement of 
conduction velocities of the remyelinated axons (Akiyama et al., 2001). When mouse 
NSCs were transplanted into the embryonic and neonatal CNS of wild-type mice, they 
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differentiated into both neurons (Brustle et al., 1995; Stemple and Anderson, 1992) and 
oligodendrocytes (Hammang et al., 1997; Milward et al., 2000) but when grafted into the 
adult CNS they only differentiated into astrocytes (Lundberg and Bjorklund, 1996). 
Therefore, the differentiation of NSCs following grafting is indeed dependent on 
environmental signals. Grafts might also provide growth factors or improve conduction in 
spared axons (Reier et al., 1994; Bregman et al., 2002). When fetal spinal cord 
transplants  are combined with neurotrophin delivery after complete spinal cord 
transection in adult rats, recovery of function was observed (Coumans et al., 2001), with 
some supraspinal and propriospinal axons growing into the caudal spinal cord (Bregman 
et al., 2002).  
The best current tissue source for human NSCs is considered to be fetal tissue. 
However, a major concern in future clincal applications would be along the line of ethical 
issues with respect to using fetal tissue as a source for the cells. The other important issue 
that needs to be resolved is the highly proliferative nature of the progeny of stem cells, a 
feature that may contribute to the formation of tumors (Bjorklund et al., 2002).  
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CHAPTER 2.0  Specific Aims 
In recent years, a number of studies have examined the potential beneficial effect 
of transplantation of OECs into, or adjacent to, a SCI in rats (Barnett and Chang, 2004; 
Coumans et al., 2001; Deumens et al., 2005; Koopmans et al., 2005; Li et al., 2005; Nash 
et al., 2002; Sasaki et al., 2004). Some of these studies have reported improvements in 
motor and sensory function (Chuah et al., 2004; Imaizumi et al., 2000; Nash et al., 2002, 
Raisman, 2001, Ramon-Cueto et al., 2000, Woodhouse et al., 2005). While these data 
provide support for the suggestion that OEC transplantation can be beneficial for neural 
repair after SCI, more experiments are needed in order to better understand the signals 
that induce transplanted OECs to migrate towards sites of injury. Although it has been 
reported that OECs possess the ability to migrate within the adult mammalian CNS in 
animal models of SCI (Li et al., 1998; Ramon-Cueto and Nieto-Sampedro, 1994; Ramon-
Cueto et al., 1998), there has been no systematic examination of the factors inducing or 
guiding this migration. Migration of the OECs that accompany the axons that are 
regenerating is thought to be critical to promoting axonal growth. However, little is 
known about the extracellular and intracellular factors that regulate the migration of 
OECs. The migratory signals coming from a lesion and along the migratory path may 
participate in various aspects of neural repair. Microglia, which respond to CNS trauma 
both at the site of injury and along the length of degenerating fiber tracts, are 
extraordinarily sensitive to microenvironmental changes within the CNS, thus making 
them ideally suited to playing an important role in directing the repair of neural tissue. 
My Ph.D. research project concentrated on the potential contribution of reactive 
microglia to the generation of a migratory signal for OECs by applying different injury 
paradigms to activate the microglia in different ways and in different fiber tracts within 
the white matter of the spinal cord, and to assess the effect of these experimental 
manipulations on the migration of OECs.  There were four specific aims: 
 
Specific Aim # 1 To determine the time-frame in which Wallerian degeneration 
induced glial reactivity occurs in the lower thoracic spinal cord of 
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adult rats following aspiration of the contralateral sensorimotor 
cortex. (Addressed in Chapter 4) 
 
Specific Aim # 2 To determine whether OECs are induced to migrate in response to 
glial reactivity arising as a result of Wallerian degeneration 
following sensorimotor cortex aspiration in adult rats and whether 
the migratory signal(s) is dependent on microglial reactivity. 
(Addressed in Chapter 4). 
 
Specific Aim # 3 To identify concentrations of TNF-α that when injected into the 
posterior funiculus of the T11 spinal cord segment of an adult rat 
will induce glial reactivity either along at least a 5 mm distance 
from the injection site or confined to the immediate vicinity of the 
injection site. (Addressed in Chapter 5) 
 
Specific Aim # 4 To examine whether a focal injection of TNF-α gives rise to a 
migratory signal(s) that induces OECs to migrate and whether this 
migration occurs only if reactive microglia are present along the 





CHAPTER 3.0      MATERIALS AND METHODS 
3.1  OEC Cultures 
3.1.1  Tissue Dissection 
On day 18 (E18) of pregnancy female Wistar rats were killed by CO2 inhalation, 
using sterile techniques the abdomen was opened, and the uterine horns were removed 
and placed into a 100 ml Petri dish containing Hank’s balanced salt solution (HBSS). 
Embryos that were at Theiler stage 23 of development (Theiler, 1972) were selected for 
further dissection.  Four phenotypic features were used to assign embryos to Theiler stage 
23: A) the presence of hair follicles over all the skin of the embryos; B) the complete 
separation and divergence of the digit in both the forelimbs and the hind limbs; C) an ear 
pinna that covered more than half of the external auditory meatus; and D) the presence of 
an umbilical hernia.  Under a dissecting microscope, the Theiler stage 23 embryos were 
decapitated, their heads transferred to a 1:1 mixture of Dulbecco’s Modified Eagle’s 
Medium (DMEM; 4.5 g/l of glucose; Sigma-Aldrich Canada Ltd.) and F12 containing 
10% fetal bovine serum (FBS; Hyclone, Logan, UT). 
The OBs were dissected from the heads of each Theiler stage 23 rat embryo using 
the technique described by Doucette (2001). The details are as follows.  One at a time the 
heads were dissected inside a 60 mm Petri dish containing growth medium 
(DMEM/F12/10%FBS). Under a dissecting microscope, a pair of Dumont forceps was 
used to position each head upright by inserting the prongs of the forceps into the tissue 
lying to either side of the nose. Using a pair of spring scissors the cranium was cut along 
the midline between the right and left cerebral hemispheres, with the cut continuing 
caudally along the midline overlying the cerebellum. Using a #11 scalpel blade a 
midsagittal cut was then gently made through the thickness of the head to separate it into 
right and left halves. The exposed OBs were dissected out of their position in the anterior 
cranial fossa by cutting the olfactory peduncle. The OBs were collected in growth 
medium in a 60 mm Petri dish. The remainder of the head was then discarded. This 
procedure was then repeated for each head (Fig 3.1). 
FIGURE 3.1: Dissection of embryos and setting up cell culture.
(A) The head of a rat embryo (E18) prior to beginning the dissection to obtain the OBs
for setting up the OEC cultures.  The view is from the superior surface, with the nose to
the right side of the image.  (B) The left-hand side of this embryo’s head as seen after
cutting the head in two by means of a midsagital cut.  The circle shows the location of
the OBs, which is dissected from both the left and right sides of the head.  (C) A phase
contrast micrograph of an OEC culture initiated from the nerve fiber layer that is
stripped off the OBs dissected in the previous step.  Scale bar in ‘C’ = 100 µm.
OECs
Midsagital Section of Head Embryos
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3.1.2 Tissue Disaggregation and Expansion of Cell Cultures 
Two pairs of sharp forceps were used to dissect the ONL off the OB.  The prongs 
of one pair of forceps were placed in the tissue in the cut end of the OB in the area that 
previously had been attached to the olfactory peduncle. The second pair of forceps were 
used to grasp the free edge of the ONL at the cut end of the bulb; the ONL was then 
gently peeled off the deeper layers of the bulb. The ONLs were pooled together in growth 
medium (DMEM/F12/10%FBS) in a 35 mm Petri dish. 
Once all the ONLs were dissected they were mechanically disaggregated using 
Nitex mesh (75µm pore size). The resulting cell suspension was diluted with 
DMEM/F12/10% FBS to a final volume of 40 ml. This cell suspension was plated into a 
total of eight 25 cm2 Falcon tissue culture flasks by placing 5 ml of cell suspension into 
each flask.  The cells from these flasks were used for DiI (1, 1’, di-octadecyl-3, 3, 3’3’-
tetramethylindocarbocyanine perchlorate) labeling and cell grafting. For immuno-
staining, 2 ml of the cell suspension were plated into each of at least ten 35 mm Falcon 
dishes containing glass coverslips; the remainder of the cell suspension was plated into 
25 cm2 Falcon tissue culture flasks (5 ml per flask). All cell cultures were incubated at 
37°C in a humidified atmosphere of 5% CO2 in air.    
After 3-4 days in vitro, the cell cultures in the flasks were switched to a modified 
G5 medium (mG5). The basal medium of mG5 consisted of DMEM (4.5 g/l of glucose), 
to which was added insulin (5 mg/ml), transferrin (50mg/ml), selenium (5.2ng/ml), 
hydrocortisone (3.63ng/ml), and biotin (10ng/ml); this growth medium was referred to as 
mG5 because in contrast to the G5 medium it contained neither epidermal growth factor 
nor fibroblast growth factor. In fact, this serum-free and mitogen-free growth medium is 
not a suitable medium for any contaminating meningeal fibroblasts that may have been 
carried into the primary cell culture along with the OECs. After 10-14 days in mG5, the 
growth medium was changed back to DMEM/F12/10% FBS and the cell cultures were 
fed with this medium twice per week until they approached confluence. 
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 3.1.3 Harvesting and Long Term Storage of OECs 
Once the cell cultures were approximately 80% confluent, the following 
harvesting procedure was used. The cell cultures were washed three times with Puck’s 
balanced salt solution (PBSS) to remove all traces of serum. Then they were incubated in 
0.025% trypsin/0.01% ethylenediaminetetraacetic (EDTA)/PBSS for 5 min at room 
temperature. The progress of the trypsinization was monitored with a phase contrast 
microscope. The flasks were gently tapped on the countertop several times to accelerate 
cell detachment from the substratum. Also, the trypsin solution was triturated to assist in 
dislodging the cells. The resulting cell suspension was transferred to a 50 ml sterile 
plastic centrifuge tube and was centrifuged at the centrifugal force of 160G (800 RPM) 
for 10 min and then resuspended in DMEM/F12/10% FBS. In order to determine the 
number of viable cells, 100µl of 0.3% Nigrosin dye was added to 400µl of cell 
suspension.  With this technique, dead or dying cells are stained purple-black by the 
Nigrosin dye due to the leakiness of their plasma membranes, whereas living (i.e. viable) 
cells are left unstained. The number of viable (i.e. Nigrosin-excluding) cells was counted 
in four corners of an Improved Neubauerlevy Hemacytometer (Hausser Scientific 
Partnership, Horsham, PA, 19044). The number of viable cells per ml was calculated 
based on the following formula: 
Total # Viable Cells  X  10  X  1000  X  5 = number of viable cells/ml. 
4         4 
 
Based on the viable cell count, the original trypsinized cell suspension was diluted 
in DMEM/F12/10% FBS to the desired cell concentration of 1 x 106 cells per ml.   
 
3.1.4 Prelabelling Cells with DiI 
In order to label OECS with DiI, which is a fluorescent dye that becomes 
incorporated into the plasma membrane, the cells were harvested and viable cell counts 
done as described in Section 3.1.3. The resulting cell suspension was incubated in 
DMEM/F12/10% FBS containing 40 µg/ml of DiI for 1 hour at 37 °C in a humidified 
atmosphere of 5% CO2 in air. Then the cell suspension was centrifuged at 160G (800 
RPM) for 10 min and resuspended in DMEM/F12/10% FBS. After a second 
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centrifugation and resuspension in DMEM/F12/10% FBS, a cell count was performed to 
determine the number of viable cells that had survived the DiI prelabelling and the cell 
suspension was diluted once more to a viable cell count of 1 x 106 cells per ml.  This cell 
suspension was frozen in 1 ml aliquots using Nalgene cryovials (1 x 106 cells per ml) 
with 110 µl of dimethyl sulfoxide (DMSO) being added to each vial prior to sealing them 
and placing them into a NALGENE Cryo 1°C Freezing Container (Nalge Company, 
Rochester, N.Y., USA) containing isopropyl alcohol. The NALGENE Cryo Container 
was stored overnight in a -80°C freezer. The next day, the cryovials were transferred to 
the vapor phase of liquid nitrogen in a Locator (JR Plus, Cryo Biological Storage System) 
for long term storage. 
 
3.2 Surgery  
 All surgical procedures were performed using aseptic techniques. All 
experimental protocols in this research work were approved by the animal care 
committee of the University of Saskatchewan in accordance with policies established in 
the Guide to the Care and Use of Experimental Animals prepared by the Canadian 
Council of Animal Care. Rats were housed in conventional cages on a 12:12 hr light-dark 
cycle and had free access to food and water throughout the period of study.  
 
3.2.1 Anesthesia and Analgesia 
  Female Wistar rats (3-4 months old) weighing 220-260 grams (U of S Laboratory 
Animal Service Unit) were anesthetized by inhalation of Halothane (MTC 
Pharmaceuticals, Ontario, Canada). A mixture of 3% halothane in 100% oxygen was 
applied by using a Boyle anesthetic machine (Ohmeda, Mississauga, ON) to induce 
anesthesia. After approximately 5 min the animal became immobile and unresponsive to 
a pinch test on their hind paws (pedal reflex). To minimize animal pain and distress a 
single intramuscular injection of Buprenex (0.05 mg/kg) was administered prior to 
making a skin incision along the midline of the rat’s back. The concentration of 3% 
Halothane was maintained during the initial parts of the surgery and laminectomy. The 
Halothane concentration was reduced, however, to 2-2.5% during cell grafting and 
cytokine injection. When suturing the wound, the concentration of Halothane used was 1-
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1.5%. Throughout the surgery, each animal was carefully monitored (every 3-5 min) for 
both physiological parameters and analgesia, including their respiration, heart rate, pedal 
reflexes, and the color of their paws (pink in color).  
 
3.2.2 Laminectomy 
A rectangular area of the skin (5 x 2 cm) was shaved on the back of each rat and 
sterilized with a 1:1 mixture of Betadine antiseptic solution (10% provide-iodine topical 
solution UPS) and 70% ethanol. A midline incision was made using a #23 Almedic 
stainless steel scalpel blade and the paravertebral muscles attached to each side of the 
vertebral column were reflected from the spinous processes. A laminectomy was 
performed on the T8 and T9 vertebrae in order to expose the thoracic spinal cord 
segments (i.e. T11 or T12) under visual guidance using a surgical microscope (Nikon-
SMZ-1B) until only a very thin layer of bone remained.  A small hole was then drilled in 
this thin layer of bone using a dental drill to expose the dura matter. Under higher 
magnification and with the aid of a surgical microscope the exposed dura matter was cut 
longitudinally by traversing the surface of the dura with the tip of a 22-gauge needle, a 
procedure that resulted in the leakage of a small amount of CSF. The T8 spinous process 
was rigidly clamped using forceps to fix the vertebral column, and hence the spinal cord, 
in position and prevent the slight movement that might occur, for example, during 
respiration. 
 
3.2.3 Grafting DiI-Labeled OECs   
The Cryovials containing DiI-labeled OECs were removed from storage in the 
liquid nitrogen locator and transferred to a bath of lukewarm water to thaw the cells. In 
order to dilute the DMSO, the 1.1 ml of thawed cell suspension was then gradually added 
to 5 ml of growth medium (DMEM-F12/10%FBS) in a 15 ml Falcon centrifuge tube. The 
cell suspension was centrifuged at 160G twice (10 min each), followed each time by 
resuspension in growth medium. Following the last wash in growth medium, a viable cell 
count was done (see Section 3.1.3) and the cell density adjusted to 50,000 cells/µl using a 
grafting solution containing 1µg/ml of CaCl2, 1µg/ml of MgCl2, and 0.1% glucose in 
0.1M PBS. The cell viability after thawing averaged 74.5% (Table 3.1).  A total of 5µl of  
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Table 3.1 Viability of Thawed OECs Used for Cell Grafting 
 
Cell Culture # # of Viable 
Cells  Frozen 
# of Viable Cells After 
        Thawing 
% Viability After 
       Thawing 
K586 1,000,000 750,000 75.0 
K586 1,000,000 820,000 82.0 
K586 1,000,000 820,000 82.0 
K586 1,000,000 740,000 74.0 
K586 1,000,000 720,000 72.0 
K577 1,000,000 710,000 71.0 
K577 1,000,000 700,000 70.0 
K577 1,000,000 740,000 74.0 
K577 1,000,000 770,000 77.0 
K594 1,000,000 660,000 66.0 
K594 1,000,000 710,000 71.0 
K56-13 1,000,000 650,000 65.0 
K56-13 1,000,000 770,000 77.0 
K56-13 1,000,000 810,000 81.0 
K56-13 1,000,000 800,000 80.0 
 Average = 744,666.7 74.5 
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this cell suspension was loaded into a 32 Gauge needle attached to a 5 µl Hamilton 
syringe. After zeroing the XYZ coordinates of the stereotaxic apparatus, the 32 Gauge 
needle was slowly lowered into the right dorsal funiculus of the spinal cord to a depth of 
1 mm; the needle was inserted immediately to the right of the dorsal spinal artery. The 
needle was left in position for 2 min after which time 1 µl of DiI-labeled OECs was 
injected over 10 min with a flowrate of 0.01µl/min using the KDS 310 syringe pump. 
After completion of the injection, the needle was left in position in the spinal cord for 5 
min prior to being slowly withdrawn. The syringe and needle were rinsed with dH2O, 
followed by two washes with acetone, and a few final rinses with dH2O at the completion 
of the cell grafting. 
 
3.2.4 Wound Closure and Postoperative Care 
Using Ethicon 4-0 surgical silk, the dorsal spinal muscles were sutured along the 
spine. For antiseptic purposes, the surgical area was washed with a 3% solution of 
hydrogen peroxide (diluted in dH2O). Then the skin wound was sutured with 3-4 silk 
sutures and betadine solution diluted 1:1 with 70% ethanol was applied to the wound to 
prevent infection. A 2% Xylocaine local anesthetic gel was applied on top of the sutured 
skin wound (Lidocaine Hydrochloride Jelly, USP Sterile Topical Anesthetic, Astra 
Pharma Inc., ON, Canada).   
During the first hour postoperatively the animal was monitored every 5 min for 
their respiration rate and for the color of their paws. Each rat was kept on a heated 
blanket for the first 15-30 min and then was transferred to their own cage once they 
started to move and once their respiration and paw color were normal. The rats were then 
checked every hour post-surgically for the next three hours and also the following 
morning to ensure they were drinking water and eating food. Subsequently, each rat was 
checked daily with particular attention being paid to the sutures and to the healing of the 
wound. None of the rats had any problem with the sutures and there were no 
complications with postoperative healing of the wounds, which typically occurred within 
2-3 weeks. The postoperative scar was covered with new hairs by 4 weeks after the 
surgery. The rats were also checked for their general behavioral status including their 
mobility, alertness, and their food and water consumption. No noticeable mobility 
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problems were observed in any of the rats, including sensorimotor cortex aspirated and 
TNF-α injected animals, as a result of the surgical manipulations. Also, their activities 
and behaviors appeared to be normal. 
 
3.3 Necropsy of Tissue 
3.3.1 Perfusion of the Rats 
The rats were deeply anesthetized by administering a lethal dose (90 mg/kg body 
weight) of sodium pentobarbital (Somnotol) injected intraperitoneally (i.p.). Once the rat 
failed to respond to either a tail or a paw pinch the animal was placed on its back in a 
dissection tray and a surgical cut was made with scissors along the midline of the chest to 
separate the rib cage into right and left halves, thus opening the thoracic cavity. The tip of 
the apex of the left ventricle was cut off with scissors and a large bore (18 gauge) blunt 
needle, which was connected to the tubing of a Variable Flow Tubing Pump (VMP 
Scientific Products, VWR Canlab), was inserted through the apex of the left ventricle and 
up into the ascending aorta. The needle was clamped in place with a pair of hemostat 
forceps. Using a pair of small sharp tipped scissors a slit was made in the right atrium to 
allow the blood and fixative to leave the body during perfusion. Perfusion was begun 
with approximately 300 ml of a 1% solution of sodium nitrite dissolved in 0.03 M PBS 
(pH 7.4) for the purpose of washing out the blood. When the fluid exiting the opening in 
the right atrium was clear, the perfusate was changed to the fixative solution and  
approximately 300 ml of a freshly made cold solution of 4% paraformaldehyde (PF) in 
0.03 M PBS (pH 7.4) was perfused through the circulatory system over a period of 20-30 
min. 
 
3.3.2  Dissection of Brain and Spinal Cord 
Following completion of the perfusion a #23 scalpel blade was used to make a 
longitudinal cut along the dorsal midline from the skull to the tail base. Using a bone 
rongeur, the spinous processes and vertebral laminae were removed beginning caudally 
and proceeding to the rostral end of the spinal cord. The rongeurs were also used to 
remove the cranium. The spinal cord with its short rootlets as well as the brain were 
gently dissected out, immersed in fresh fixative (4% PF), and stored overnight at 4oC. On 
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the next day, the spinal cord and brain were immersed in a 30% solution of sucrose 
dissolved in 0.03 M PBS (pH 7.4). If the specimens were kept in 30% sucrose for more 
than 2 weeks, then they were transferred to fresh sucrose solution. 
 
3.3.3 Cutting Free-Floating Frozen Tissue Sections  
  The short rootlets that were left attached to the spinal cord during dissection from 
the vertebral column were counted to identify the T11 spinal cord segment; the counting 
began at the cervical rootlets and proceeded caudally. A unilateral (left side) and narrow 
longitudinal cut was performed on the left site of the spinal cord segments using a #11 
scalpel blade prior to cutting the segment out from the spinal cord. The idea was to use 
this longitudinal cut to distinguish the right and left sides of tissue sections used for cell 
counting and for immunohistochemical analysis of glial reactivity. The specimen holder 
of a sliding microtome (American Optical Company, Scientific Instrument Division, 
Buffalo, New York, USA) was kept enclosed within a Styrofoam box containing dry ice  
for approximately 15-20 min prior to application of  Tissue-Tek O.C.T. 4583 compound 
(Sacura Finerek U.S.A., Inc., Torrance, CA 90504 USA) onto its surface. Then the 
specimen (i.e T11 spinal cord segment) was placed onto the specimen holder, covered 
with O.C.T. medium, and covered with dry ice to keep the tissue frozen for sectioning. 
Serial coronal tissue sections (40µm thick) were cut with a sliding microtome and 
collected in groups of 10 sections in the wells (10-12 wells) of a 96 well plate; the 
sections were stored in cryoprotectant (a solution of 0.11 M sodium phosphate monobasic 
and 0.38 M sodium phosphate dibasic in distilled water, containing 3% glycerin and 3% 
ethylene glycol).  The plates were stored at -20 ºC until sections were removed for 
mounting onto slides for cell counting or for immunostaining. 
 
3.4 Immunofluorescent and Immunohistochemical Staining 
3.4.1 Single and Double Labeling of Cell Cultures 
To assess the phenotype of the cells in the OEC cultures the OECs were grown on 
glass coverslips in 35 mm Petri dishes.  Beginning with the first feed, these cell cultures 
were fed with mG5 medium for 10-14 days, following which they were fed with 
DMEM/F12/10%FBS for an additional 2-3 weeks.  The cell cultures were then 
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immunostained with a select set of antibodies (see below) to determine the phenotype of 
the cells.  
The following protocol was used for single immunostaining of intracellular 
antigens expressed by the OECs.  The cells were first fixed for 15 min at room 
temperature in either 0.2% picric acid and 4% paraformaldehyde in 0.2M phosphate 
buffer, pH 7.4 (Zamboni’s fixative) or 0.2% picric acid/4% paraformaldehyde/0.05% 
glutaraldehyde (PPG; in 0.2 M phosphate buffer, pH 7.4).  The PPG fixative was used 
when the cells were to be immunostained with the rabbit polyclonal anti-S100; 
Zamboni’s fixative was used for immunostaining with monoclonal mouse anti-nestin and 
mouse anti-smooth muscle alpha actin (SMA). Fixation was followed by two rinses in 
0.03M PBS (30 sec each at room temperature), followed by a third PBS wash for 30 min 
at 4°C and a fourth PBS rinse for 1 min at room temperature. The next step was to 
permeabilize the cell membrane by incubation of the cells in 0.2% triton X-100 (TX-100) 
diluted in 0.03M PBS for 5 min, which was followed by a 10 min rinse in PBS.  The cells 
were then incubated for 10 min in a blocking solution of 2% skim milk powder (SMP) 
dissolved in 0.2% TX-100 followed by a 30 min incubation at room temperature in a 
mixture of mouse anti-nestin (1:100, clone Rat 401, Developmental Studies Hybridoma 
Bank, Deptartment of Biological Sciences, University of Iowa, Iowa City, IA, USA) and 
rabbit anti-S100 (1:200, Dimension Labs, Dako A/S, Denmark) antibodies. These 
primary antibodies were diluted in 1% SMP/0.2% TX-100 in 0.03 M PBS.  Control 
sections were incubated in diluent only.  The cells were then rinsed in 0.03 M PBS for 10 
min after which they were incubated in a cocktail mixture of secondary antibodies for 30 
min at room temperature; the secondary antibodies used were swine anti-rabbit IgG FITC 
(1:100, Dimension Labs, Dako A/S, Denmark) and goat anti-mouse IgG Texas Red 
(1:100, Bio/Can Scientific, Misissauga, ON, Canada).  At the end of this incubation 
period in the secondary antibodies, the coverslips were rinsed in 0.03 M PBS for 5 min. 
Following this rinse, the cells were incubated in a Hoechst solution (1µM) for 15 min at 
room temperature to stain the cell nuclei. The cells were then given a final rinse in 0.03 
M PBS for 5 min, the coverslips were mounted onto slides using Citifluor (Marivac Ltd, 
Halifax, NS, Canada) mounting medium (a Glycerol/PBS solution), and the edges of the 
coverslips were sealed with clear nail polish. Controls for the specificity of the secondary 
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antibodies (by omitting the primary antibodies) yielded no specific immunofluorescence 
staining in any of the cell cultures.   
The following protocol was used for single immunostaining of cell surface 
antigens expressed by OECs.  The cells were first incubated for 5 min at room 
temperature in DMEM medium containing 5% horse serum (HS) and 15 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The cells were then incubated 
for one hour in rabbit anti mouse p75 NGFR (1:100, Chemicon International Inc., 
Temecula, CA 92590, USA) diluted in DMEM/5% HS/15 mM HEPES. The control 
sections were incubated in diluent only.  Dulbecco’s phosphate buffered saline (DPBS) 
was used as a rinse solution after incubation in the primary antibody; the coverslips were 
rinsed four times (5 min each at 4°C) in DPBS, which contained 2.68 mM potassium 
chloride, 1.47 mM potassium dihydrophosphate, 0.14 M sodium chloride, 8.1 mM di-
sodium hydrophosphate, 0.49 mM magnesium chloride and 1.19 mM calcium chloride 
dissolved in distilled water.  The cells were then fixed by immersion in Zamboni’s 
fixative (0.2% picric acid/4% PF in 0.2 M phosphate buffer, pH 7.4) for 15 min at room 
temperature. Then the coverslips were washed three times in DPBS (30 sec each at room 
temperature), followed by a fourth wash in DPBS for 1 min. A swine anti-rabbit FITC-
conjugated secondary antiserum (1:100, Dimension Labs, Dako A/S, Denmark) was 
applied to the coverslips for 30 min at room temperature. There then followed four rinses 
in DPBS over a 20 min time period (5 min each at 4 °C).  After the final rinse, the cells 
were incubated in a Hoechst solution (2 µg/ml) for 15 min at room temperature to stain 
the cell nuclei. The cells were rinsed 4 additional times in DPBS (5 min each), after 
which the coverslips were mounted onto slides using Citifluor mounting medium 
(Marivac Ltd, Halifax, NS, Canada).  
The following protocol was used for double immunostaining of an intracellular 
protein (nestin) and a cell surface protein (p75) expressed by OECs. The cells were first 
incubated for 5 min at room temperature in DMEM medium containing 5% HS and 15 
mM HEPES. The cells were then incubated for one hour in rabbit anti mouse p75 NGFR 
(1:100, Chemicon International Inc., Temecula, CA 92590, USA) diluted in 
DMEM/5%/HS/15 mM HEPES. The control sections were incubated in diluent only.  
DPBS was used as a rinse solution after incubation in the primary antibody; the 
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coverslips were rinsed four times (5 min each at 4°C) in DPBS, as described in the 
previous paragraph. The cells were then fixed by immersion in Zamboni’s fixative (see 
above) for 15 min at room temperature. Then the coverslips were washed three times in 
DPBS (30 sec each at room temperature), followed by a fourth wash in DPBS for 1 min. 
The cells were then incubated for 15 min in a solution of 0.2% TX-100, 5% HS and 0.1% 
BSA in 0.03M PBS (pH 7.4). The next step was to permeabilize the cell membrane by 
incubation of the cells in a solution of 0.2% TX-100, 5% HS and 0.1% bovine serum 
albumen (BSA) in 0.03 M PBS (Ph 7.4). A 30 min incubation in the mouse anti-nestin 
(1:100, Clone Rat 401, Developmental Studies Hybridoma Bank, Department of 
Biological Sciences, The University of Iowa, Iowa City, IA, USA) monoclonal antibody 
followed immediately after the TX-100 incubation.  DPBS was used as a rinse solution 
after incubation in this primary antibody; the coverslips were rinsed four times (5 min 
each at 4°C) in DPBS.  The cells were then incubated in a cocktail mixture of secondary 
antibodies for 30 min at room temperature; the secondary antibodies used were swine 
anti-rabbit IgG FITC (1:100, Dimension Labs, Dako A/S, Denmark) and goat anti-mouse 
IgG Texas Red (1:100, Bio/Can Scientific, Mississauga, ON, Canada). There then 
followed four rinses in DPBS over a 20 min time period (5 min each at 4 °C).  After the 
final rinse, the cells were incubated in a Hoechst solution (2 µg/ml) for 15 min at room 
temperature to stain the cell nuclei. The cells were rinsed 4 additional times in DPBS (5 
min each), after which the coverslips were mounted onto slides using Citifluor mounting 
medium (Marivac Ltd, Halifax, NS, Canada).  
The following protocol was used for immunostaining of SMA, which is an 
intracellular protein that is expressed by OECs. The Zamboni-fixed cells were first 
incubated for 10 min at room temperature in a solution of proteinase K (0.05 mg/ml) in 
0.1M TBS. The cells were then incubated for 1 hour in a blocking solution of 2% SMP 
diluted in 0.1M TBS plus 0.25% TX-100 for 1 hour at room temperature. After a rinse 
(10 min) with 0.1M TBS, the cells were incubated with mouse anti-SMA (1:1000) 
monoclonal antibody for 48 hours at room temperature. The cultures were then rinsed in 
0.1M TBS (30 min) and incubated in an FITC-conjugated donkey anti mouse IgG (1:50; 
Medicorp, Montreal, QC, Canada) for 2 hours at room temperature in the dark. After the 
final rinse (10 min), the cells were incubated in a Hoechst solution (2 µg/ml) for 15 min 
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at room temperature to stain the cell nuclei. The cells were rinsed 1 additional time in 
0.1M TBS (5 min), after which the coverslips were mounted onto slides using Citifluor 
mounting medium (Marivac Ltd, Halifax, NS, Canada) 
The following protocol was used for immunostaining of calponin, which is an 
intracellular protein that is expressed by OECs. The Zamboni-fixed cells were first 
incubated for 10 min at room temperature in a solution of proteinase K (0.05 mg/ml) in 
0.1M PBS. The cells were then incubated for 15 min in a blocking solution of 0.2% TX 
100/5% HS/0.1% BSA at room temperature. After a rinse (10 min) with 0.03M PBS the 
cells were incubated with mouse anti-calponin (1:100 diluted in 0.2% TX 100/5% HS) 
monoclonal antibody for 1 hour at room temperature. The cells were then rinsed in 0.03M 
PBS (10 min) and then incubated in an FITC-conjugated goat anti-mouse IgG (1:100, 
Dimension Labs, Dako A/S, Denmark) for 30 min at room temperature in the dark.  After 
a final rinse (10 min) in 0.03M PBS, the cells were incubated in a Hoechst solution (2 
µg/ml) for 15 min at room temperature to stain the cell nuclei. The cells were rinsed 1 
additional time in 0.03M PBS (5 min), after which the coverslips were mounted onto 
slides using Citifluor mounting medium (Marivac Ltd, Halifax, NS, Canada) (Fig 3.2). 
 
3.4.2 Immunohistochemical Staining of Tissue Sections 
The OX42 antibody recognizes complement receptor type 3 (CR3) on the surface 
of resting and phagocytic microglia (Kaur & Ling, 1992; Perry et al., 1993; Mander and 
Morris, 1995; Streit et al., 2004). In the normal CNS, resident (ramified) microglia 
constitutively express the CR3 receptor (Perry et al., 1993; Mander and Morris, 1995; 
Streit et al., 2004).  In contrast to that of OX42 expression, many studies have shown that 
the MHC class I antigen, which is recognized by the OX18 antibody, is absent or present 
only at low levels in parenchymal microglia of normal spinal cord tissue (Ling et al., 
1991, 1992; Mander and Morris, 1995; Streit et al., 2004). OX35 recognizes an antigenic 
epitope on the rat CD4 antigen (Brostoff and White, 1986; Wang et al., 1996; Wu et al., 
1997), which is expressed by reactive microglia. The ED1 antibody recognizes a 
lysosomal membrane-associated antigenic epitope that is expressed by macrophages 
(Flariz et al., 1993; Graeber et al., 1990).  In the brains of young animals, macrophages in 




FIGURE 3.2: Phenotype of OECs in vitro.
Double immunostaining of OECs in vitro shows their co-expression of S-100 (A) and
nestin (B), and of p75 NGFR (C) and nestin (D).  The OECs are also calponin +ve (E)
and SMA +ve (F). Hoecsht staining of the nucleus (blue) shown in (A-F).  Scale bar in
‘F’ = 50 µm.
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an occasional cell within the young animal brain parenchyma also expresses the ED1 
antogenic epitope. Based on small and heterochromatic nuclei, Perry et al. (1993) 
concluded the ED1+ve cells within the brain parenchyma were microglia.  Microglia in 
adult rats greatly downregulate their expression of the ED1 antigenic epitope, in contrast 
to the developing brain where ED1+ve cells are abundant (Sminia et al., 1987).  A 
striking feature of the aged rat brain is the large number of ED1+ve cells throughout the 
parenchyma, and although the intensity of the immunostaining varies from cell to cell it 
is nevertheless readily detectable (Sminia et al., 1987). Since the ED1 antigenic epitope is 
a cytoplasmic marker and primarily confined to the cell body, immunostaining with the 
ED1 monoclonal antibody does not stain the cell processes. However, the density, 
distribution, and small heterochromatic nuclei of ED1+ve cells strongly suggest they are 
microglia (Perry et al., 1993). 
GFAP is expressed in mature and reactive astrocytes in the CNS of adult 
mammals (Martinez et al., 1998; Pekny and Pekna, 2004).  Following brain or spinal cord 
injury, astrocytes become reactive, change their shape to become more fibrous in 
morphology, and also up-regulate their expression of GFAP (Martinez et al., 1998; 
Raivich et al., 1999). Vim is found in mesoderm-derived cells, including endothelial cells 
and pericytes (Takehana et al., 1992), as well as in neuroectodermal precursors of 
neurons and glial cells (Pixley and Vellis 1984; Schnitzer et al., 1981). In normal spinal 
cord tissue, Vim+ve cells are limited to just the ependymal cells of the central canal, the 
leptomeninges, and an occasional astrocyte (Farooque et al., 1995). Nestin is an 
intermediate filament protein expressed in dividing cells during the early stages of 
development in the CNS (Lendahl et al., 1990). Upon differentiation, nestin expression is 
downregulated and the cells express instead tissue-specific intermediate filament proteins 
(Lendahl et al., 1990; Moky and Nemeck, 1998). Interestingly, nestin expression is 
reinduced in the adult nervous system during pathological situations, such as the 
formation of the glial scar after CNS injury, with reactive astrocytes being the cells that 
re-express this protein (Ernst and Christie, 2006). 
For each rat, tissue sections were chosen from wells corresponding to rostral, 
middle and caudal parts of T11. The chosen tissue sections were briefly rinsed in 0.03 M 
PBS and mounted on subbed coverslips; the subbing solution contained 1% gelatin and 
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0.5% chrome alum dissolved in distilled water. The tissue sections were left to air dry 
and to adhere to the coverslips for approximately 2-3 hours prior to initiating the 
immunostaining. The coverslips were then first washed three times in 0.03 M PBS  (30 
sec each at room temperature), followed by a fourth PBS rinse for 30 min at 4°C. An 
incubation for 30 min in a solution of 3% SMP and 0.1% TX-100 in 0.03 M PBS (pH 
7.4) was then done in order to permeabilize cell membranes and block non-specific 
binding sites. 
Each coverslip was covered with one primary antibody (approximately 500 µl per 
coverslip), with incubation in each antibody being done overnight (16-18 hours) at 4°C.  
The primary antibodies used on the tissue sections were for assessing the presence and 
location of microglial and astrocytic reactivity. These primary antibodies included: 
mouse anti-rat MHC class I (1:9600, Clone OX-18, Secotec, Kidlington Oxford, 
England), mouse anti-CD11b (1:3200, Clone MRC OX-42, Serotec, Kidlington Oxford, 
England), mouse anti-CD4 (1:3000, Clone OX-35, Serotec, Kidlington Oxford, England), 
mouse anti-rat CD68 (ED1) (1:2000, Serotec, Kidlington Oxford, England), mouse anti-
GFAP (1:500, Clone G-A.5, Sigma, St. Louis, MO 63178, USA), mouse anti-vimentin 
(1:1000, Clone V9, Sigma, St. Louis, MO 63178, USA) and mouse anti-nestin (1:2000, 
Clone Rat 401, Developmental Studies Hybridoma Bank, Department of Biological 
Sciences, University of Iowa, Iowa City, IA, USA). All primary antibodies were diluted 
in 0.03 M PBS. The control sections were incubated in diluent only.  
The next morning the tissue sections were rinsed twice in 0.03 M PBS and then 
were incubated in blocking solution (3% SMP/0.1% TX-100 in 0.03 M PBS) for 30 min. 
Horse anti-mouse biotinylated IgG was used as the secondary antiserum (1:150, Vector 
Laboratories, Burlingame, Ca 94010 USA) with the sections being incubated in the 
secondary antibody for 30 min at room temperature. The coverslips were then immersed 
in a 1% solution of hydrogen peroxide (H2O2) in 30% methanol for 15 min to quench 
endogenous peroxidase activity, followed by two rinses in 0.03 M PBS (pH 7.4), and a 30 
min incubation in a 3% solution of SMP in 0.03 M PBS (pH 7.4). The Avidin DH 
(reagent A)/ biotinylated horseradish peroxidase (HRP) H (reagent B) cocktail was made 




as the Vectastain AB reagent (Vector Laboratories, Inc., Burlingame, CA 94010 USA) 
and was made at least 30 min prior to being used. Then the sections were covered with 
this Vectastain AB reagent for one hour at room temperature.   The sections were then 
washed two times in 0.03 M PBS (pH 7.4) followed by a rinse in 0.175 M sodium acetate 
(pH 6.8) for 10 min. A solution of 0.0185 M diaminobenzidine tetrahydrochloride (DAB) 
and 0.1586 M nickel sulfate (NiSO4) in 0.175 M sodium acetate (pH 6.8) was made one 
hour prior to use and kept in the dark until needed.  Immediately prior to use, 63.75 µl of 
a 30% solution of H2O2 was added to each 75 ml volume of 0.0185 M DAB/0.1586 M 
NiSo4 solution, and the sections were then immersed in this DAB/NiSO4/H2O2 solution 
for 5 min in the dark.  The sections were then rinsed once (for 10 min) in 0.175 sodium 
acetate (pH 6.8), rinsed in 0.03 M PBS (pH 7.4) for 10 min, and dehydrated in an 
ascending series of ethanols (70%, 95%, 100%). The sections were cleared in xylene for 
2 min and then mounted onto slides using Shandon xylene substitute mountant (Shandon, 
Pittsburgh, PA15275, USA). 
 
3.5 Data Collection and Statistical Analysis 
3.5.1 Counting DiI-Labeled Cells 
Approximately 120 tissue sections (40 µm thick) were obtained when cutting the 
T11 spinal cord segment from rostral to caudal.  The tissue sections were pooled in 
groups of 10 and stored in cryoprotectant solution in approximately 12 wells of a 96 well 
plate (see Section 3.3.3).  For cell counting, one section was randomly chosen from each 
well, stained with Hoechst dye (2 µg/ml), mounted onto a microscope slide, and 
coverslipped using Citifluor anti-quenching mounting medium (Marivac Ltd, Halifax, 
NS, Canada).  Once mounted, each tissue section was assigned an alphanumeric code by 
a lab technician so that all cell counts could be done blindly. 
For the purpose of the experiments reported in this thesis, tissue sections collected 
into the first four wells were considered to comprise the rostral one-third of T11; sections 
in the second four wells comprised the middle one-third, and the final four wells 
comprised the caudal one-third of T11. Each tissue section was examined to determine 
whether it contained any DiI+ve cells, to identify the specific location in which the cells 
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were found, and to count the total number of DiI+ve cells either within specific fiber 
tracts (see Section 4.2.6) or within the entire dorsal funiculus (see Section 5.2.6). For 
statistical analysis, the mean cell count for each group of 4 sections was computed.  Only 
DiI+ve profiles that were associated with a nucleus were counted.  
 
3.5.2 Reliability of Cell Counts 
Seven 40 µm tissue sections from the T11 spinal cord segment of one rat in each 
of Groups 1 and 2 were randomly picked, stained with Hoechst dye (2 µg/ml), mounted 
onto a microscope slide, and coverslipped using Citifluor (Marivac Ltd, Halifax, NS, 
Canada) anti-quenching mounting medium.  Once mounted, each tissue section was 
assigned an alphanumeric code by a lab technician so that all cell counts could be done 
blindly. The number of DiI+ve cells was counted in four separate quadrants of the white 
matter on the dorsal surface of the T11 spinal cord segment; these quadrants included the 
right corticospinal tract (dCST), left dCST, right dorsal ascending tract (DAT) and left 
DAT.  The cell counts were done twice on each tissue section, with the time between cell 
counts being 10 days apart. The purpose of this study was to determine the repeatability 
of the cell counts. The data were analyzed for statistical significance using a t-test. 
 
3.5.3 Statistical Analysis of Data 
The initial data analysis showed there were differences among the data collected 
from the rostral, middle and caudal portions of each spinal cord segment. Therefore, for 
the statistical analysis of the data they were analyzed separately, rather than pooling the 
data to obtain average cell counts for the entire T11 segment. The T11 cell counts 
collected for Groups 1-10 were statistically compared using a two-factor analysis of 
variance (ANOVA) (Prism software program), with the data for the rostral, middle and 
caudal thirds of the right and left dorsal funiculi of this spinal cord segment being 
analyzed separately for statistical significance (Prism software program). The 
independent variables for the two sets of experiments are listed in Sections 4.2.6 and 
5.2.6.  The significance level was set at p < 0.05. Multiple post hoc comparisons were 
performed with Bonferonni’s multiple comparison post-test (Prism software program) 
with the significance level being set at p < 0.05. 
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CHAPTER 4.0 OEC Migration in Response to Wallerian Degeneration-Induced Glial 
                           Reactivity 
4.1 Introduction 
4.1.1 Wallerian Degeneration 
Waller in 1850 described axon degeneration in transected frog peripheral nerves 
distal to the site of injury, a process that was later referred to as Wallerian degeneration 
(WD). The usual cause of axonal degeneration has diverse underlying etiologies, 
including traumatic, metabolic and inflammatory causes (Raff et al., 2002). Degeneration 
of the distal segments of axons in the PNS is generally followed by their regeneration, 
whereas in the CNS axon regeneration is usually not successful (Franson and Ronnevi, 
1984).  
Nevertheless, there are some similarities in the molecular and cellular pattern of 
WD in the PNS and CNS including the breakdown of the lesioned axons and the 
degradation of the myelin sheaths (Franson and Ronnevi, 1984; George and Griffin, 
1994a).  An early step of WD is granular disintegration of the cytoskeleton (GDC), which 
is an event found in both the CNS and PNS. During GDC, the neurofilaments and 
microtubules of the cytoskeleton are rapidly degraded to granular and amorphous debris 
(Griffin et al., 1992; George and Griffin, 1994b). GDC occurs in both central and 
peripheral nerve fiber tracts between 18 and 72 h after the lesion and progresses away 
from the site of initial injury (George and Griffin, 1994b). GDC occurs mostly as a 
consequence of the activation of proteases such as calpains through an increase in the 
intra-axonal concentration of Ca2+ (Coleman and Perry, 2002; George et al., 1995). In the 
CNS, oligodendrocyte apoptosis is a noticeable event following WD; however, Schwann 
cells survive in the distal segments of lesioned peripheral nerves and form new myelin 
sheaths around the regenerating axons (Stoll and Muller, 1999).  
A rapid invasion of macrophages from the peripheral blood has been reported 
following PNS axonal injury (Shamash et al., 2002). Endogenous endoneurial 
macrophages, and to a lesser extent Schwann cells, are responsible for the rapid 
phagocytosis of the injured axons and their myelin sheaths (Bruck, 1997). In contrast to 
peripheral nerves, invasion of degenerating CNS nerve fiber tracts by macrophages 
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occurs in much lower numbers (Aldskogius and Kozlova, 1998; Stoll and Jander, 1999). 
Instead, endogenous microglia are activated following CNS injury, including 
morphological alteration and the upregulation or de novo expression of several microglial 
activation markers; microglia are responsible for the phagocytosis of the axonal and 
myelin debris (Aldskogius and Kozlova, 1998; Stoll and Jander, 1999). The time course 
of the removal of the degenerated tissue is greatly delayed in the CNS as compared to the 
PNS (Griffin et al., 1992; George and Griffin, 1994). In the rodent, axonal degeneration 
is completed 3 days after nerve section in the PNS and CNS (George and Griffin, 1994). 
Despite this rapid axonal degeneration in both the CNS and PNS, the axonal debris is 
cleared within 14 days in the PNS (George and Griffin, 1994), but axonal debris can still 
be detected in the CNS 90 days post-axotomy (Bignami et al., 1981).  Myelin degradation 
and removal are complete within 25 days in the rat sciatic nerve (Stoll et al., 1989). In the 
CNS, degraded myelin becomes apparent by 4 days after injury but myelin proteins can 
still be detected in the degenerating rat optic nerve up to 90 days after axotomy (Bignami 
and Eng, 1973).  
It appears that macrophages are more important in the later stages of PNS myelin 
removal (Perry et al., 1995). In the CNS there is a significant rise in mononuclear 
phagocytes 2-3 days later than in the PNS, which is primarily due to the proliferation of 
microglia rather than to macrophage recruitment (Lawson et al., 1994). The phagocytic 
activity of microglia could possibly be incompetent or at least less competent than that of 
macrophages, although phagocytic and endocytic related molecules are promptly 
expressed by microglia activated during WD (Lawson et al., 1994).  A small percentage 
of blood borne macrophages are present at the site of transection in the CNS where the 
BBB is disrupted. However, along the length of the degenerating distal part of the fiber 
tract the BBB remains intact (George and Griffin, 1994); in the PNS the blood-nerve 
barrier breaks down within 48 h along the whole length of the degenerating nerve 
(Bouldin et al., 1990). The inefficient breakdown of myelin and the slow removal of 
axonal and myelin debris in the CNS has been attributed to an inadequate response by 
microglia (Lawson et al., 1994), or to differences between oligodendrocytes and Schwann 
cells in terms of their capacity for differentiation and proliferation (Stoll et al., 1989; 
Perry et al., 1995). Shortly after axotomy, Schwann cells in the degenerating sciatic nerve 
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dedifferentiate, proliferate, and secrete molecules such as NGF and BDNF, both of which 
play important roles in the repair process (Martinni et al., 1988; Meyer et al., 1992).  
Schwann cells also actively initiate myelin degradation or phagocytosis during WD in the 
PNS (Stoll et al., 1989). 
Proteolytic enzymes have been implicated in WD at several stages, including 
degradation of the axon itself (Schlaepfer, 1974) and myelin degradation (Hallpike and 
Adams, 1969). Proteolytic activity is elevated as early as 12 h after transection of a 
rodent sciatic nerve and continues to rise during the first week (Hallpike and Adams, 
1969). Axonal neurofilament proteins in transected nerves undergo calcium-activated 
proteolysis (Schaepfer, 1974). Increased proteolytic activity could also facilitate 
macrophage invasion and contribute to the disruption of the blood nerve barrier (Hughes 
et al., 1998). Although proteolytic activity is elevated during WD in the PNS, the 
identities of the enzymes and their physiological roles have only been partially 
determined. The involvement of calpains in axonal degeneration was confirmed using 
cell permeable specific inhibitors, which preserved axons for up to 4 days following 
nerve transection in a DRG explant (George et al., 1995).   
Rho GTPases are a family of highly related proteins best known for their effect on 
the actin cytoskeleton. It was reported (Yamagishi et al., 2005) that Rho, a small GTPase, 
is involved in WD in vitro and in vivo. The breakdown of neurofilaments depends on an 
influx of Ca2+ and the activation of the Ca2+-dependent protease, calpain (Messier and 
Stewart., 1997). Inhibition of the ubiquitin proteosome system delays axon degeneration 
both in vitro and in vivo (Zhai et al., 2003). However, the molecular target of ubiquitin 
proteosome system-mediated proteolysis is unknown. It is noted that Rho-kinase inhibitor 
partially prevents WD.  Rho/Rho-kinase is associated with the inability of CNS neurons 
to regenerate (Tanaka et al., 2004). Inactivation of Rho-kinase by Y-27632 significantly 
promotes the regeneration of corticospinal tract (CST) axons after SCI (Tanaka et al., 
2004).  Thus, Rho/Rho-kinase may play an important role in the pathogenesis of SCI, 
perhaps by delaying the clearance of myelin debris.  
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4.1.2 The Corticospinal Tract  
In rats, the CST is the longest descending axonal pathway in the CNS and is mainly 
involved in skilled motor functions, such as grasping, handling and eating of food 
(Whishaw et al., 1998); it is less involved in simple locomotion (Matz et al., 1998; Muir 
and Whishaw, 1999). The neurons that give rise to the CST are located in layer V of the 
cerebral cortex. Most CST neurons are located in the primary motor cortex and in the 
forelimb and hindlimb parts of the primary somatosensory cortex. Neurons in the 
forelimb area of motor and somatosensory cortex project to the cervical enlargement, 
while those in the hindlimb area project to the lumbar enlargement (Li et al., 1990). CST 
neurons are not restricted to primary motor and somatosensory cortex, but are also found 
in the supplementary motor area and prefrontal cortex (Li et al., 1990; Miller, 1987), as 
well as in the posterior parietal cortex, visual association cortex, and anterior cingulate 
cortex (Miller, 1987). 
Most CST axons (90%-95%) decussate in the caudal medulla in the pyramidal 
decussation (Schreyer and Jones, 1982; reviewed in Joosten and Bar, 1999) and in the rat 
all but a small number of these decussated axons run in the base of the dorsal columns 
(Armand, 1982). A small population of decussated axons descends within the lateral 
funiculus. As found in humans, rats also have a ventral uncrossed CST that descends 
within the ventral funiculus (Brosamle and Schwab, 1997).  In the rat, as the CST axons 
travel through the brainstem they send collaterals to neurons of the red nucleus in the 
midbrain and to the trigeminal nuclei (Killackey et al., 1989). The CST is the last 
descending tract to enter the rat spinal cord white matter during development, doing so 
approximately at postnatal day 1 (Schreyer and Jones, 1982).  Myelination of CST axons 
begins around day 10 postnatal in the rat spinal cord (Matthews and Duncan, 1971; 
Schreyer and Jones, 1982; Schwab and Schnell, 1989), with the number of myelinated 
axons in the CST increasing steadily during the third and fourth postnatal weeks.  By four 
weeks postnatally, the majority of CST axons have also established their mature 
functional contacts with interneurons, with a much smaller number of synaptic contacts 
being made directly with motoneurons in the rat spinal gray matter (Karimi-Abdolrezaee 
et al., 2002).   
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Thereafter, during the second and third postnatal months, the total number of 
myelinated CST axons in rats increases more slowly than it did during the first month 
(Gorgels, 1990) and myelination may continue even beyond the third postnatal month 
(Leenen et al., 1989). Several studies have reported large numbers of thin unmyelinated 
CST fibers, which constitute approximately 45% of the total number of fibers located at 
the mid-thoracic level (Gorgels, 1990; Schreyer and Jones, 1988) within the CST in 
mature rats. It has been argued that, in monkeys at least, many of the cross-sectional 
profiles in the lateral CST that were presumed to be unmyelinated axons, in longitudinal 
sections were seen instead to be astroglial processes (Ralston et al., 1987). While this 
may be true in monkeys, a study at the electron microscopic level in six-month-old rats 
that had received injections of the anterograde tracer HRP into the entire sensorimotor 
and frontal cortex of the left hemisphere demonstrated that both unmyelinated and 
myelinated axons within the CST were labeled (Joosten and Gribnau, 1988). Thus the 
CST in adult rats does indeed contain a number of unmyelinated axons. During 
myelination of the CST, the larger diameter axons are the first to become myelinated 
(Gorgels et al., 1989; Gorgels 1990) and it appears that some axons may increase in 
diameter just prior to myelination (Gorgels, 1990). Later, while myelination of the large 
corticospinal axons continues, some smaller diameter axons become myelinated as well. 
The diameters of the HRP-labeled unmyelinated CST axons remained fairly constant at 
about 0.2µm, whereas myelinated CST axons had variable diameters between 0.5-3 µm 
(Joosten and Gribnau, 1988). Furthermore, as in the PNS and in other CNS pathways, 
there is a fairly strong correlation between the diameter of corticospinal axons and the 
thickness of their myelin sheath (Gorgels, 1990). 
 
4.1.3 Microglial response to Wallerian degeneration 
Microglia are important players in WD, with several of the steps, such as axonal 
breakdown and clearance of myelin debris, requiring a reactive microglial response 
(Ludwin and Bisby, 1992). Microglial numbers rise in response to WD 2–3 days later 
than does the number of macrophages in response to PNS injury (Lawson et al., 1994). 
After dorsal root rhizotomy, it takes almost two weeks for microglia inside the dorsal 
funiculus to express immunoreactivity for ED-1, which recognizes one of the antigenic 
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epitopes expressed by reactive microglia (see Section 1.4.2). Phagocytic microglia 
express MHC classes I and II during WD (Stoll et al., 1989). Nonetheless, microglia clear 
myelin extremely slowly (Aldskogius et al. 1974). The contribution of factors that 
regulate clearance of cellular debris in the CNS is incompletely understood. The very 
slow microglial clearance of axonal and myelin debris from degenerating CNS fiber 
tracts and the limited peripheral macrophage influx into the CNS during WD collectively 
contribute to the delayed clearance of debris in CNS fiber tracts undergoing WD. 
One key difference between the response of the PNS and the CNS to injury is that 
the BBB is disrupted at the site of injury but not along the entire length of the distal nerve 
tract (George and Griffin, 1994), unlike what happens with the blood nerve barrier in the 
PNS (George and Griffin, 1994). The lack of BBB breakdown post injury may limit the 
infiltration of hematogenous macrophages into degenerating CNS tracks (George and 
Griffin, 1994), thus leaving the job of cleaning up the axonal and myelin debris primarily 
to microglia. Another difference between PNS and CNS injury is a slower rate of 
clearance of the debris by the reactive microglia; for example, the rate of myelin 
phagocytosis in optic nerve explants is far slower than in sciatic nerve explants due to 
decreased  microglial activity measured using the fluorescence-activated cell sorter 
(FACS) technique (Kuhlmann et al., 2002). 
Transmembrane molecules expressed by reactive microglia/macrophages have 
important roles in regulating the phagocytic response by these cells. Recognition of 
specific molecules on dead cells and on cellular debris, in particular phosphatidylserine, 
triggers phagocytosis by macrophages (Fadok and Henson, 2003).  The expression of 
certain cell surface molecules including CD47 and CD200 inhibits phagocytosis of live 
cells by microglia/macrophages (Hoek et al., 2000). In CD200 knockout mice, microglia 
show faster activation. CD200 deficiency in the CNS was shown to affect microglial 
responsiveness to nerve damage, as demonstrated using the facial nerve transection 
model to induce localized microglial activation (Graeber et al., 1988). The course of 
microglial activation in the facial motor nucleus of wild-type mice is well documented 
(Graeber et al., 1988) and can first be detected 4 days after facial transection; the peak of 
activation is at day 7 after transection (Hoek et al., 2000). In CD200-/- mice the microglial 
response was accelerated dramatically, with a detectable microglial reaction seen after 2 
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days and maximal activation by 4 days after transection, as detected by quantifying the 
number of CD11b-expressing cells (Hoek et al., 2000). In healthy wild-type mice, 
microglia are quiescent cells expressing molecules such as MHC class I and II, CD11b, 
and CD45 at low or negligible levels and show an ordered, ramified appearance 
(Kreutzberg, 1996). In contrast, the microglia of CD200-/- mice spontaneously exhibited 
many features of activation, including less ramified, shorter cytoplasmic processes and 
increased CD11b and CD45 expression. Microglia in CD200-/- animals formed 
aggregates and strongly expressed CD11b and CD45, especially in the spinal cord (Hoek 
et al., 2000). 
The abilities of microglia and macrophages to phagocytose debris are highly 
regulated by cellular and humoral immune responses, and the role of the immune system 
in regulating myelin phagocytosis is only just beginning to be explored. Following spinal 
transection, microglia/macrophages were identified immunohistochemically using 
antibodies to complement type 3 receptor, CD11b (OX-42 monoclonal antibody), the 
macrophage lysosomal antigen CD68 (ED1 monoclonal antibody), major 
histocompatibility complex class II (MHC II), and CD163 (ED2 monoclonal antibody). 
One week after spinal cord transection at T8 in adult rats, the density of OX-42+ve 
microglia/macrophages had nearly doubled (McKey et al., 2007). In the white matter, 
microglia/macrophages became enlarged, often having retracted cytoplasmic processes 
and exhibiting an amoeboid morphology. After 8 weeks, ED1+ve microglia/macrophages 
were prominent in fiber tracts undergoing WD, including within the dorsolateral, lateral 
and ventral funiculi (McKay et al., 2007). Notably, microglia in these tracts transformed 
into activated microglia/macrophages and began to phagocytose degenerating myelin. 
Prolonged activation of ramified microglia in the grey matter may reflect ongoing 
degenerative processes that are both retrograde (Streit et al., 1999) and transsynaptic 
(Banati, 2002).  
Differences in the pattern and degree of inflammation were present between the 
segments controlling the hindlimbs (L4/5) and the pelvic organs (L6/S1) after mid 
thoracic spinal transaction (McKey et al., 2007). The focus on a region of the cord 9 to 12 
spinal segments (4-5 cm) beyond the lesion has revealed inflammatory responses not only 
in the vicinity of the neuronal cell bodies of the axotomized axons but also a markedly 
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increased density of OX42+ve microglia throughout the lumbosacral spinal cord after 
spinal transection at T8 in adult female Wistar rats (McKey et al., 2007). Furthermore, 
the duration of microglial activation in the spinal cord was prolonged relative to that of 
other axotomized CNS pathways such as in the thalamocortical and corticothalamic 
pathways after a cortical aspiration lesion in male Wistar rats. The latter rats were killed 
3, 7, 14 and 28 days after sensorimotor cortex aspiration. Histological analysis of the 
thalamus showed the presence of OX42+ve, OX18+ve and OX6+ve reactive microglia in 
the ventrolateral, posterior, and ventrobasal thalamic nuclei, along with ongoing 
retrograde and anterograde neuronal degeneration (Sorensen et al., 1996).  Microglial 
proliferation has been demonstrated at other sites far from a lesion; for example, in the 
axotomized facial motor nucleus and in the spinal cord after cerebral infarction (Wu and 
Ling, 1998).  
There was no evidence of vascular infiltration after perforant path axonal 
lesioning in adult female SJL/N and C57/BL6 mice. Using bone marrow chimeras, only a 
few bone marrow-derived microglia/macrophages appeared in the areas with anterograde 
axonal degeneration in the first few days after a lesion (Ladeby et al., 2005). The 
immediate triggers for the microglial response distal to a spinal cord transection are likely 
to be the degeneration of synaptic terminals in the spinal grey matter (Jensen et al., 1994) 
and the onset of WD in the descending fiber tracts (Koshinaga and Whittrmore, 1995). 
Furthermore, microglia accumulate rapidly in response to axotomy of nearby neurons 
(Kobbert and Thanos, 2000), likely in response to chemokine signals released from the 
damaged neurons (Flugel et al., 2001).  
Activated microglia/macrophages appeared in the outer white matter of L4/5 and 
extended through the depth of the ventral columns in L6/S1 during WD. The likelihood is 
low that the additional microglia were hematogenous because WD occurs a distance 
away from a lesion and there is no break down in the BBB (Streit et al., 1999). In 
contrast, deep in the dorsal and ventral columns (i.e. in the 2 components of the CST 
where myelination is limited (Brosamle and Schwab, 1997), activated and ramified 
microglia showed both OX42 and MHC II expression. 
In CNS regions undergoing WD the microglia are usually described as possessing 
a "bushy" morphology, with greatly enlarged somata and short thickened processes 
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(Sorensen et al., 1996). However, reactive microglia at the level of the spinal cord do not 
assume this morphology after spinal cord transection. Within grey matter in brain regions 
containing both anterograde and retrograde degeneration, microglia/macrophages cluster 
around dying neurons (Sorensen et al., 1996). Rapid expression of ED1+ve antigenic 
epitopes by reactive microglia in the spinal cord is prominent during transganglionic 
degeneration early after peripheral nerve injury (Ramer et al., 2001), tissue inflammation 
(Guo et al., 2005) and experimental neuritis (Beiter et al., 2005). Ramified microglia 
containing ED1+ve antigenic epitopes in their lysosomes also appeared throughout the 
brain during the relapse phase of EAE (Bauer et al., 1994). MHC II is also expressed by 
activated microglia/macrophages at the later stages of WD (Graeber et al., 1998). MHC 
II+ve ramified microglia were localized to a broad band through the medial cord, 
extending from the CST to the ventral columns in L4/5. These sites in lamina VII, VIII, 
and X in L4/5 give rise to the propriospinal and supraspinal projections (Dado and 
Giesler, 1990). MHC II+ve microglia were rare in the grey matter one week after spinal 
transection, consistent with terminal degeneration being largely complete by this time 
(Weaver et al., 1997).   
Taken together, hematogenous macrophage entry into the CNS post injury is 
limited to the site of injury and is much slower than occurs at the site of injury in the PNS 
(Popovich and Hicky, 2001; Schnell et al., 1999). Currently there is little evidence for 
entry of large numbers of peripheral macrophages during WD in the CNS. This 
difference may be an important contributor to why myelin debris is robustly cleared in 
the PNS but not in the CNS.  
 
4.1.4 Astrocytic Response to Wallerian degeneration 
Although the relative contributions of hypertrophy and hyperplasia to the 
astrocytic response to WD is not clear, most studies report only a slight increase in 
astrocyte numbers in the degenerating fiber tracts (Hajos et al., 1993; Privat et al., 1981).  
In contrast, astrocyte hypertrophy is a more prominent event as a result of WD (Hajos et 
al., 1993; Murray et al., 1990). The astrocyte reaction to WD in the rat optic nerve entails 
a reduction in the number of cytoplasmic processes and a thickening of the remaining 
processes (Hajos et al., 1993). Astrocytes in the fiber tract undergoing WD express GFAP 
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and vimentin (Baldwin and Scheff, 1997; Butt and Kirvell, 1996). It has been suggested 
vimentin may label astrocytes only when they are reactive (Schiffer et al., 1986; 
Takamiya et al., 1988). During WD, reactive astrocytes express increased levels of 
clusterin (Liu et al., 1998). In addition, reactive astrocytes increase their expression of 
endothelin receptors along the pathway undergoing WD (Rogers et al., 1997). In human 
neurological disorders in which WD occurs as a result of CNS neurodegeneration or 
neural injury to the CNS, astrocytes display an isomorphic reaction in which they 
hypertrophy without proliferating. Accordingly, there is no formation of a dense, 
permanent astroglial scar (Reier et al., 1983; Fernaud-Espinosa et al., 1993; Ridet et al., 
1997).  
In contrast to the experimental data obtained from animals, some unexpected 
findings have been described in postmortem human brain tissue. A detailed investigation 
of fiber tracts undergoing WD in penetrating spinal cord injuries in humans has revealed 
a slow astrogliosis taking place around the lesion site (Buss et al., 2004). Astrocytes close 
to the lesion demonstrated an anisomorphic response, whereas astrocytes located further 
away from the primary lesion, particularly in the degenerating nerve fiber tracts, 
demonstrated an isomorphic response without the formation of a permanent glial scar or 
distortion of the local cytoarchitecture (Mansour et al., 1990; Fernaud-Espinosa et al., 
1993; Ridet et al., 1997). There is also a centrifugal pattern of axonal degeneration away 
from the site of injury, a gradual loss of the major component of compact myelin (i.e. 
MBP) and a delayed astroglial reaction in the myelinated fiber tracts undergoing WD 
(Oberheim et al., 2006).  
Tissue homeostasis is a balance between proliferation and apoptosis. Various 
lesions in the brain are accompanied by proliferation and subsequent death of glial cells. 
It was reported that Fas and FasL is strongly upregulated on astrocytes in the zone of WD 
after an entorhinal cortex lesion in adult rats (Bechmann et al., 2000).  After such a 
lesion, the mitotic activity of astrocytes reached a peak 5 days postlesion, then returned to 
the control levels by 10 days postlesion (Bechmann et al., 2000). However, there was no 
evidence for astrocyte cell death either by TUNEL staining, or from 
immunohistochemical staining for c-Jun or the apoptosis specific protein (ASP). Thus, 
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increased expression of Fas and FasL by reactive astrocytes is not accompanied by their 
death during WD (Bechmann et al., 2000).   
 
4.2 Material and Methods 
4.2.1 Anesthesia, Laminectomy, Analgesia, Wound Closure and Postoperative Care 
In the experiments comprising this portion of the research project the rats 
underwent either one or two surgeries; for rats receiving two surgeries they were 8 weeks 
apart.  One of the surgeries was aspiration of the left sensorimotor cortex (Groups 1 and 
2); in the pilot study reported in Section 4.3.1 the rats were subjected to only one surgery, 
namely for aspiration of the left sensorimotor cortex.  The other surgery was a 
laminectomy done to graft OECs into the dorsal funiculus of the T12 spinal cord segment 
(Groups 1-4).  Group 1 and 2 rats received both a sensorimotor cortex lesion and an OEC 
graft at T12, whereas Group 3 and 4 rats received only the OEC graft.  The general 
surgical procedures related to anesthesia, analgesia, laminectomy, wound closure and 
postoperative care were as described in Sections 3.2.1, 3.2.2, and 3.2.4.   
 
4.2.2 Sensorimotor Cortex Aspiration 
Once the halothane inhalation had induced a sufficient level of anesthesia such 
that the rat was immobile and unresponsive to a pinch test on their hind paws (pedal 
reflex) (see Section 3.2.1), the scalp was shaved with an electric razor, the rat positioned 
in a stereotactic apparatus, and the incision site was swabbed with Betadine antiseptic 
solution (see Section 3.2.2). A single intramuscular injection of Buprenex (0.05 mg/kg 
body weight) was then administrated prior to making a midline incision in the scalp, with 
the incision beginning just caudal to the eyes and continuing caudally to approximately 
10 mm behind the ears. The periostium was deflected and a rectangular craniotomy was 
done using a surgical drill; this craniotomy extended rostrocaudally from approximately 4 
mm rostral to the coronal suture to approximately 2 mm rostral to the lambdoid suture, 
and medio laterally from approximately 1 mm lateral to the sagittal suture all the way to 
the temporal ridge. Upon completion of the craniotomy, the dura was carefully reflected 
out of the way. A Pasteur pipette was connected to a rubber tube, which in turn was 
connected to a vacuum pressure created from the tap running. With the aid of a surgical 
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microscope (Nikon-SMZ-1B) the cortical brain tissue (predominantly sensorimotor 
cortex) was aspirated by suction, with the brain tissue being removed from the area 
exposed by the carniotomy as deep as the cortical white matter (Fig 4.1). 
 
4.2.3 Grafting DiI-Labeled OECs 
For Groups 1 to 4, OECs from the K586 cell cultures (see Table 3.1) were used 
for the grafting of DiI-labelled OECs.  A final cell concentration of 50,000 DiI-labelled 
OECs per µl was loaded into a 5 µl Hamilton syringe and the cells grafted into the right 
dorsal funiculus of T12 as described in Section 3.2.3. 
 
4.2.4 Minocycline Treatment 
Minocycline, a second generation tetracycline, is an antibiotic that possesses 
better penetration into the CNS via the BBB in comparison to other tetracycline drugs 
such as methacycline (Aronson, 1980).  One critical CNS target of minocycline is 
inhibition of the proliferation and activation of microglia (Tikka and Koistinaho, 2001). 
In vitro, minocycline prevents the excitotoxicity of glutamate on neurons, presumably via 
the inhibition of N-methyl-D-aspartate-induced activation of microglia (Tikka and 
Koistinaho, 2001). In vivo, the protection afforded by minocycline in various models of 
CNS diseases is correlated with a lack of the activation of microglia (Yrjanheikki et al., 
1998; Popovic et al., 2002).  In the experimental design described in Section 4.3.4, 
minocycline was used to dampen the WD-induced microglial reactivity and thus to 
address the extent to which microglial reactivity contributed to the generation of a 
migratory signal(s). Minocycline was freshly prepared in saline each time before use and 
heated briefly in a water bath until completely dissolved. Then the minocycline solution 
was buffered to pH 7.2-7.4 using 0.1 N NaOH. Group 1 and 3 rats received daily 
intraperitoneal injections of minocycline (45 mg/ kg) whereas Group 2 and 4 rats 
received daily intraperitoneal injections of an equivalent volume of vehicle (i.e. 0.9% 
saline).  The minocycline and saline injections were begun exactly 2 weeks prior to the 
grafting of OECs and continued for an additional 4 weeks after the cell grafting.  Daily 
examination of each rat prior to performing the intraperitoneal injection did not show any 
observable evidence of adverse reactions to either the minocycline or saline injections.  
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4.2.5 Necropsy, Tissue Sectioning and Immunohistochemistry 
Rats were deeply anesthetized by administering a lethal dose (90 mg/kg body 
weight) of sodium pentobarbital injected intraperitoneally (i.p.) 8 weeks after receiving 
the OEC graft.  They were perfused through the heart with 1% sodium nitrite followed by 
4% PF as described in Section 3.3.1.  The brain and brainstem were dissected from the 
cranium and the spinal cord from the vertebral column, as described in Section 3.3.2.  
Serial, free-floating 40 µm tissue sections (see Section 3.3.3) were cut in the coronal 
plane from the forebrain of all rats that had received a sensorimotor cortex lesion to 
determine the size and location of this lesion. A small longitudinal cut was made on the 
left side of each piece of CNS tissue to distinguish the right from the left side after 
sectioning and staining. Serial, free-floating 40 µm tissue sections (see Section 3.3.3) 
were cut in the coronal plane from the medulla and from the C6 and T11 spinal cord 
segments of the sensorimotor cortex-lesioned rats used in the pilot study to determine the 
survival time (2-16 weeks) at which the microglial and/or astrocytic reactivity first 
appeared at these three rostral-caudal levels of the dCST.  Finally, in the Group 1 and 2 
rats, glial reactivity was assessed only at the T11 segment. 
Every 10th tissue section collected through the forebrain of left sensorimotor 
cortex lesioned rats was mounted onto 1% gelatin and 0.5% chrom alum-subbed 
coverslips (see Section 3.4.2); the tissue sections were left to air dry for 2-3 hours at room 
temperature to allow the tissue to adhere to the coverslip before starting the staining. The 
tissue sections were then rinsed for 10 min in 0.03M PBS followed by 10 min in distilled 
water. The tissues were dehydrated in an ascending series of ethanols (70%, 90% 95% 
and 100%) for 2 min in each concentration. The sections were then stained with 0.2% 
nuclear fast red (diluted in distilled water) for 3 min, followed by a quick rinse in distilled 
water. This was then followed by quick rinses (30 seconds each) in 70%, 90% and 100% 
ethanol. The sections were then rinsed in a 1:1 mixture of xylene and absolute alcohol for 
1 min, were cleared in three changes of xylene, and were mounted on slides using 
Shandon xylene substitute mountant (Fig 4.6). Four different mouse monoclonal 
antibodies were used to assess microglial reactivity, including: mouse anti-rat MHC Class 
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FIGURE 4.1: Schematic of dorsal corticospinal tract (dCST) pathway in the rat.
To induce Wallerian degeneration-induced glial reactivity in the dorsal corticospinal
tract (d-CST), the neurons giving rise to this fiber tract were lesioned in the
sensorimotor area of the contralateral cerebral cortex (blackened area in left cortex).
The left sensorimotor cortex was lesioned by aspiration of cortical tissue.  Neurons in
the sensorimotor cortex send their axonal projections all the way down to the lower
levels of the spinal cord.  Decussation of the fiber tract occurs in the pyramidal
decussation in the caudal medulla just prior to the fibers entering the spinal cord;
approximately 95% of the axons decussate at this level and enter the dCST located in
deepest portion of the dorsal funiculus.  The dCST extends the entire length of the
spinal cord. The histological section on the lower right shows microglial reactivity, as
detected with the OX42 monoclonal antibody, confined to the right dCST (red circle)




mouse anti-CD11b (Clone MRC OX-42, 1:3200, Serotec Product Datasheet, Kidlington 
Oxford, England), mouse anti-CD4 (Clone OX-35, 1:3000, Serotec Product Datasheet, 
Kidlington Oxford, England) and mouse anti-rat ED1 (1:2000; Serotec, Oxford, England) 
(Section 3.4.4). Three different mouse monoclonal antibodies were used to assess 
astrocytic reactivity, including mouse anti-GFAP (1:1000 Dimension Labs, Dako A/S 
Denmark), mouse anti-vimentin (Clone V9, 1:1000, Sigma, St. Louis, MO 63178, USA), 
and mouse anti-nestin (1:2000, Clone Rat 401, Developmental Studies Hybridoma Bank, 
Department of Biological Sciences, University of Iowa, Iowa City, USA) (Section 3.4.2). 
All primary antibodies were diluted in 0.03 M PBS. The control sections were incubated 
in diluent only. See Section 3.4.2 for a description of the procedure used for the 
immunostaining of the tissue sections from the medulla, and from the C6 and T11 
segments of the spinal cord.  
 
4.2.6 Data Collection and Statistical Analysis 
Assessment of the presence or absence of glial reactivity in the sensorimotor 
cortex lesioned rats used in the pilot study was done subjectively.  For the purpose of the 
experiments reported in Sections 4.3.7- 4.3.8 of this chapter, tissue sections collected into 
the first four wells were considered to comprise the rostral one-third of T11, sections in 
the second four wells comprised the middle one-third, and the final four wells comprised 
the caudal one-third of T11.  Each tissue section was examined to determine whether it 
contained any DiI+ve cells, to identify the specific location in which the cells were found, 
and to count the total number of labelled cells within the dCST and the dorsal ascending 
tract (DAT).  The numbers of DiI-labelled cells within the dCST and the DAT on the 
right and left sides were computed separately.  For statistical analysis, the mean cell 
count within each of the fiber tracts for each group of 4 sections was computed.  Only 
DiI+ve profiles that were associated with a nucleus were counted.  
To ensure consistent identification of the border between the dCST and the 
adjoining DAT when counting cells on the fluorescence microscope (40X objective), it 
was necessary to determine the dorsal-ventral height of the dCST.  Tissue sections (24 
sections) from the T11 segment of the spinal cord from saline-treated sensorimotor cortex 
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aspirated rats (i.e., Group 2) were immunostained with the OX18 monoclonal antibody.  
The immunostaining of the reactive microglia, which the pilot study had revealed was 
confined to the dCST, was used to measure the height of the right dCST with respect to 
the adjacent central grey matter.  Using a rectangular eyepiece graticule that was 250 µm 
tall when using the 40X objective, it was determined the portion of the white matter of 
the dorsal funiculus that contained OX18+ve reactive microglia was approximately the 
height of the graticule (i.e. ~250 µm tall).  Thus, for the purpose of counting the DiI+ve 
cells the entire white matter on the dorsal surface of the spinal cord was divided into four 
unequal sized quadrants, with the two deep, smaller quadrants comprising the right and 
left dCSTs each being 250 µm tall and the reminder of this area of white matter up to the 
pial surface comprising the right and left DATs.  The eyepiece graticule and the 40X 
objective was used to view the Hoechst-stained tissue sections to count the number of 
DiI+ve cells in each of the four unequal sized quadrants; namely, the right and left dCSTs 
(the two smallest and deepest quadrants) and the right and left DATs (the two largest and 
most superficial quadrants). Due to unequal size of quadrants (dCST vs. DAT) the mean 
DiI+ve cell counts were converted to cell densities per 0.05 mm2. 
The T11 cell counts collected for Groups 1-4 were statistically compared using a 
two-factor analysis of variance (ANOVA), with the data for the rostral, middle and 
caudal thirds of the right and left dCST and DAT of this spinal cord segment being 
analyzed separately for statistical significance (see Section 3.5.3).  The independent 
variables were lesion (i.e. sensorimotor cortex lesion vs. no lesion) and treatment (i.e. 
minocycline vs. vehicle). 
 
4.2.7 Measuring the size of dCST and DAT using Northern Eclipse software  
In order to measure the size of the dCST and DAT on tissue sections from the 
T11 spinal cord segment of rats in Group 1 (n=3 tissue sections) and Group 2 (n=9 tissue 
sections), the tissue sections were immunostained with the OX42 monoclonal antibody.  
Digital images of the dorsal part of the spinal cord were analysed using Northern Eclipse 
5.0 software (Empix Imaging Inc. Mississauga, ON). The intensity of OX42 
immunostaining within the deepest part of the dorsal funiculus (i.e. in the dCST) was 
used as a criterion for determining the border between the dCST and the DAT. For 
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calculating the density of DiI+ve OECs within the dCST vs the DAT, the area of the right 
and left dCST, as well as the area of right and left DAT, were measured on each tissue 
section that was used for counting the number of DiI+ve OECs.  
 
4.3 Results 
4.3.1 Timing of Wallerian Degeneration-Induced Glial Reactivity: Experimental  
Design  
In order to address specific aim #1 a pilot study was conducted to determine the 
timing for the appearance of WD-induced microglial reactivity in the right dCST at the 
level of T11 following aspiration of the left sensorimotor cortex. This timing had to be 
determined before specific aim #2 (see Section 4.4.4) could be tested. Following 
destruction of the left sensorimotor cortex, WD would gradually progress down the entire 
length of the right dCST.  In order to address the first hypothesis, grafting of OECs at 
T12 needed to be done at a time when microglial reactivity was present at T11.  In the 
Pilot Study, immunohistochemistry was used to determine the time course of this WD-
induced glial reactivity as it reached progressively more distal parts of the right dCST. 
Antibodies used included the OX42, OX18, OX35 and ED1 monoclonal antibodies for 
immunostaining of reactive microglia.  Antibodies to GFAP, to Vim, and to nestin were 
used to determine the time course of the astrocytic response to the axonal degeneration. 
Since the axonal degeneration would be confined to the right dCST, it was predicted the 
glial reactivity (i.e. microglial and astrocytic) would also be restricted to this fiber tract. 
Three distinct proximal-distal levels of the CST pathway were examined to 
determine the morphology, distribution and immunophenotype of microglia and 
astrocytes between 1 day and 16 weeks (Table 4.1) after sensorimotor cortex aspiration.  
Histological analysis of the cerebral hemispheres of each rat was done to determine the 
location and extent of the cortical lesion.  Only rats with a lesion that removed tissue 
from sensorimotor cortical areas M1 and M2 over a distance of several mm were used for 
the immunohistochemical examination of glial reactivity in the medullary pyramid, C6 
and T11 portions of the CST pathway (Paxinos and Watson, San Diego: Academic Press, 
1998). The postlesion survival time at which microglial or astrocytic reactivity were first 
seen at each of these levels was noted for each of the microglial (OX42, OX18, OX35, 
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ED1) and astrocytic (GFAP, Vim, nestin) markers; the findings are summarized in Table 
4.1 and in Figs. 4.2 and 4.3. As expected, there was a proximal to distal gradient in the 
appearance of glial reactivity along the length of the CST pathway, with the microglial 
reactivity being seen as early as 3 weeks in the left pyramid, by 4 weeks in the right 
dCST at C6, and by 6 weeks in the right dCST at T11 (Table 4.1 and Fig. 4.2).  
Astrocytic reactivity lagged behind that of the microglial response at each level of the 
CST pathway (Table 4.1 and Fig. 4.3).  These data are described in more detail in 
Sections 4.4.2 and 4.4.3. 
 
4.3.2 Wallerian Degeneration-Induced Glial Reactivity in Pyramid and at C6 
In the pyramidal tract at the level of the medulla the intensity of immunostaining 
with OX42 was greater for microglia on the ipsilateral side by 3 weeks after left 
sensorimotor cortex aspiration; these reactive microglia had small cell bodies and short 
cytoplasmic processes. Furthermore, round-shaped ED1+ve reactive microglia were first 
seen at the same time point in the ipsilateral medullary pyramid, namely by 3 weeks after 
cortical injury.  OX18+ve and OX35+ve reactive microglia, both having amoeboid cell 
bodies, were not seen in the ipsilateral pyramid until 4 weeks following sensorimotor 
cortex aspiration (Fig 4.2 and Table 4.1). The first intense GFAP+ve reactive astrocytes 
were seen in the ipsilateral pyramid by 4 weeks after cortical injury.  These GFAP+ve 
astrocytes had star-shaped cell bodies and possessed numerous, short cytoplasmic 
processses.  In contrast, Vim+ve reactive astrocytes, which had small cell bodies and a 
few long cytoplasmic processes, were not seen in the ipsilateral pyramid prior to 6 weeks 
after sensorimotor cortex aspiration.  Furthermore, it was not until 12 weeks after cortical 
injury that even the first weakly-immunostained nestin+ve reactive astrocytes were seen 
in the ipsilateral pyramid of sensorimotor cortex lesioned rats; these weakly-
immunostained nestin+ve reactive astrocytes were morphologically similar to the 
Vim+ve reactive astrocytes also present within the ipsilateral pyramid.  
In the cervical level of the spinal cord (i.e. at C6) OX42+ve reactive microglia 
were first seen at 4 weeks after left sensorimotor cortex injury and were confined to the 
contralateral (i.e. right) dCST; with OX42 immunostaining, no detectable microglial 
reactivity was seen in any of the other CST tracts. The morphology of OX42+ve reactive 
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microglia in the right dCST at C6 was similar to that seen in the medullary pyramid 1 
week earlier.  OX18+ve reactive microglia with short cytoplasmic processes were also 
seen in the right dCST at C6 by 4 weeks after left sensorimotor cortex aspiration, while 
OX35+ve and ED1+ve reactive microglia were first seen only at 6 weeks. It also took 6 
weeks for the first GFAP+ve reactive astrocytes to be seen in the right dCST at C6, 
whereas only very low numbers of Vim+ve reactive astrocytes were seen in the same 
fiber tract even by 8 weeks after cortical injury.  Furthermore, even by 16 weeks after 
cortical injury, the astrocytes in the right dCST remained nestin-ve; however, nestin+ve 
cells were always seen around the central canal of the C6 spinal cord segment. 
 
4.3.3 Wallerian Degeneration-Induced Glial Reactivity at T11 
The OX42+ve microglia displayed shorter, thicker processes and stronger 
immunoreactivity in the right dCST of T11 at the 6 week time point after cortical injury, 
in comparison to the left dCST in which the corticospinal axons remained intact (Fig. 
4.2C). In the present study, OX18+ve microglia, with sparse, short cytoplasmic 
processes, were localized to the right dCST and were found in this fiber tract only in 
sensorimotor cortex lesioned rats (Fig. 4.2F). OX42 and OX18 immunostaining revealed 
that the earliest microglial reactivity was seen in the right dCST at T11 only by 6 weeks 
after the cortical lesion.  By 8 weeks after cortical injury microglia of the right dCST 
began to express the OX35 (Fig. 4.2I) and ED1 (Fig. 4.2L) antigenic epitopes, in addition 
to being OX42+ve and OX18+ve. No OX35+ve or ED1+ve cells were seen elsewhere in 
the parenchyma of the T11 spinal cord of sensorimotor cortex lesioned rats or anywhere 
in the parenchyma of the spinal cord of control rats.  In the present study a more intense 
GFAP immunostaining, similar to what has been reported in other studies where 
astrocytes become reactive in response to injury (Martinez et al., 1998; Raivich et al., 
1999), was seen at T11 only in sensorimotor cortex lesioned rats, only in the right dCST, 
and only by 8 weeks after the cortical lesion (Fig. 4.3C).  It took approximately 12 weeks 
after the left-sided sensorimotor cortex lesion for Vim+ve reactive astrocytes to appear in 
the right dCST of T11 in response to degeneration of the CST axons (Fig. 4.3F). 
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Table 4.1 Pilot Study: WD-Induced Glial Reactivity 
Survival time Medulla (left pyramid) C6 (Right CST) T11 (Right CST) 
1 day     (n=1) 
 
   
3 day      (n=2) 
 
   
1 week    (n=2) 
 
   
2 week    (n=4) 
 
   
3 week    (n=3) 
 
OX42, ED1   
4 week    (n=4) 
 
OX18, OX35, GFAP OX42, OX18  
6 week    (n=4) 
 
Vim OX35, ED1, GFAP OX42, OX18 
7 week    (n=2) 
 
   
8 week    (n=4) 
 
 Vim OX35, ED1, GFAP 
10 week  (n=2) 
 
   
12 week  (n=2) 
 
Nestin (Rat 401)  Vim 
16 week  (n=2) 
 
   
n= numbers of rats for each survival time 
Three distinct proximal-distal levels of the CST pathway (i.e. pyramid, C6 and T11) were 
examined to determine the immunophenotype of microglia and astrocytes between 1 day and 





































FIGURE 4.2: Time frame of microglial reactivity following sensorimotor cortex
aspiration.
Wallerian degeneration-induced microglial reactivity was detected using OX-42 (A-C),
OX-18 (D-F), OX-35 (G-I) and ED1 (J-L) monoclonal antibodies.  The data show the
microglial reactivity was first seen in the ipsilateral (i.e. left) medullary pyramid (A, D,
G, J) by 3 (A, J) or 4 (D, G) weeks after cortical injury, depending on the antibody that
was used to stain the tissue.  In the contralateral dCST at the level of C6 (B, E, H, K)
the first signs of microglia reactivity were seen using OX-42 antibody (B) at 3 weeks
after cortical injury but only after 6 weeks using the other three microglial markers (E,
H, K).  At T11 (C, F, I, L).  It took 6 (C, F) to 8 (I, L) weeks before microglial
reactivity could be detected.  The red arrows show the location of the left pyramid in
the medulla (A, D, G, J), and of the right dCST at C6 (B, E, H, K) and T 11 (C, F, I,
L).  At all levels, the microglial reactvity was confined to the corticospinal pathway.






























FIGURE 4.3:  Time frame of astrocyte reactivity following sensorimotor cortex
aspiration.
Wallerian degeneration-induced astrocytic reactivity was detected using GFAP (A-C),
vimentin (D-F) and nestin (G-I) antibodies.  The data show the astrocytic reactivity
was first seen in the ipsilateral (i.e. left) medullary pyramid (A, D, G,) by 4 (A), 6 (D),
or 12 (G) weeks after cortical injury, depending on the antibody that was used to stain
the tissue.  In the contralateral dCST at the level of C6 (B, E, H) the first signs of
astrocytic reactivity were seen using the GFAP antibody (B) at 6 weeks after cortical
injury but only after 8 weeks using the vimentin antibody (E).  At T11 (C, F, I). it took
8 (C) to 12 (F) weeks before astrocytic reactivity could be detected.   Even as late as 16
weeks after cortical injury, the reactive astrocytes of the dCST remained nestin-ve at
both C6 (H) and T11 (I); red circles in ‘H’ and ‘I’ highlight nestin+ve staining around
the ependymal lining of the central canal.   The red arrows show the location of the left
pyramid in the medulla (A, D, G), and of the right dCST at C6 (B, E) and T 11 (C, F).
At all levels, the astrocytic reactvity was confined to the corticospinal pathway. Scale
bar = 300 µm.
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  Although the intensity of the Vim immunostaining was usually very low (Fig. 4.3F), 
there was no staining of adjacent parts of the white or grey matter, except around the 
central canal. Reactive astrocytes in the right dCST of T11 of sensorimotor cortex 
lesioned rats were nestin-ve up to at least 16 weeks after injury, which was the longest 
survival time studied (Fig. 4.3H & I).  However, nestin+ve cells were consistently seen 
surrounding the central canal of T11, even in control rats (Fig. 4.3H and I), thus serving 
as a positive control for the nestin immunostaining.  As shown in Section 4.4.2, nestin+ve 
cells were seen in the medullary pyramid at both 12 and 16 weeks after cortical injury 
(Fig. 4.3G), thus indicating expression of nestin by reactive astrocytes in more rostral 
parts of the CST undergoing WD. 
In summary, OX42+ve, OX18+ve, OX35+ve and ED1+ve microglia were 
detected only in the right dCST of T11 and only in rats that had received a sensorimotor 
cortex lesion at least six (OX42+ve and OX18+ve) or eight (OX35+ve and ED1+ve) 
weeks beforehand (Fig. 4.2 and Table 4.1).  GFAP+ve and Vim+ve reactive astrocytes 
were also detected only in the right dCST of T11 and only in rats that had received the 
cortical injury at least 8 (GFAP+ve) and 12 (Vim+ve) weeks beforehand (Fig. 4.3 and 
Table 4.1). Based on the intensity of OX18+ve, OX42+ve and OX35+ve immunostaining 
of reactive microglia as well as GFAP+ve and Vim+ve reactive astrocytes in the right 
dCST of T11 there was no detectable difference in glial reactivity in rats killed 12-16 
weeks after the cortical injury. Furthermore, there was no morphological variation in the 
reactive microglia or astrocytes between 12-16 weeks after the cortical injury. The timing 
data obtained in this Pilot Study revealed that at least a 6 week time interval is required 
after lesioning the left sensorimotor cortex before WD-induced microglial reactivity 
could be detected in the right dCST at T11. By 8 weeks after cortical injury the 
microglial reactivity was more prominent and astrocytic reactivity was now detected as 
well.  Based on these data, the 8 week time point was chosen for injecting DiI+ve OECs 
into the right DAT of T12 for the purpose of addressing the second objective. 
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4.3.4 Sensorimotor Cortex Injury and OEC Migration: Experimental Design 
On the basis of the findings of the pilot study (specific aim #1)  (see Sections 
4.4.1-4.4.3), 8 weeks after sensorimotor cortex injury was chosen as the time point at 
which to graft DiI+ve OECs into the right DAT of the T12 segment of the spinal cord.  
The rationale for choosing this time point was that although OX42+ve and OX18+ve 
reactive microglia were present in the right dCST at T11 by 6 weeks after left 
sensorimotor cortex aspiration, it was 8 weeks after cortical injury before OX35+ve and 
ED1+ve reactive microglia were seen inside the same fiber tract.  At 8 weeks after 
cortical injury there was minimal astrocyte reactivity in the right dCST at T11, with 
GFAP being the only astrocytic marker used that showed any indication the astrocytes 
were even responding to the WD of axons in this fiber tract.  It was at least 12 weeks 
before even a small number of Vim+ve reactive astrocytes were detected in the right 
dCST of sensorimotor cortex lesioned rats, with these reactive astrocytes being nestin-ve 
even up to 16 weeks after cortical injury.  Furthermore, at survival times longer than 8 
weeks there was no detectable change in the intensity of immunostaining, the distribution 
of the cells, or the morhology of OX18+ve, OX42+ve and OX35+ve and ED1+ve 
reactive microglia in the dCST of the T11 segment of the spinal cord.   
Thus, in rats it takes at least 6 weeks after lesioning the left sensorimotor cortex 
before WD-induced microglial reactivity can first be detected in the right d-CST at T11.  
By 8 weeks after cortical injury the microglial reactivity was more prominent and by now 
the first sign of astrocytic reactivity was also seen.  Based on these data, we chose to use 
the 8 week time point for injecting DiI+ve OECs into the right DAT of T12 for the 
purpose of addressing the second objective.  In order to ensure the minocycline treatment 
would successfully dampen the WD-induced microglial reactivity, the daily injection of 
either minocycline or vehicle was begun 2 weeks prior to the OEC grafts and the 
injections were continued for an additional 4 weeks after the cell grafts (Fig. 4.4).  Half 
of the rats received a left sensorimotor cortex injury and the other half comprised the no 
lesion controls.  All rats were killed 8 weeks after the OECs were grafted at T12 and the 
brains processed for histological analysis of the lesion location and size, whereas the T11 
segment of the spinal cord of each rat was processed for immunohistochemical analysis 
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of microglial and astrocytic reactivity and for quantification of the numbers of DiI+ve 
OECs in the right and left dCSTs and DATs (Fig. 4.4). 
 
4.3.5 The Size and Location of the Cortical Lesion 
The topographical extent of damage following aspiration lesion of the 
sensorimotor cortex was assessed in neutral fast red stained sections.  Lesions produced 
by aspiration were similar in the anterior-posterior and medial-lateral directions in all 
lesioned animals. The lesion included all six layers of the cortex and most also involved 
the corpus callosum. The principle difference between the largest and smallest lesions 
was the extent to which the injury extended into subcortical areas (Fig 4.5). Based on 
comparisons of the location of the lesions with respect to coronal sections in a rat brain 
atlas (Paxinos and Watson, San Diego: Academic Press,, 1998) all rats had cortical 
lesions that extended from 3.70 mm rostral to bregma to 3.60 mm caudal to bregma; the 
lesion extended mediolaterally from 0-2 mm. The comparable location of cortical injury 
in all rats demonstrated the reproducibility of the sensorimotor cortex aspiration. Miller 
(1987) determined precisely the somatotopic distribution of CST neurons in the 
sensorimotor cortex of adult rats by injecting the retrograde tracer horseradish peroxidase 
(HRP) into the cervical (C5-C6), upper thoracic (T2-T3), lower thoracic (T8-T9), and 
lumbar (L2-L3) segments of the spinal cord. His study demonstrated that retrogradely 
labelled neurons were distributed throughout brodmann areas 3, 4, 6/8, 18b and 24b; 
however, the density of HRP rerogradely labelled neurons was greatest in area 4, which 
forms part of the motor cortex area and corresponds to the M1 and M2 motor areas 
(Paxinos and Watson, San Diego: Academic Press, 1998). 
 
4.3.6 Minocycline Dampens Wallerian Degeneration-Induced Microglial 
Reactivity 
To confirm that the minocycline treatment had been effective in dampening the 
intensity of the microglial response and in assessing the treatment’s effect on astrogliosis, 
tissue sections from the rostral, middle and caudal levels of T11 of all groups of rats were 
stained with the same panel of antibodies as was used in the Pilot Study to identify 
reactive microglia (i.e., OX42, OX18, OX35 and ED1 monoclonal antibodies) and 
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reactive astrocytes (i.e., GFAP, Vim and nestin monoclonal antibodies).  In the lesion 
saline-treated rats (Group 2), OX42+ve microglia were detected throughout the tissue 
sections, but the immunostaining was more intense in the right dCST (Fig 4.6).  In 
contrast, in the lesion minocycline-treated rats (Group 1) the intensity of the 
immunostaining of microglia in the right dCST with the OX42 monoclonal antibody was 
not detectably different from elsewhere in the tissue section. In the no lesion saline-
treated (Group 4) and minocycline-treated (Group 3) rats the OX42+ve microglia in right 
dCST were also indistinguishable from the OX42+ve microglia in the remainder of the 
same tissue section. Likewise, OX18+ve and OX35+ve reactive microglia, each with 
short cytoplasmic processes, as well as round ED1+ve reactive microglia were detected 
in the right dCST of saline-treated rats that had received a cortical lesion (Group 2). It 
was noted that the minocyline treatment in Group 1 rats had dramatically reduced the 
immunostaining intensity of OX18, OX35, and ED1 antibodies following aspiration of 
the left sensorimotor cortex (Fig 4.6).  No cell counts of microglia or other tests to 
determine the level of OX42, OX18, OX35 and ED1 expression were performed on 
spinal cord tissue of rats in any of the 4 groups who were treated either with saline or 
with minocycline.  
In the rats that had received the cortical injury (Groups 1 and 2), Vim+ve reactive 
astrocytes in the T11 spinal cord segment were primarily seen along the pial surface and 
within the right dCST, regardless of whether the rats had been treated with saline or 
minocycline (Fig 4.6).  Also, GFAP+ve astrocytes were seen throughout both the grey 
and white matter of T11 of the Group 1 and 2 rats, with no detectable reduction in the 
intensity of immunostaining in rats treated with minocyline.  In all four groups, nestin+ve 
cells were only seen around the central canal of T11, regardless of whether the rats had 
been treated with saline or minocycline. In summary, the minocycline treatment 
effectively dampened the WD-induced microglial reaction in the right dCST, as 
evidenced by immunostaining with the OX18, OX42, OX35 and ED1 antibodies.  The 
daily minocycline injections were timed so they began at a time point at which microglial 
reactivity (OX42+ve and OX18+ve) was first detectable in the right dCST of T11 in rats  
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FIGURE 4.4: Summary of experimental design 
Four groups of adult female rats (n=4 per group) received grafts of DiI labeled OECs in 
the right dorsal funiculus of T12. In Groups 1 and 2, the left sensorimotor cortex was 
aspirated 8 weeks previously to induce a glial reaction in the right dorsal corticospinal 
tract (dCST) as a result of the Wallerian degeneration of axons.  Groups 3 and 4 rats 
served as unlesioned controls.  As an additional experimental manipulation, each rat 
received a daily i.p. injection of either minocycline (Groups 1and 3) or vehicle (Groups 2 
and 4) over a six week period beginning two weeks prior to and continuing for four 
weeks after the OECs were grafted at T12.  All rats were killed eight weeks after cell 
grafting. 
OEC grafted in T12 eight weeks 
after aspiration or no lesion
Brain aspiration or no lesion
Perfusion 





















Minocycline or vehicle 







FIGURE 4.5: Size of the sensorimotor cortex lesion in rats of Groups 1 and 2.
Sections of the forebrain were cut in the coronal plane of all rats in Groups 1 and 2 to
determine the size and location of the cortical lesion.  The tissue sections in this figure,
which were cut from an unoperated control rat and stained with neutral fast red, are
arranged from most rostral (A) to most caudal (H).  These images were used to
compare directly the size and location of the cortical lesion in all rats of Groups 1 and
2.  Of the 8 rats whose left sensorimotor cortex was lesioned, the rat who had the
smallest lesion (depicted here in blue colored shading) belonged to Group 2 and the rat
with the largest lesion (depicted here in green colored shading) belonged to Group 1.
Scale bar =1000 µm.
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receiving a sensorimotor cortex lesion; the daily injections continued over a total period 
of 6 weeks.  The WD-induced astrocytic reactivity in the right dCST was less prominent 
than that of microglia and the minocycline treatment had no apparent effect on the 
astrocytic response to the degeneration of CST axons, at least as evidenced by 
immunostaining with GFAP and Vim antibodies. 
 
4.3.7 Reproducibility of DiI+ve cell counts  
A pilot study was performed to confirm the reproducibility of DiI+ve cell counts. 
This pilot study used a total of 14 tissue sections from the T11 spinal cord segment; these 
tissue sections were obtained from rats in Groups 1 (n=7 tissue sections) and 2 (n=7 
tissue sections).  To confirm the reproducibility of the cell counts, the number of DiI+ve 
cells in the right and left dCST (R-dCST and L-dCST) as well as in the right and left 
DAT (R-DAT and L-DAT) were counted twice, with the counts being done 10 days 
apart. The data obtained from the two cell counts were analyzed statistically using a t-
test, which showed no significant differences between the first and second cell counts for 
any of the four fiber tracts.   
The Northern Eclipse software was used to measure the area of the R-dCST, L-
dCST, R-DAT, and L-DAT in tissue sections that were immunostained with the OX42 
monoclonal antibody and in other tissue sections in which the nuclei had been stained 
using Hoechst dye.  These measurements were made on tissue sections from the T11 
spinal cord segment and were used to compare the size of these fiber tracts as measured 
using brightfield microscopy (n=12 OX42-immunostained sections) vs. using 
immunofluroescence (n=12 Hoechst-stained sections). The OX42 immunostaining of 
microglia as seen in light microscopy was used to identify the dCST, with the DAT being 
the remainder of the funiculus up to the pial surface. For the Hoechst-stained sections, the 
rectangular eyepiece graticule (~250 µm tall) used for cell counting was used to identify 
the approximate border between the dCST and DAT on the fluorescence microscope 
because we were not able to determine the border using Hoechst staining. This eyepiece 
graticule was the one used for cell counting, whereas the OX42 immunostained tissue 
sections were the ones used to measure the area of the dCST and of the DAT for 
computation of DiI+ve cell densities. Statistical analysis of these data by t-test showed 
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significantly larger areas of the R-dCST and L-dCST when they were measured on the 
OX42 immunostained tissue sections as compared to the Hoechst-stained sections. 
Conversely, the t-tests showed significantly smaller areas for the R-DAT and L-DAT 
when they were measured on the OX42 immunostained tissue sections as compared to 
the Hoechst-stained sections (Fig 4.12).  The importance of these findings is that using 
the eyepiece graticule to identify the approximate border between the dCST and DAT on 
the fluorescence microscope for cell counting includes the entire DAT and a small part of 
the superficial component of the adjacent dCST. 
 
4.3.8 Wallerian Degeneration-Induced OEC Migration in the dCST at T11 
            We found that WD-induced microglial reactivity was associated with increased 
OEC migration into the right dCST at T11 when DiI+ve OECs were injected into the 
right dorsal funiculus of T12 eight weeks after aspiration of the left sensorimotor cortex. 
Due to the much smaller size of the dCST (0.06 mm2) with respect to the DAT (0.2 mm2) 
(see Fig. 4.13), the cell counts of DiI+ve OECs were converted to the number of cells per 
0.05 mm2. A two-factor analysis of variance (ANOVA) was applied to these data, with 
the data for the rostral (A), middle (B) and caudal (C) thirds of the right (Fig. 4.13) and 
left (Fig. 4.15) dCST at T11 being analyzed separately for statistical significance.  The 
independent variables were lesion vs. no lesion and minocycline vs. saline treatment.  
Multiple post hoc comparisons were performed with Bonferonni’s multiple comparison 
post-test. 
The two-factor ANOVA on the data for the right dCST, which being contralateral 
to the cortical lesion contained WD-induced glial reactivity, showed a significant main 
effect of the sensorimotor cortex aspiration at all levels of the right dCST in the T11 
spinal cord segment; F(1,10) = 13.48, p<0.0043 (Fig. 4.13A; rostral), F(1,10) = 28.70, 
p<0.0003 (Fig. 4.14B; middle), and F(1,10) = 143.0, p<0.0001 (Fig. 4.14C; caudal).  
There was also a significant main effect of the minocycline treatment at all levels of the 
right dCST in the T11 segment of the spinal cord; F(1,10) = 45.97, p<0.0001 (rostral), 
F(1,10) = 35.70, p<0.0001 (middle), and F(1,10) = 150.8, p<0.0001 (caudal). The two-
factor ANOVA revealed a significant interaction between the lesion/no lesion and 
minocycline/saline variables in the right dCST of the middle (Fig. 4.13B), F(1,10) = 
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7.131, p<0.0235) and caudal (Fig. 4.13C), F(1,10) = 74.51, p<0.0001) part of the T11 
spinal cord segment. The average number of DiI+ve OECs per 0.05 mm2 in the right 
dCST of the saline-treated cortical lesion group was 5.86 +/- 0.40 (rostral T11), 9.77 +/- 
1.11 (middle T11), and 10.73 +/- 0.37 (caudal T11), which were all significantly higher 
(p<0.05; Bonferroni’s post-test; Fig. 4.14) than the average cell density in the right dCST 
of the saline-treated no lesion group at the rostral (3.94 +/- 0.16), middle (4.19 +/- 0.01), 
and caudal (4.89 +/- 0.06) levels of T11. The density of DiI+ve OECs in the right dCST 
was also significantly higher at each level of T11 in the saline-treated cortical lesion 
group as compared to the minocycline-treated cortical lesion group, which had cell 
densities of 2.59 +/- 0.60, 3.77 +/- 0.35, and 4.80 +/- 0.24 DiI+ve OECs at the rostral, 
middle and caudal parts of T11, respectively (p<0.05; Bonferroni’s post-test; Fig. 4.14). 
The post-test also revealed a significant reduction in the density of DiI+ve OECs in the 
right dCST of the no lesion group as a consequence of the minocycline treatment (1.31 
+/- 0.19) in comparison to the saline-treated no lesion group (3.94 +/- 0.16), but this 
significant difference was only seen in the right dCST at the rostral level of T11 (p<0.05; 
Bonferroni’s post-test; Fig. 4.13A).  
A two-factor ANOVA was applied to the data for the left dCST, which being 
ipsilateral to the cortical lesion contained no WD-induced glial reactivity. The two-factor 
ANOVA showed a significant main effect of the sensorimotor cortex aspiration on cell 
densities in the left dCST at the middle level of T11 (Fig. 4.16B; F(1-10) = 9.218, 
p<0.0125), but not at the rostral (Fig. 4.15A) or caudal (Fig. 4.16A) levels of T11. There 
was, however, a significant main effect of the minocycline treatment in the left dCST at 
all levels of T11; F(1,10)=9.928, p<0.0103 (A), F(1,10)=11.30, p<0072 (B),  and 
F(1,10)=9.020, p<0.0133 (C). The two-factor ANOVA revealed no significant interaction 
between the lesion/no lesion and minocycline/saline variables in the left dCST at any of 
the three levels of T11. Bonferonni’s post-test revealed the density of DiI+ve OECs in the 
left dCST was significantly higher (p<0.05; Fig. 4.16, brackets) in the saline-treated 
cortical lesion group than in the minocycline-treated cortical lesion group at the rostral 
(2.21 +/- 0.69 vs. 0.48 +/- 0.22, respectively), middle (3.16 +/- 0.59 vs. 1.27 +/- 0.50, 
respectively) and caudal (2.85 +/- 0.52 vs. 1.42 +/- 0.10, respectively) levels of T11 (Fig. 
4.16). Although these differences in cell densities in the left dCST were statistically 
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significant, the actual numerical differences between the cell densities ranged from 1.43 
to 1.89 cells per 0.05 mm2, which are small enough to make it questionable whether they 
are of any therapeutic interest. 
 
4.3.9 OEC Migration in the Dorsal Ascending Tract (DAT) at T11 
There was very little migration of DiI+ve OECs into the right DAT of T11 
following injection of the cells into the right dorsal funiculus of T12 eight weeks after 
aspiration of the left sensorimotor cortex. It should be borne in mind that although the 
differences reported below were statistically significant, the actual numerical differences 
between the cell densities ranged from 0.80 to 1.65 cells per 0.05 mm2, which are so 
small it is questionable whether they are of any therapeutic interest. A two-factor 
ANOVA was applied to the data for the right DAT, which although being contralateral to 
the cortical lesion contained no WD-induced glial reactivity since in the dorsal white 
matter of the spinal cord the CST axons are confined to the dCST. The two-factor 
ANOVA showed a significant main effect of the sensorimotor cortex aspiration at all 
levels of the T11 spinal cord segment; F(1,10) = 10.54, p<0.0088 (A), F(1,10) = 16.58, 
p<0.0022 (B), and F(1,10) = 58.31, p<0.0001 (C).  There was also a significant main 
effect of the minocycline treatment at all levels of T11; F(1,10) = 40.99, p<0.0001 (A), 
F(1,10) = 61.72, p<0.0001 (B), and F(1,10) = 250.6, p<0.0001 (C). The two-factor 
ANOVA revealed a significant interaction between the lesion/no lesion and 
minocycline/saline variables in the right DAT of the middle portion of the T11 spinal 
cord segment (B); F(1,10) = 5.064, P<0.0481. The average number of DiI+ve OECs per 
0.05 mm2 in the right DAT was significantly higher in the saline-treated cortical lesion 
group (3.80 +/- 0.09) as compared to the saline treated no lesion group (2.92 +/- 0.03) 
only at the caudal level of T11 (p<0.05; Bonferroni’s post-test; Fig. 4.13C). Bonferroni’s 
post-test also revealed that the density of DiI+ve OECs in the right DAT of the saline-
treated cortical lesion group was significantly higher than the average cell density in the 
right DAT of the minocycline-treated cortical lesion group at the rostral (2.79 +/- 0.12 vs. 
1.81 +/- 0.24), middle (3.03 +/- 0.17 vs. 2.23 +/- 0.16), and caudal (3.80 +/- 0.09 vs. 2.15 



















FIGURE 4.6:  Microglial reactivity in the right dCST of T11 in Groups 1 and 2.
OX42+ve (A,B), OX18+ve (C,D), OX35+ve (E,F) and ED1+ve (G,H) microglia in the
right dCST of T11 at 16 weeks after left sensorimotor cortex aspiration. The
minocycline treatment dramatically reduced the microglial reactivity (B, D, F, and H)
as compared to vehicle controls (A, C, E, and G).  The red arrows denote the location
of the right dCST. Scale bar = 400 µm. Insets in A, C, E and G show the morphology




















FIGURE 4.7: Microglia in the right dCST of T11 in Groups 3 and 4.
OX42 (A,B), OX18 (C,D), OX35 (E,F) and ED1 (G,H) immuno-staining showed no
microglial reactivity in the right dCST of T11 in rats who received a DiI+ve OEC graft
at T12 but who received no cortical lesion.  Aside from a reduction in the intensity of
the OX42 immunostaining (B), there was no apparent difference between tissue
sections from rats treated with minocycline (D, F, and H) and those treated with
vehicle (C, E, and G).  The red arrows denote the location of the right dCST.  Scale bar
= 400 µm.
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FIGURE 4.8: Astrocyte reactivity in the right dCST of T11 in Groups 1 and 2.
There was astrocyte reactivity in the right dCST of T11 at 16 weeks after left
sensorimotor cortex aspiration. The presence of increased GFAP+ve (A,B)
immunostaining and of light immunostaining for vimentin (C,D) in the right dCST are
indicative of astrocytic reacitivity, but these reactive astrocytes were nestin-ve (E,F).
The minocycline treatment had no detectable effect on the astrocytic reactivity (B, D) as
compared to vehicle controls (A, C).  Scale bar = 400 µm.  Insets in A and C show the






























FIGURE 4.9: Absence of astrocyte reactivity in the right dCST of T11 in Groups 3
and 4.
GFAP (A,B), vimentin (C,D) and nestin (E,F) immunostaining showed no astrocyte
reactivity in the right dCST of T11 in rats who received a DiI+ve OEC graft at T12 but
who received no cortical lesion.  There was no apparent difference between tissue
sections from rats treated with minocycline (B, D and F) and those treated with vehicle




 The density of DiI+ve OECs in the right DAT was also significantly higher in the saline-
treated no lesion group as compared to the minocycline-treated no lesion group at the 
rostral (2.31 +/- 0.04 vs. 1.27 +/- 0.02), middle (2.77 +/- 0.10 vs. 1.33 +/- 0.02) and 
caudal (2.92 +/- 0.03 vs. 1.59 +/- 0.07) parts of T11 (p<0.05; Bonferroni’s post-test; Fig. 
4.14).   
There was also very little migration of DiI+ve OECs into the left DAT of T11 
following injection of the cells into the right dorsal funiculus of T12 eight weeks after 
aspiration of the left sensorimotor cortex. As mentioned above with respect to the cell 
densities in the right DAT, although the differences reported below were statistically 
significant the actual numerical differences between the cell densities ranged from 0.46 to 
0.86 cells per 0.05 mm2, which are so small it is questionable whether they are of any 
therapeutic interest.  A two-factor ANOVA was applied to the data for the left DAT, 
which also contained no WD-induced glial reactivity.  The two-factor ANOVA revealed 
a significant main effect of the sensorimotor cortex aspiration only at the middle level of 
T11 (B); F(1,10) = 14.10, p<0.0038.  There was also a significant main effect of the 
minocycline treatment at all levels of the T11 spinal cord segment; F(1,10) = 21.42 
p<0.0009 (A), F(1,10) = 26.95, p<0.0004 (B), and F(1,10) = 46.91, p<0.0001 (C). The 
average number of DiI +ve cells per 0.05 mm2 in the left DAT was significantly higher in 
the minocycline-treated cortical lesion group (1.29 +/- 0.10) as compared to the 
minocycline-treated no lesion group (0.76 +/- 0.05) only at the middle level of T11 
(p<0.05; Bonferroni’s post-test; Fig. 4.16B). Bonferroni’s post-test also revealed that the 
density of DiI+ve OECs in the left DAT of the saline-treated cortical lesion group was 
significantly higher than the average cell density in the left DAT of the minocycline-
treated cortical lesion group at the rostral (1.35 +/- 0.15 vs. 0.89 +/- 0.08), middle (1.78 
+/- 1.31 vs. 1.29 +/- 0.10), and caudal (1.85 +/- 0.21 vs. 1.01 +/- 0.04) levels of T11 
(p<0.05; Fig. 4.16). The density of OECs in the left DAT was also significantly higher in 
the saline-treated no lesion group as compared to the minocycline-treated no lesion group 
at the rostral (1.19 +/- 0.08 vs. 0.69 +/- 0.02), middle (1.46 +/- 0.14 vs. 0.76 +/- 0.05) and 
caudal (1.66 +/- 0.01 vs. 0.80 +/- 0.04) parts of T11 (p<0.05; Bonferroni’s post-test; Fig. 




FIGURE 4.10:    Quantification of DiI+ve OECs in the right and left dCST and DAT 
A) A coronal section obtained from the T11 segment of the spinal cord of a rat from 
Group 2.  The section has been stained with the OX18 monoclonal antibody to show the 
location of the right dCST (R-dCST), which is the only location containing Wallerian 
degeneration-induced microglial reactivity.  The entire white matter on the dorsal surface 
of the spinal cord was divided into 4 quadrants, with the two deep, smaller quadrants 
comprising the right (R-dCST) and left (L-dCST) dorsal corticospinal tracts.   The 
remainder of the white matter on the dorsal surface comprised the other two quadrants, 
the right (R-DAT) and left (L-DAT) dorsal funiculi.  Using an eyepiece graticule on a 
microscope equipped with both brightfield and fluorescence optics it was determined the 
area containing OX18+ve reactive microglia was approximately 250 µm high.  B) The 4 
quadrants used for cell counting are indicated in this Hoechst-stained coronal section, 
which is representative of the tissue sections used for computing the cell counts.  The cell 
counts were done using a 40X objective; at this magnification the dCST on each side 
filled the entire height of a rectangular eyepiece graticule (~250 µm high) on the 
fluorescence microscope.  Cell counts for the right and left DAT were then computed for 
the remainder of the white matter up to the pial surface of the cord.  C) and D) Higher 
power views of the L-dCST and R-dCST, respectively, showing single DiI+ve cells and 
their Hoechst-stained nuclei.  Each DiI+ve cell with a red fluorescent cell body (red 
arrowhead) and a blue Hoechst stained nucleus (white arrow) was counted.  Bar in ‘A’ = 













FIGURE 4.11:     Reproducibility of DiI+ve Cell Counts 
Histogram depicting the mean number (+/- SEM) of DiI+ve cells (Y-axis) in the R-
dCST/L-dCST (A) and in the R-DAT/L-DAT (B) of 14 tissue sections from the T11 
spinal cord segment of rats in Groups 1 (n = 7 sections) and 2 (n = 7 sections).  The first 
and second cell counts for the dCST, L-dCST, R-DAT and L-DAT were each computed 
10 days apart.  A t-test was applied to the data, with the data for the R-dCST (A), L-
dCST (A), R-DAT (B), and L-DAT (B) being analyzed separately for statistical 
significance.  The t-tests showed no significant differences between the first and second 



















































































































FIGURE 4.12:     Comparison of OX42 immunostained and Hoechst fluorescence 
defined areas of the dCST and of the DAT. 
Histogram depicting the mean area (+/- SEM) in square microns (Y-axis) of the R-
dCST/L-dCST (A) and of the R-DAT/L-DAT (B) as measured using fluorescence optics 
(Hoechst-stained sections; n = 12 tissue sections) and brightfield optics (OX42 
immunostaining; n = 12 sections) on tissue sections from the T11 spinal cord segment of 
rats in Groups 1 (n = 3 sections) and 2 (n = 9 sections).  The left sensorimotor cortex of 
each rat had been lesioned 16 weeks prior to perfusion, with the grafting of DiI+ve OECs 
into the right DF of T12 being done 8 weeks prior to perfusion.  The rats received daily 
injections of either saline (Group 2) or minocycline (Group 1) for 6 weeks, with the daily 
treatments beginning 2 weeks before and ending 4 weeks after the OECs were grafted at 
T12.  A t-test was applied to the data, with the area measurements for the R-dCST (A), L-
dCST (A), R-DAT (B), and L-DAT (B) being analyzed separately for statistical 
significance.  The t-tests showed significantly larger areas for the R-dCST and L-dCST 
when they were measured on the OX42 immunostained tissue sections as compared to 
the Hoechst-stained sections; t(22) = 9.1, p<0.0001 (single asterisk) (R-dCST); t(22) = 
6.4, p<0.0001 (single asterisk) (L-dCST).  Conversely, the t-tests showed significantly 
smaller areas for the R-DAT and L-DAT when they were measured on the OX42 
immunostained tissue sections as compared to the Hoechst-stained sections; t(22) = 5.0, 

















































































FIGURE 4.13:     Density of DiI+ve cells in the right dCST of T11 in Groups 1-4. 
 
Histograms depicting the mean number (+/- SEM) of DiI+ve cells per 0.05mm2 area in 
the right dCST of the rostral (A), middle (B) and caudal (C) third of the T11 spinal cord 
segment at 8 weeks after grafting DiI+ve OECs into the right DF of T12.  The left 
sensorimotor cortex of rats in Groups 1 and 2 was lesioned 8 weeks prior to the cell 
grafting. All rats received daily injections of either saline (Groups 2 and 4) or 
minocycline (Groups 1 and 3) for 6 weeks, with the daily treatments beginning 2 weeks 
before and ending 4 weeks after the OECs were grafted at T12 (n=4 for each Group). A 
two-factor analysis of variance (ANOVA) was applied to the data, with the data for the 
rostral (A), middle (B) and caudal (C) thirds of T11 being analyzed separately for 
statistical significance.  Multiple post hoc comparisons were performed with 
Bonferonni’s multiple comparison post-test. Bonferonni’s post-test revealed the density 
of DiI+ve cells in the right dCST was significantly higher (p<0.05; brackets) in the 
saline-treated cortical lesion group than in either the saline-treated no lesion group or the 
minocycline-treated cortical lesion group at the rostral (A), middle (B) and caudal (C) 
levels of T11.  The post-test also revealed a significant reduction in the density of DiI+ve 
cells in the right dCST of the no lesion group as a consequence of the minocycline 
treatment (p<0.05; brackets), but this significant difference was only seen in the dCST of 










































































FIGURE 4.14:     Density of DiI+ve cells in the right DAT of T11 in Groups 1-4. 
Histograms depicting the mean number (+/- SEM) of DiI+ve cells per 0.05 mm2 area in 
the right DF of the rostral (A), middle (B) and caudal (C) third of the T11 spinal cord 
segment at 8 weeks after grafting DiI+ve OECs into the right DF of T12.  The left 
sensorimotor cortex of rats in Groups 1 and 2 was lesioned 8 weeks prior to the cell 
grafting. All rats received daily injections of either saline (Groups 2 and 4) or 
minocycline (Groups 1 and 3), with the daily treatments beginning 2 weeks before and 
ending 4 weeks after the OECs were grafted at T12 (n=4 for each Group). A two-factor 
analysis of variance (ANOVA) was applied to the data with the data for the rostral (A), 
middle (B) and caudal (C) thirds of T11 being analyzed separately for statistical 
significance.  Multiple post hoc comparisons were performed with Bonferonni’s multiple 
comparison post-test. Bonferonni’s post-test revealed the density of DiI+ve cells in the 
right DAT was significantly higher (p<0.05; brackets) in the saline-treated cortical lesion 
group than in the minocycline-treated cortical lesion group at the  rostral (A) middle (B) 
and caudal (C) levels of T11.  The post-test also revealed a significant reduction in the 
density of DiI+ve cells in the right DF of the no lesion group as a consequence of the 
minocycline treatment (p<0.05; brackets), at all levels of the T11 spinal cord segment. In 
addition, the density of DiI +ve cells in the right DAT was significantly higher (p<0.05 
bracket) in the saline-treated cortical lesion group than in the saline treated no lesion 







































































FIGURE 4.15:     Density of DiI+ve cells in the left dCST of T11 in Groups 1-4. 
Histograms depicting the mean number (+/- SEM) of DiI+ve cells per 0.05 mm2 area in 
the left dCST of the rostral (A), middle (B) and caudal (C) third of the T11 spinal cord 
segment at 8 weeks after grafting DiI+ve OECs into the right DF of T12.  The left 
sensorimotor cortex of rats in Groups 1 and 2 was lesioned 8 weeks prior to the cell 
grafting. All rats received daily injections of either saline (Groups 2 and 4) or 
minocycline (Groups 1 and 3) with the daily treatments beginning 2 weeks before and 
ending 4 weeks after the OECs were grafted at T12 (n=4 for each Group). A two-factor 
analysis of variance (ANOVA) was applied to the data with the data for the rostral (A), 
middle (B) and caudal (C) thirds of T11 being analyzed separately for statistical 
significance.  Multiple post hoc comparisons were performed with Bonferonni’s multiple 
comparison post-test. Bonferonni’s post-test revealed the density of DiI+ve cells in the 
left dCST was significantly higher (p<0.05; brackets) in the saline-treated cortical lesion 
group than in the minocycline-treated cortical lesion group at the rostral (A), middle (B) 






































































FIGURE 4.16:     Density of DiI+ve cells in the left DAT of T11 in Groups 1-4. 
Histograms depicting the mean number (+/- SEM) of DiI+ve cells per 0.05mm2 area in 
the left DAT of the rostral (A), middle (B) and caudal (C) third of the T11 spinal cord 
segment at 8 weeks after grafting DiI+ve OECs into the right DF of T12.  The left 
sensorimotor cortex of rats in Groups 1 and 2 was lesioned 8 weeks prior to the cell 
grafting. All rats received daily injections of either saline (Groups 2 and 4) or 
minocycline (Groups 1 and 3), with the daily treatments beginning 2 weeks before and 
ending 4 weeks after the OECs were grafted at T12 (n=4 for each Group). A two-factor 
analysis of variance (ANOVA) was applied to the data with the data for the rostral (A), 
middle (B) and caudal (C) thirds of T11 being analyzed separately for statistical 
significance. Multiple post hoc comparisons were performed with Bonferonni’s multiple 
comparison post-test. Bonferonni’s post-test revealed the density of DiI+ve cells in the 
left DAT was significantly higher (p<0.05; brackets) in the saline-treated groups than in 
their respective minocycline-treated groups at the rostral (A), middle (B) and caudal (C) 
levels of T11.  In addition, the density of DiI +ve cells in the left DAT` was significantly 
higher (p<0.05; brackets) in the minocycline-treated cortical lesion group than in the 










































































4.4.1 Sensorimotor Cortex Aspiration as a Tool for Confining Wallerian 
Degeneration-Induced Glial Reactivity to a Single CNS Fiber Tract 
The simplest model of axon degeneration known to date is the self-destructive 
process observed at the distal portion of transected axons upon injury, termed “Wallerian 
degeneration”. The Process of WD is common in a variety of degenerative disorders 
(Raff et al., 2002).  Given that WD is an active progression, it was hypothesized (Finn et 
al., 2000) that this self-destructive process of injured axons might be a type of 
cytoskeletal reorganization. Interestingly, axons undergoing WD do not possess 
detectable activation of the caspase family of cysteine proteases (Finn et al., 2000), 
suggesting that WD in axons and programmed cell death in the neuronal perikarya may 
be two distinct self-destruct programs (Raff et al., 2002). Since the objective of this part 
of the study was to determine whether WD-induced microglial reactivity contributed to 
the generation of a migratory signal(s), it was important to restrict such glial reactivity to 
a specific CNS fiber tract.  Although WD is known to occur in many types of chronic 
neurodegenerative diseases and after injury to axons caused by toxic, ischemic, or 
traumatic insults (Raff et al., 2000), the sensorimotor cortex aspiration model used in this 
experiment has several advantages over models used by other investigators to induce WD 
of CNS axons. The first advantage was that it induced glial reactivity by means of an 
irreversible injury; as a result of destroying the neuronal cell body of CST axons, there 
was no possibility of these axons regenerating into the CST at T11 and influencing the 
responsiveness of the microglia and astroctyes.  A second advantage was the restriction 
of the glial reactivity in the dorsal funiculus of the spinal cord to a single fiber tract, 
leaving axons in the remainder of this area of white matter intact. Thirdly, it eliminated 
the need for toxic or direct SCI to cause WD-induced glial reactivity. Fourthly, since the 
BBB in the spinal cord is left intact after sensorimotor cortex aspiration, the recruitment 
of inflammatory-blood borne cells (e.g., monocytes, neutrophils, etc.) into the dorsal 
funiculus of T11 should be no greater than in normal tissue.  
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4.4.2 Wallerian Degeneration-Induced Glial Reactivity: Microglial Contribution to 
Generation of a Migratory Signal(s) 
Over the last decade, there has been increasing interest in the role of reactive 
microglia in the process of SCI and repair (Dihne et al., 2001; Giordana et al., 1994; 
Kreutzberg, 1996; Stence et al., 2001). In the experiments reported in this chapter, the 
reactive microglia, and to a lesser extent reactive astrocytes, accumulated in the right 
dCST of T11 in response to the WD of axons in this fiber tract.  Following CNS damage 
in which the BBB is broken down, the activated microglia at the site of the lesion are 
derived mainly from blood-borne recruited monocytes (Giulian et al., 1989). However, in 
CNS fiber tracts undergoing WD, reactive microglia are primarily derived from resident 
microglia (Lawson et al., 1994; Liu et al., 2003).  Thus, in addition to contributing to the 
removal of axonal debris, the conversion of resting microglia into reactive microglia, and 
with the assistance of reactive astrocytes, might partly have functioned in filling the space 
created by the loss of axons in the dCST during WD.  
The confinement of a significantly higher number of DiI+ve OECs to the right 
dCST of sensorimotor cortex lesioned rats (i.e. Group 2) and a significant reduction in the 
number of DiI+ve OECs in this fiber tract after minocycline treatment (i.e. Group 1) 
collectively point to reactive microglia as a potential source of migratory signals inducing 
the migration of OECs within the right dCST. This study revealed that OECs 
preferentially migrated along the path of microglial reactivity in the right dCST as 
compared to the adjoining parts of white matter in the right DAT.  In fact, the presence of 
large and significant number of DiI+ve OECs in the right dCST (i.e Group 2) where the 
reactive microglia and any remnants of WD debris were located supports a potential key 
role of microglia in guiding OEC migration toward the lesion site. In addition, the OECs 
that migrated along this path of WD-induced microglial reactivity might have a potential 
role in neural repair, a subject that was not the focus of this research project.  
 Further support for the contribution of microglia to generation of a migratory 
signal(s) is provided by the significant reduction in numbers of DiI+ve OECs that were 
seen in the right dCST of minocycline-treated rats in Group 1. After peripheral nerve 
injury, macrophages rapidly infiltrate the distal nerve stumps and remove axonal debris 
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and growth inhibitory myelin debris (Bruck, 1997; Stoll et al., 1989).  However, 
macrophages are virtually excluded from CNS fiber tracts (George and Griffin., 1994), 
leaving the job of phagocytic removal of the debris arising from WD to microglia (Flaris 
et al., 1993). The lack of spontaneous nerve regeneration in the CNS might be due to the 
microglia not being activated to the same extent as macrophages in the PNS (Stoll et al., 
1989). In the present study, microglia expressed the complement receptor 3 (OX42), CD4 
(OX35), MHC class I (OX18), and the ED1 antigenic epitope.  Reactive microglia in the 
right dCST contralateral to the cortical lesion continued to express each of these markers 
up to at least 16 weeks after cortex aspiration. The prominent presence of ED1+ve cells 
in the right dCST of sensorimotor cortex lesioned rats (Groups 1 and 2) (Fig. 4.6) also 
indicated the responsiveness of the microglia to the degenerated fibers and myelin debris. 
Stoll et al. (2004) proposed that TGF-ß2 is a major player in the slower phagocytic 
response by microglia to WD. They showed, for example, that TGF-ß2 almost 
completely blocked the myelin phagocytosis by microglia in vitro. Similarly, they 
reported that 1`phagocytosis of myelin debris by peritoneal macrophages that were added 
to degenerating peripheral nerve segments in vitro was reduced by 50% in the presence of 
TGF-ß2 (Stoll et al., 2004).   
The purpose of the present study was to examine the effect of reactive microglia 
on the migration of OECs using an irreversible injury model that involved destroying the 
sensorimotor cortex. The activation of microglia in the dCST at T11 as a consequence of 
WD of the axons in this fiber tract is slow to appear, as indicated by the use of antibodies 
to the OX42, OX18, OX35 and ED1 antigenic epitopes.  It took at least 4-6 weeks for the 
first reactive microglia to be detected in the spinal cord (i.e. at both C6 and T11). This 
slow microglial response to axonal degeneration may have effects on the expression and 
secretion of chemotactic factors that may be needed to produce a favorable environment 
for OEC migration. The presence of reactive microglia within the right dCST may not 
only assist in clearance of the axonal and myelin debris but also could release various 
bioreactive substances that may facilitate not only OEC migration but also collateral 
sprouting by axons left intact due to the exclusion of their perikarya from the aspiration 
lesion. Although the intent was to use an irreversible injury model, due to the 
incompleteness of the sensorimotor cortex injury (due in large part to the vast surface 
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area of cerebral cortex contributing axons to the CST) it is possible there was some 
axonal sprouting from spared CST axons, particularly unmyelinated ones. If such 
sprouting occurred, then the presence of OECs within the dCST may facilitate this aspect 
of neural repair. At this time no study was done on the effect of reactive microglia on 
promoting sprouting of dCST axons. 
 
4.4.3 Wallerian Degeneration-Induced Glial Reactivity: Potential Migratory 
Signal(s) Inducing OECs to Migrate 
The WD-induced microglial reactivity directly and/or indirectly contributed to the 
generation of a migratory signal(s) inducing OECs to migrate along the dCST that 
contained this glial reactivity.  Although much more work is required to identify the 
specific migratory signal(s) at the molecular level, it is possible to speculate on likely 
candidates for these signals, which may include cytokines, chemokines, growth factors, 
and MMPs. For example, since OECs express at least one type of cytokine receptor (i.e. 
the IL-6 receptor; Nan et al., 2001) it is possible their migration along the right dCST was 
chemotactically guided by this as well as other chemotactic molecules secreted as a result 
of the WD-induced microglial reactivity. Whether OECs express any additional cytokine 
receptors remain to be determined, but it is well documented that microglia are an 
important source of both cytokines and chemokines. 
Mechanical injury to nervous tissue, ischemia, or ATP release following injury 
cause microglial activation that induces these cells to secrete various substances 
including various chemokines and cytokines (Perrin et al., 2005) as well as neurotrophic 
factors (Neumann et al., 2006). That might be the case in  the present study as well. 
Reactive microglia that accumulate at a lesion site would release neurotrophins such as 
BDNF, NGF, and NT3 (Batchelor et al., 1999; Batchelor et al., 2002), all of which have 
been shown to enhance axonal growth and neuronal survival (Batchelor et al., 1999). In 
addition, in the rat it has been shown that damage to the lens causes macrophages to 
release proteins that promote regeneration of retinal ganglion cell axons (Leon et al., 
2000; Yin et al., 2006). It is possible that these survival factors may also contribute to 
migratory signals inducing the migration of OECs along the path of microglial reactivity 
in the right dCST, as seen in this study. 
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Microglia have been shown to be in contact with axon sprouts extending into 
collagen gels in vitro (Blackshaw et al., 1997; Babington et al., 2005). In the CNS of 
leech, an important role for the initial accumulation of microglia in the area of injury is in 
the sprouting of severed axons (Ngu et al., 2007). A key observation in the study by Ngu 
et al. (2007) was that when microglial cell migration and accumulation at the lesion site 
were reduced, axon sprouting was also reduced. How microglia might enhance sprouting 
and possibly regeneration of axons is not completely clear. However, there is evidence 
that in the leech CNS, microglia can secrete laminin and other growth-promoting 
molecules of the extracellular matrix in a path in front of the growing axons (Von 
Bernhardi and Muller, 1995). 
Although this study did not determine which cytokines and/or chemokines were 
expressed in the right dCST of left sensorimotor cortex lesioned rats, a variety of these 
molecules can be assumed to have been present as a result of the WD-induced microglial 
reaction. For example, there is a rapid increase in expression of MCP-1, MIP-1α and IL-
1ß at the lesion site in the hemisected spinal cord in adult mice by day 1 after injury 
(Perrin et al., 2005). The increased expression of MIP-1α, MCP-1 and IL-1ß mRNA after 
spinal cord hemisection may correlate with the rapid influx of immune cells and to the 
activation of macrophages at the site of lesion (Schnell et al., 1999).  Even higher levels 
of expression of chemokines (MCP-1, MIP-1α, CCL2, CCL3) and cytokines (TNF-α, IL-
1ß, IL-6), have also been reported in the first 24-48 h at the site of a spinal cord contusion 
injury (Rice et al., 2007; Pan et al., 2002). Differences in the expression levels of specific 
cytokines and chemokines may reflect the fact that a hemisection, in comparison to a 
contusion injury, is a much smaller lesion. Likewise, large traumatic injuries to the 
cerebral cortex or to the entorhinal cortex cause a substantial increase in MCP-1 
(Glabinski et al., 1996; Babcock et al., 2003), IL-1ß and TNF-α (Rostworowski et al., 
1997) at the site of the lesion.  
In contrast to the rapid recruitment of large numbers of macrophages at the site of 
a lesioned peripheral nerve (Ma et al., 2002; Popovich et al., 1999), macrophages are 
recruited much more slowly into areas of CNS white matter undergoing WD (Bendszus 
and Stoll, 2003; Buss and Schwab, 2003).  However, minimal expression of MCP-1, 
MIP-1α and IL-1ß in these areas of white matter may account for the lack of recruitment 
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and activation of microglia.  The injection of recombinant MCP-1 and MIP-1α into areas 
of spinal cord white matter undergoing WD induced a rapid increase in the number of 
activated microglia and rapid myelin phagocytosis (Perrin et al., 2005). The origin of 
these activated microglia is not known, but they are likely to be of endogenous microglial 
origin. It has been reported that monocyte recruitment and myelin clearance at the site of 
a contusion injury in the spinal cord is reduced in CCR2 chemokine receptor null mice; 
this receptor is a major receptor for MCP-1 (Ma et al., 2002). It has also been shown that 
MCP-1 and MIP-1α contribute to the recruitment of monocytes and activation of 
macrophages in lysophosphatidylcholine-induced demyelination in mouse spinal cord 
(Ousman and David, 2001). These and other studies indicate that under certain 
conditions, peripheral macrophages can be recruited into the CNS (Tran et al., 1998; 
Popovich et al., 1999). In addition to their potential beneficial effects on axon 
regeneration by means of clearing myelin debris, microglia/macrophages have also been 
shown to secrete growth factors that promote remyelination by oligodendrocyte 
progenitor cells (Kotter et al., 2001).  
Growth factors may also have played a role in regulating OEC migration. For 
example, GDNF has been shown to be involved in cell migration; GDNF signaling 
through the Ret receptor tyrosine kinase and a glycosyl phosphatidylinositol (GPI)-linked 
ligand-binding subunit known as GFR -1 was required for the migration of 
parasympathetic neuronal precursors during early embryonic development (Enomoto et 
al., 2000).  In an in vitro and in vivo study, GDNF also significantly promoted OEC 
migration (Cao et al., 2006).  In addition, GDNF has been reported to be a potent survival 
factor for midbrain dopaminergic neurons (Lin et al., 1993) and has been proposed as a 
potential therapeutic agent for the treatment of neurodegenerative diseases (Lapchak, 
1996). Previous studies have shown that the transplantation of OECs genetically modified 
to secrete high levels of GDNF resulted in significantly improved recovery after SCI 
(Cao, et al., 2004). Although the underlying mechanisms are not understood, it is likely 
that the GDNF secreted by these genetically modified OECs had not only promoted 
neural repair, but also influenced the OECs themselves, given the suggested chemotactic 
role of this growth factor as supported by the findings of Cao et al. (2006).   
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Interestingly, Lai and Todd (2006) showed that minocycline had no effect on 
GDNF expression by microglia in vitro. Whether microglial expression of GDNF is 
similarly unaffected by minocycline treatment in vivo is not known at present. However, 
the findings of the experiments reported in this chapter demonstrated that the minocyline 
treatment reduced the microglia reactivity and was also accompanied by a significant 
decrease in the number of DiI+ve OECs in the right dCST. If GDNF is one of the 
migratory signals secreted by reactive microglia in the right dCST, then one can speculate 
that the minocycline treatment in our in vivo animal model must have decreased GDNF 
expression by the microglia in addition to having dampened their reactivity to the WD of 
the CST axons. 
The motility of a cell depends on reorganization of the actin cytoskeleton and the 
development of cell polarity. Actin polymerization, extension of lamellipodia and 
filopodia, and the formation of new attachment to the substratum must be coordinated 
with contractile elements to pull the cell along the substratum and to disrupt trailing 
attachments (Ridley, 2001). It was found that treatment of OECs in vitro with GDNF 
induced actin filament redistribution as well as an upregulation of cytoskeleton proteins 
in the cytoplasmic processes of OECs.  Such an effect of GDNF on the cytoskeleton of 
OECs is likely to influence their migration. However, further study is necessary to 
elucidate the underlying mechanism. A recent report has demonstrated that NCAM can 
act as a receptor for GDNF.  GDNF binding to NCAM stimulated Schwann cell 
migration as well as axonal growth by hippocampal and cortical neurons (Paratcha et al., 
2003).  In addition, the JNK signaling pathway has been shown to play a role in 
regulating cell migration (Yamauchi et al., 2002).  Cao and coworkers (2006) showed 
that Src kinase activation, which plays a role in JNK activation during cell migration, was 
essential for the GDNF-induced migration of OECs. Further study is necessary to clarify 
the details of the signaling mechanism through which JNK is involved in GDNF-
mediated OEC migration. It has been reported that during development, OECs migrating 
toward the OB were guided by soluble factors from the OB (Liu et al., 1995). Moreover, 
GDNF is highly expressed in the OB neurons (Buckland and Cunningham, 1998). 
Therefore, it is likely that the secreted GDNF from OB might be one of the factors that 
promote OECs migration toward the OB during embryonic development. Whether GDNF 
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may have contributed towards the generation of migratory signal(s) to induce OEC 
migration into the right dCST in saline-treated sensorimotor cortex aspirated rats should 
be addreesed in future experiments.  
BDNF is part of the neurotrophin family of secreted proteins, which are essential 
for the development and functioning of the vertebrate nervous system. BDNF can signal 
through two types of cell-surface receptors: the tyrosine kinase receptor TrkB and the p75 
pan-neurotrophin receptor (Segal et al., 1995).  Previously, several studies have shown 
that OECs produce BDNF in vitro, in addition to other neurotrophic factors (Woodhall et 
al., 2001 and Lipson et al., 2003). Furthermore, BDNF has been found in vivo in 
association with OEC grafts in the injured rat spinal cord (Sasaki et al., 2006). However, 
direct evidence implicating BDNF in the stimulation of non-olfactory CNS axon growth 
by grafted OECs is still lacking. BDNF is expressed in cerebellar granule cells 
(Rocamora et al., 1993) and the level of BDNF expression increases during development. 
Granule cells also express the high affinity BDNF receptor TrkB (Segal et al., 1995). It 
was shown that BDNF stimulates the migration of granule cells. Both in vivo and in vitro 
studies demonstrated that the migration of granule cells was impaired in the absence of 
BDNF (Borghesani et al., 2002). Interestingly the impaired migration of granule cells can 
be rescued by exogenous BDNF, indicating that it is a direct result of the lack of BDNF. 
That microglial-derived BDNF may have had a chemotactic effect on OECs is thus a 
possibility worth considering since the BDNF receptor (i.e. trkB) is also expressed by 
OECs (Bianco et al., 2004). 
Matrix metalloproteases released by reactive microglia in response to the WD 
may also have contributed to the generation of a migratory signal(s) for OECs by creating 
a more favorable extracellular milieu. For example, the MMPs could break cell-matrix 
contacts and possibly activate cytokine precursor molecules (e.g. pre-IL-6); any of these 
processes would contribute to the generation of a chemotactic gradient for OEC 
migration. It was shown that OECs expressed the IL-6 receptor (Nan, 2001). A recent 
study by Pastrana et al. (2007) showed that the proportion of adult neurons that 
regenerate their axons was increased on OEC monolayer by adding BDNF. Combining 
BDNF with MMP2 further enhanced this effect. The possible release of both MMP2 and 
BDNF by activated microglia in our experimental animal model can be speculated. These 
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factors might contribute to the creation of a migratory path that supports and enhances 
OEC migration into the right dCST. 
 
4.4.4 Potential Direct Effect of Minocycline Treatment on OEC Migration 
It appears that minocycline offers neuroprotection via the overall down-regulation 
of factors produced by reactive microglial, but it is also well known that reactive 
microglia produce a number of neuroprotective molecules as well (Polazzi and 
Contestabile, 2002). Such neuroprotective molecules include neurotrophic factors that 
activate neuronal survival cascades and non-secreted proteins such as transporters and 
enzymes, which function to scavenge toxic extracellular substances. Compared to the 
conventional harmful  microglial factors, these beneficial  proteins have been 
relatively overlooked in the past. The minocycline-induced inhibition of the production of 
these beneficial proteins by reactive microglia is likely to have deleterious effects.  In 
both in vivo and in vitro models of stroke, minocycline was found to attenuate the 
production of microglial mediators of inflammation, such as nitric oxide (NO), pro-
inflammatory cytokines, cyclooxygenases, and prostaglandins (Yrjanheikki et al., 1998; 
Suk, 2004). The anti-inflammatory effects of minocycline on WD-activated microglia are 
unknown, but the result of the sensorimotor cortex aspiration experiment showed a 
dampening of microglial response to this axon degeneration as indicated by 
immunohistochemical staining with the ED1, OX18, OX35 and OX42 monoclonal 
antibodies (Fig 4.6). The six week treatment with minocycline clearly also reduced the 
number of OECs that migrated into the R-dCST, supportive of a link between microglial 
reactivity and the migration of OECs.  However, we cannot rule out the possibility that 
the minocycline might have had a direct effect on the OECs, an effect that might have 
influenced their migratory ability or their responsiveness to chemotactic cues.   
 
4.5 Conclusion 
The pilot study demonstrated that glial reactivity in the dCST of the T11 segment 
of the spinal cord that arises as a result of WD of CST axons was very slow to appear. It 
was concluded that 8 weeks after the sensorimotor cortex lesion was the best time point 
for grafting OECs into the T12 segment of the spinal cord since at this time point both 
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microglia and astrocytes in the dCST were reactive at the level of T11. From the 
immunostaining data, it appears that the intensity of the microglial reaction to these WD 
of CST axons is higher than that of astrocytes, which never did express detectable levels 
of nestin in the R-dCST.  
Two conclusions can be drawn from the cell grafting experiment reported in this 
chapter.  Firstly, the migratory path taken by DiI+ve OECs was preferentially within 
areas containing reactive microglia (i.e. within the R-dCST).  Thus, there appears to be 
something different in areas of white matter containing reactive microglia that creates a 
more favourable environment for OEC migration than is present in adjacent areas of 
white matter that contain resting microglia.  Secondly, the minocycline treatment both 
dampened microglial reactivity and significantly reduced the number of migrating DiI+ve 
OECs (summarized in Fig 4.17).  The findings of this study link the presence of a 
migratory signal(s) both spatially and temporally with the WD-induced microglial 
reactivity.  The sensorimotor cortex aspiration model may be useful for dissecting out the 
migratory signal(s) driving the migration of OECs in the adult rat spinal cord. 
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FIGURE 4.17:      Main findings of cortical lesion study  
 
OX42 immunostained tissue sections from the middle third of the T11 segment of the 
spinal cord at 16 weeks after left sensorimotor cortex aspiration in rats of Groups 2 (A, 
D) and 4 (C, F) show the microglial reactivity is confined to the right dCST.  The 
histograms in ‘B’ and ‘E’ are the same one’s depicted in Figs 4.14B and 4.15B, 
respectively.  These micrographs and histograms illustrate the major findings of this 
study: (i) there was a significantly higher density of DiI+ve OECs within the right dCST 
of cortical lesioned rats as compared to rats with no cortical lesion; and ii) the migratory 
path taken by DiI+ve OECs was preferentially within areas containing reactive microglia 
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CHAPTER 5.0   OEC Migration in Response to TNF-α-Induced Glial   Reactivity   
5.1 Introduction 
5.1.1 Tumor Necrosis Factor-  (TNF-α) 
 Tumor necrosis factor-  (TNF-α) is a potent, pleiotropic, proinflammatory 
cytokine that is produced by hematopoietic and nonhematopoietic cells, mainly 
macrophages, and in the CNS can be produced by activated astrocytes and microglia as 
well as CNS-infiltrating lymphocytes and macrophages (Palladino et al., 2003; Ware, 
1995). TNF was named because of its ability to cause necrosis of tumors in experimental 
animal models when it was administrated in pharmocological doses (Carswell et al., 
1975). TNF-α exerts its effect on cells by binding to one of two structurally related, but 
functionally distinct, receptors, namely the TNF-R1 (the p55 TNF receptor) and the TNF-
R2 (p75 TNF receptor) receptors; these receptors are coexpressed by most cell types 
(Aggarwal, 2003; Peschon et al., 1998; Wallach et al., 1997), including glial, neuronal, 
and endothelial cells of the CNS (Dopp et al., 1997). The complexity of the action of 
TNF-α in vivo reflects factors such as the differential presence and activity of the soluble 
17-kDa and cell-associated 26-kDa molecular forms of TNF-α, and to differential 
expression and cell signaling function of TNF-R1 and TNF-R2.  
 
5.1.2  TNF-α signaling   
Most biological activities classically attributed to TNF-α are mediated by binding 
to the TNF-R1 receptor. This receptor belongs to the death receptor family and can signal 
cell death by apoptosis (Wallach et al., 1997). In contrast, the TNF-R2 induces 
proliferation of thymocytes in vitro and possibly also plays a role in suppressing TNF-α 
mediated inflammatory responses in vivo (Peschon et al., 1998). The role of TNF-α in 
acute CNS pathology is complex. This may be largely due to the highly complex 
intracellular signaling pathways associated with the TNF-Rs, and to the fact that many 
ligands in addition to TNF-α can bind the TNF-Rs (reviewed in Wajant et al., 2003). The 
existence of two receptors contributes significantly to the diversity of cellular activities 
affected by the binding of TNF-α to these receptors due to their different tissue 
distribution and to their distinctly different intracellular signaling pathways following 
binding of the ligand (Aggarwal, 2003). Although TNF-R1 is constitutively expressed on 
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virtually all nucleated cells, expression of TNF-R2 is limited to immune cells and 
endothelial cells (Aggarwal, 2003). TNF-R2 does appear to have specific signaling 
functions in T-cells that lack the TNF-R1 receptor (Grell et al., 1998).  
A big difference between the two receptors is the presence of a death domain on 
the cytoplasmic portion of TNF-R1 that is not found on TNF-R2. After TNF-α binding, 
signaling through TNF-R1 proceeds by recruitment of the TNF-receptor associated death 
domain (TRADD), the receptor-interacting protein (RIP), and TNF-R- associated factor 2 
(TRAF2) to the cytoplasmic portion of TNF-R1. At this point, the presence in the cell of 
various accessory proteins determines whether signaling will lead to apoptosis or 
inhibition of apoptosis. Further recruitment of the Fas associated death domain (FADD) 
leads to the binding and activation of procaspase 8, which in turn activates caspase 3 to 
induce apoptosis (Ashkenazi et al., 1998). Alternatively, TRAF2 can recruit cellular 
inhibitors of apoptosis (cIAP-1 and cIAP-2) and activate signaling pathways leading to 
nuclear translocation of the anti-apoptotic NF-kB and activating protein 1 (AP-1) 
transcription factors, which upregulate genes necessary to increase inflammation and cell 
proliferation as well as block apoptosis (Baud and Karin, 2001).  
Although TNF-R2 lacks the death domain and therefore cannot trigger apoptosis, 
it can still recruit TRAF2 and activate the NF-kB and AP-1 pathways. The path that a 
given cell takes is thus dependent on which receptor(s) is present as well as the gathering 
of other accessory proteins present in the cell. It has been reported that internalization of 
the TNF/TNF-R1 signaling complex is necessary for activation of apoptosis (Micheau et 
al., 2003; Schutze et al., 1999), whereas clustering of the TNF/TNF-R1 signaling 
complex in lipid rafts results in activation of the NF-kB and AP-1 pathways (Legler et al., 
2003). This means of regulating the decision between cell death or cell survival could in 
part be controlled by the form of TNF-α encountered by the cell. The binding of soluble 
TNF-α is favored by TNF-R1 and therefore could signal in either direction. However, the 
binding of transmembrane TNF-α to TNF-R2 would result in a complex that is not 
internalized and is therefore unable to signal cell death.  
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5.1.3 Detrimental and Beneficial Proinflammatory Properties of TNF-α  
TNF-α is recognized predominantly for its detrimental proinflammatory 
properties and their contribution to disease, but there is compelling evidence that chronic 
TNF-α expression in vivo leads to unique regulatory properties and that may be of benefit 
to tissue repair (Jacob et al., 1990). TNF-α can suppress the progression of autoimmune 
diseases in vivo when present systemically (Jacob et al., 1990) or expressed by target 
tissues (McSorley et al., 1997), and disease suppression is associated with depressed 
antigen-specific T-cell responses. 
It would be interesting to induce EAE in transgenic mice that over express TNF-α 
in their glial compartments to determine whether similar beneficial effects are mediated 
during CNS autoimmunity induced pathology. Several mechanisms for such suppressive 
effects have been proposed, for example the attenuation of T-cell receptor (TCR) 
signaling (Cope et al., 1998). TNF-α can also directly induce apoptosis of CD8+ve and 
CD4+ve T cells in vivo (Zheng et al., 1995; Sytwu et al., 1996) and thereby may 
contribute to FasL/Fas-mediated signaling in the elimination of autoreactive T cells. It is 
particularly relevant that EAE induced in TNFR1-deficient mice results in a chronic 
disease with a profound increase in the number of inflammatory cells in the CNS tissue at 
late stages of disease progression (day 60 after immunization) and a marked reduction in 
T-cell apoptosis in the inflammatory infiltrates (Bachmann et al., 1999). These data 
indicate that TNF/TNFR1 signaling plays a major role in the removal of T cells from 
lesions, and therefore there may be undesirable endpoints when anti-TNF-α therapy is 
used during active T-cell-driven disease phases. Further evidence for regulatory effects 
has been obtained in TNF-deficient mice where myelin-specific T-cell reactivity fails to 
regress and expansion of activated/memory T cells results in an exacerbated pathology in 
the EAE animal model (Kassiotis and Kollias, 2001).  
There is also evidence that TNF-α has an impact on the mechanisms involved in 
brain repair. For instance, TNF-deficient animals displayed a significant delay in 
remyelination, which was associated with reductions in the pool of proliferating 
oligodendrocyte progenitors and in the number of mature oligodendrocytes. TNF-R2, but 
not TNF-R1, mediated this detrimental effect on the reparative role of TNF-α (Arnett et 
al., 2001). TNF-R1 and TNF-R2 may also have opposing direct effects on neurons, with 
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the former having detrimental effects and the latter being neuroprotective (Fontaine et al., 
2002). TNF-R1 has recently been shown to inhibit postnatal neurogenesis in the 
hippocampus (Losif et al., 2006). The exact mechanisms underlying such differential 
properties of these receptors have yet to be fully determined, but the dual activity of the 
cytokine may depend on the time and progression of the damage. In a model of traumatic 
brain injury, TNF-null mice exhibited less severe cognitive and motoneuron impairments 
than wild type mice in the acute post-traumatic period (Scherbel et al., 1999). While 
neurological functions following such traumatic brain injury recovered by 2–3 weeks 
post-injury in wild type mice, TNF-null animals still demonstrated motor deficits up to 4 
weeks after injury. Brain damage at 4 weeks post-injury was also significantly more 
extensive in the TNF-deficient mice (Scherbel et al., 1999).  
 
5.1.4 Major Role of TNF Signaling in CNS Inflammation and Demyelination 
TNF-α released from macrophages, microglia or autoreactive T cells contribute to 
the pathogenesis of immune-mediated demyelination in both MS and EAE (Selmaj et al., 
1991a, b; Probert and Selmaj, 1997). TNF-α has been detected within demyelinating 
lesions in postmortem MS brains (Hofman et al., 1989; Selmaj et al., 1991a; Woodroofe 
and Cuzner, 1993), and the concentration of TNF-α is elevated in the serum and 
cerebrospinal fluid (CSF) of patients with active MS (Hauser et al. 1990; Tsukada et al., 
1991). The effects of TNF-α on cells in vitro, such as on astrocyte proliferation, on 
microglial proliferation and reactivity, and on endothelial cell activation are all consistent 
with an inflammatory role for this cytokine in the CNS and for a role in the induction of 
immune reactivity (Merrill and Benveniste, 1996). The TNF-α ligand/receptor system can 
trigger oligodendrocyte death, which is evidence of the role of this cytokine in 
demyelination. Both the TNF-R1 and the TNF-R2 receptors are selectively expressed on 
oligodendrocytes located at the edge of active MS lesions; TNF-α has been demonstrated 
to kill oligodendrocytes in primary cell cultures and to kill oligodendrocyte cell lines 
selectively (D'Souza et al., 1995; Selmaj and Raine, 1988).  
A dominant role for the TNF-R1 in signaling both inflammation and 
demyelination in TNF-α transgenic mice was demonstrated by the finding that disease 
was completely abrogated when mice were bred onto a TNF-R1-deficient background 
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(Akassoglou et al., 1998). In contrast, expression of the TNF-α transgene on a TNF-R2-
deficient background did not alter the disease phenotype. Further information concerning 
the mechanisms by which TNF-α can induce oligodendrocyte death and primary 
demyelination has also come from transgenic studies. In these studies, TNF-α, which can 
act as a soluble protein acting upon cell targets distant from its cellular source or as a 
transmembrane molecule that can exert its action only by cell-to-cell contact, was 
overexpressed in different CNS cell types (neurons, astrocytes and oligodendrocytes) 
using cell lineage-specific promoters. These TNF-α overexpressing cells established 
different cell contacts in the CNS. Among the cell types used in this study, microglia 
were the most appropriate source of TNF-α expression since they are immune-competent 
cells capable of expressing adhesion molecules and a variety of proinflammatory 
cytokines, including TNF-α. In addition, activated microglia/ macrophages together with 
astrocytes are the major source of TNF-α in MS and EAE lesions. CNS injuries are 
commonly damaging to neurons and oligodendrocytes, indicating that these cells are 
direct or indirect targets of TNF-α action (Akassoglou et al., 1997, 1999).  
The relevance of results from transgenic studies has been supported by EAE 
studies done in mice deficient in TNF-α, or in one or both of its receptors (Frei et al., 
1997; Kassiotis et al., 1999; Korner et al., 1997b; Liu et al., 1998; Suen et al., 1997). 
These studies demonstrated that TNF-α is not essential for CNS inflammation or 
demyelination because EAE can be induced in these mice and, thus, other mechanisms 
can compensate for TNF-α in its absence. However, TNF-α plays a critical 
proinflammatory role in the initiation of EAE and in the modulation of inflammatory cell 
trafficking into the CNS parenchyma (Kassiotis et al., 1999; Korner et al., 1997b). There 
is no clear consensus on the role of TNF-α in CNS acute injuries and understanding the 




5.2 Materials and Methods 
5.2.1 Anesthesia, Laminectomy, Analgesia, Wound Closure and Postoperative          
Care 
In the experiments comprising this portion of the research project the rats 
underwent two surgeries, which were performed one after the other during the same 
surgical approach to the spinal cord. One of the surgeries was injection of vehicle (PBS) 
or of TNF-α  (0.01ng/µl - 100 ng/µl) into the dorsal funiculus of the rostral part of T11; 
in the pilot study reported in Section 5.3.1 the rats were subjected to only one surgery, 
namely for saline or TNF-α injection.   The other surgery was a laminectomy done to 
graft OECs into the dorsal funiculus exactly 5 mm caudal to the TNF-α/saline injection 
(Groups 5-10).  The general surgical procedures involving anesthesia, analgesia, 
laminectomy, wound closure and postoperative care were as described in Sections 3.2.1, 
3.2.2, and 3.2.4. 
 
5.2.2 TNF-α  Injections into Dorsal Funiculus 
A pilot study was done to determine a concentration of TNF-α that would activate 
microglial cells in the ipsilateral dorsal funiculus over at least a 5 mm distance (the 
approximate rostrocaudal length of T11) and a second concentration of TNF-α for which 
the cytokine-induced microglial reaction would be limited to the vicinity of the injection 
site. A glass microcapillary was prepared using a micropipette puller (Model M1; 
Industrial Science Assoc., Inc, NY) and the tip was broken and polished.  The 
microcapillary tip diameter was checked microscopically and only capillaries with a tip 
diameter of 15-20µm were used for the TNF-α injections.  Immediately prior to use, each 
capillary was flushed with 70% ethanol followed by sterile 0.03 M PBS. Then the glass 
needle was connected to a 5 µl Hamilton syringe, which was then mounted onto a rodent 
stereotaxic apparatus using the syringe holder of a KD Scientific Syringe Pump (KDS 
310). In the pilot study, solutions of five different concentrations of TNF-α (diluted in 
0.03 M PBS) were loaded into separate microcapillaries that were attached to the 5 µl 
Hamilton syringe. The concentrations of TNF-α that were used included 0.01 ng/µl (n=6 
rats), 0.1 ng/µl (n=6 rats), 1.0 ng/µl (n=10 rats), 10 ng/µl (n=10 rats), and 100 ng/µl (n=4 
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rats); 9 rats received an injection of vehicle (0.03M PBS) that were similarly loaded into 
separate microcapillaries, which in turn were attached to a 5 µl Hamilton syringe.  
After zeroing the XYZ coordinates of the stereotaxic apparatus, the needle was 
slowly lowered into the right dorsal funiculus of the most rostral part of the T11 spinal 
cord to a depth of 1 mm; the insertion was immediately to the right of the dorsal spinal 
artery. All injections were made under visual control using a Nikon SMZ-1B dissecting 
microscope. Prior to initiating the injection of vehicle or TNF-α, the needle was first left 
in place in the spinal cord for 5 min, after which 2 µl of vehicle or TNF-α were injected 
over 10 min using the KDS 310 syringe pump. As mentioned above, separate 
microcapillaries were used for each concentration of TNF-α injected.  No cell grafts were 
made in the spinal cords of rats used in this pilot study.  After 1, 4, 7 and 14 days (see 
Tables 5.2 and 5.3) the rats were deeply anaesthetized with Somnotol and perfused 
intracardially as described in Section 3.3.1.  For the purpose of this pilot study, a 5 mm 
length of spinal cord was dissected proceeding caudally from the site of injection of TNF-
α or of vehicle into the right dorsal funiculus of T11, frozen, and sectioned at a thickness 
of 40 µm on a sliding microtome as described in Section 3.3.3.  Approximately 120 
sections were collected from each dissected 5 mm length of cord; with each section being 
collected and stored in cryoprotectant solution in 96 well plates (see Section 3.3.3).  
The pilot study revealed that 1 ng/µl and 0.01ng/µl were the concentrations of 
TNF-α that did and did not, respectively, give rise to microglial reactivity along at least a 
5 mm distance extending caudally from the site of cytokine injection (see Section 5.3.1 
for the data).  These two concentrations of TNF-α were chosen for use in rats that were to 
receive an OEC graft.  Two groups of rats (n=4 per group; Groups 5 and 6) received a 2 
µl injection of 1 ng/µl over a period of 10 minutes in the right dorsal funiculus of the 
most rostral part of the T11 spinal cord, using the procedure described above for the pilot 
study.  An additional two groups of rats (n=4 per group; Groups 7 and 8) received an 
injection of 2 µl of 0.01 ng/µl TNF-α, whereas two other groups of rats (n=4 per group; 
Groups 9 and 10) received injections of vehicle (i.e. 0.03 M PBS).  Rats in Groups 5-10 
each received a cell graft of DiI-labelled OECs (1 µl volume) into the right dorsal 
funiculus of T12 exactly 5 mm caudal to the TNF-α (Groups 5-8) or vehicle (Groups 9-
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10) injections (see Section 3.2.3).  Stereotaxic coordinates were used to ensure the correct 
positioning of the OEC grafts exactly 5 mm caudal to the cytokine or vehicle injection.   
 
5.2.3 Grafting DiI-Labelled OECs 
For Groups 5 to 10, OECs from the cell cultures numbered K577, K594, and K56-
13 (see Table 3.1) were used for the grafting of DiI-labelled OECs.  A final cell 
concentration of 50,000 DiI-labelled OECs per µl was loaded into a 5 µl Hamilton 
syringe and the cells grafted into the right dorsal funiculus of T12 as described in Section 
3.2.3.  
 
5.2.4 Minocycline Treatment 
In the experimental design described in Section 5.3.2, minocycline was used to 
dampen the TNF-α-induced microglial reactivity and thus to address the extent to which 
microglial reactivity contributed to the generation of a migratory signal(s).  Groups 6, 8, 
and 10 rats received daily IP injections of minocycline (45 mg/ kg in 0.9% saline) 
whereas Groups 5, 7, and 9 rats received daily IP injections of an equivalent volume of 
vehicle (i.e. 0.9% saline).  The minocycline and saline injections were begun on the day 
of the surgery for injecting TNF-α/saline and grafting OECs into the dorsal funiculus; the 
injections continued on a daily basis for a total of 4 weeks.  Daily examination of each rat 
prior to performing the IP injection did not show any observable evidence of adverse 
reactions to either the minocycline or saline injections. 
 
5.2.5 Necropsy, Tissue Sectioning and Immunohistochemistry 
Rats were deeply anesthetized by administering a lethal dose (90 mg/kg body 
weight) of sodium pentobarbital injected IP. The timing of this perfusion in the pilot 
study was 1, 4, 7 and 14 days after TNF-α/saline injection; the concentrations of TNF-α 
that were used in the pilot study included 0.01 ng/µl (n = 6), 0.1 ng/µl (n = 6), 1.0 ng/µl 
(n = 10), 10 ng/µl (n = 10), and 100 ng/µl (n = 4), and 0.03M PBS (vehicle) (n=9), (See 
Table 5.1). The Group 5-10 rats, all of which had received an OEC graft, were killed 8 
weeks after receiving the cytokine injection and cell graft.  All rats were perfused through 
the heart with 1% sodium nitrite followed by 4% PF as described in Section 3.3.1.  The 
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spinal cord was dissected from the vertebral column as described in Section 3.3.2.  Prior 
to cutting free-floating frozen tissue sections on the sliding microtome, a 5 mm piece of 
spinal cord immediately rostral to the location of the OEC graft, which was primarily 
T11, as well as a corresponding 5 mm piece immediately caudal to the cell graft, which 
was primarily T12/13, were dissected out of the spinal cord.  Each piece of spinal cord 
was sectioned separately on a sliding microtome; some of the tissue sections were stained 
with Hoechst dye and mounted in CitiFlour for cell counting (see Section 3.3.3) whereas 
others were mounted and immunostained with the microglial and astrocytic markers 
described in Section 3.4.2.   The remaining tissue sections were stored in the freezer in 
cryoprotectant solution, as described in Section 3.3.3. 
 
5.2.6 Data Collection and Statistical Analysis 
Assessment of the presence or absence of glial reactivity in the 5 mm of the dorsal 
funiculus laying caudal to the TNF-α/saline injection in the rats used in the pilot study, as 
well as in the Group 5-10 rats that also received an OEC graft, was done subjectively.  
For the purpose of the experiments reported in Sections 5.3.5-5.3.6 of this chapter, tissue 
sections collected into the first four wells were considered to comprise the rostral one-
third of T11, sections in the second four wells comprised the middle one-third, and the 
final four wells comprised the caudal one-third of T11.   
For cell counting in Groups 5-10 rats, four sections were randomly chosen from 
each of the rostral, middle and caudal portions of T11 and of T12-T13 and mounted onto 
a microscope slide.  These sections were stained with Hoechst dye (2 µg/ml) prior to 
mounting with CitiFluor.  Each tissue section was examined to determine whether it 
contained any DiI+ve cells, to identify the specific location in which the cells were found 
(i.e. right vs. left dorsal funiculus), and to count the total number of labelled cells within 
the respective dorsal funiculus. The numbers of DiI-labelled cells within the dorsal 
funiculus on the right and left sides were computed separately. Only DiI+ve profiles that 
were associated with a nucleus were counted.  
For statistical analysis, the mean cell count for each group of 4 sections was 
computed.  Mean cell counts were computed for each of the rostral, middle and caudal 
portions of T11 and of T12-13. It is necessary to mention that because of the high density 
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of DiI+ve OECs at the site of cell grafting, which extended for approximately 0.4 mm in 
each direction (both rostrally and caudally) away from the injection site, it was not 
possible to visualize single DiI+ve OECs.  Thus, to be more accurate in the cell counting 
no tissue sections were chosen for counting DiI+ve cells closer than 0.4 mm rostral and 
caudal to the OEC graft.  The T11 cell counts collected for Groups 5-10 were statistically 
compared using a two-factor analysis of variance (ANOVA), with the data for the rostral, 
middle and caudal thirds of the right and left dorsal funiculi of this spinal cord segment 
being analyzed separately for statistical significance (see Section 3.5.3). Multiple post 
hoc comparisons were performed with Bonferonni’s multiple comparison post-test.  The 
independent variables were cytokine injection (i.e. TNF-α vs. vehicle) and treatment (i.e. 
minocycline vs. vehicle). 
To determine whether the OECs were induced to migrate preferentially towards 
the TNF-α injection, ratios were computed of the number of DiI+ve OECs in the dorsal 
funiculus of T11 vs. T12-T13 at 8 weeks after either TNF-α (Groups 5 and 7) or vehicle 
(Group 9) injection into the right dorsal funiculus of the rostral part of T11.  Rats in these 
groups had received daily IP injections of saline, with the daily treatments continuing for 
the first 4 weeks after the OECs were grafted.  An average ratio that was higher than 1 
was indicative of preferential migration towards the cytokine injection.  A two-factor 
ANOVA was applied to these data with the data for the right and left dorsal funiculus 
being analyzed separately for statistical significance.  Multiple post hoc comparisons 
were performed with Bonferonni’s multiple comparison post-test.  The independent 
variables for this two-way ANOVA were cytokine injection (i.e. TNF-α vs. vehicle) and 




5.3.1 Titration of TNF-α  Concentration: Focal vs. Distributed Glial Activation 
Based on the immunohistochemcial examination of the spinal cord tissue between 
1 and 14 days after TNF-α injection into the rostral part of T11, it was concluded that 1 
ng/µl of TNF-α was sufficient to induce glial reactivity ipsilaterally along at least a 5 mm 
distance from the site of cytokine injection.  In contrast, the lowest concentration of TNF-
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α, namely 0.01 ng/µl, induced glial reactivity ipsilaterally that was restricted to the 
vicinity of the injection.  These two concentrations were the ones chosen for use in the 
OEC migration experiment described in Section 5.3.2.  The complete pilot study data are 
described in more detail in the paragraphs comprising the remainder of this section of the 
results, and representative immunohistochemically stained tissue sections are presented in 
Figures 5.1-5.7. 
The vehicle injection into the rostral part of the T11 dorsal funiculus induced a 
focal glial reaction in the vicinity of the injection site that was detectable up to 7 days 
after injection.  This glial reactivity included both microglial (OX42+ve, OX18+ve, 
OX35+ve and ED1) and astrocytic (GFAP+ve, Vim+ve and nestin+ve) components.  
There was no evidence of microglial or astrocytic reactivity in either the middle or the 
caudal parts of T11 between 1 and 14 days after vehicle injection, and by the two week 
time point there also was no longer any sign of glial reactivity even in the vicinity of the 
injection site.  
In marked contrast, the two highest concentrations of TNF-α induced microglial 
(OX42+ve, OX18+ve, OX35+ve and ED1) and astrocytic (GFAP+ve, Vim+ve and 
nestin+ve) reactivity in the dorsal funiculus along the entire extent of T11 and this glial 
reactivity persisted for at least 14 days after injection, which was the longest survival 
time in the pilot study. With 100 ng /µl TNF-α this glial reactivity was bilateral along the 
entire T11 segment at both 1 and 14 days after cytokine injection.  When a 10-fold lower  
concentration of TNF-α was injected (i.e. 10 ng/µl) the microglial and astrocytic 
reactivity was ipsilateral in the dorsal funiculus at the middle and caudal parts of T11 but 
was bilateral in the rostral part of T11.   
The glial reactivity induced by injection of each of the three lowest concentrations 
of TNF-α (i.e., 0.01ng/µl, 0.1 ng/µl and 1 ng/µl) was all confined to the ipsilateral dorsal 
funiculus of T11.  They differed, however, in how far the glial reactivity extended 
caudally from the TNF-α injection.  After injection of 1 ng/µl TNF-α into the dorsal 
funiculus of T11, the microglial (OX42+ve, OX18+ve, OX35+ve and ED1) and 
astrocytic (GFAP+ve, Vim+ve and nestin+ve) reactivity was seen in rostral, middle and 
caudal levels of T11 at all survival times.  A more focal, ipsilateral microglial (OX42+ve, 
OX18+ve, OX35+ve and ED1) and astrocytic (GFAP+ve, Vim+ve and nestin+ve) 
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reaction was seen with the two lowest concentrations of TNF-α (i.e., 0.01 ng/µl, 0.1 
ng/µl). With the latter two concentrations, even at 14 days after cytokine injection there 
was no apparent spread of the glial reactivity away from the injection site, with the glial 
reactivity also remaining confined to the ipsilateral dorsal funiculus. 
Based on the findings of the pilot study, a concentration of 1 ng/µl TNF-α was 
chosen for its ability to induce glial reactivity that was confined to the entire ipsilateral 
extent of T11.  In comparison to vehicle, for which the glial reactivity was no longer seen 
by 14 days after injection, the 0.1 ng/µl and 0.01 ng/µl TNF-α concentrations both 
induced glial reactivity that was still seen in the dorsal funiculus of the rostral part of T11 
even at 14 days after injection.  The 0.01 ng/µl TNF-α was chosen for its ability to 
induce only a focal glial reaction confined to the ipsilateral dorsal funiculus in the 
vicinity of the injection.  
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Table 5.1 Pilot Study: TNF-α Induced Microglial Reactivity 
  Microglial Reactivity 
Conc. of 
TNF-α  
Survival Time Level of T11 







1 day (n=2) R, M & C Y Y N 
 R Y Y N 
4 days (n=1) M & C N N/A N/A 
 R Y Y N 
7 days (n=1) M & C N N/A N/A 
 R Y Y N 
0.01 ng/µl 
   14 days  (n=2) M & C N N/A N/A 
1 day (n=2) R, M & C Y Y N 
 R Y Y N 
4 days (n=1) M & C N N/A N/A 
 R Y Y N 
7 days (n=1) M & C N N/A N/A 
 R Y Y N 
0.1 ng/µl 
    14days (n=2) M & C N N/A N/A 
1 day (n=3) R, M & C Y Y N 
4 days (n=2) R, M & C Y Y N 
7 days (n=2) R, M & C Y Y N 
1 ng/µl 
   14 days (n=3) R, M & C Y Y N 
 R Y N Y 
1 day (n=3) M & C Y Y N 
 R Y N Y 
4 days (n=2) M & C Y Y N 
 R Y N Y 
7 days (n=2) M & C Y Y N 
 R Y N Y 
10 ng/µl 
    14 days (n=3) M & C Y Y N 
 R, M & C Y N Y 100 ng/µl 
1 day(n=2) R, M & C Y N Y 
 n= number of rat 
 R= Rostral part of T11 
M= Middle part of T11 
C= Caudal part of T11 
Y= Yes 
N= No 








Table 5.2 Pilot Study: TNF-α Induced Astrocyte Reactivity 
 
  Astrocytes Reactivity 
Conc. of 
TNF-α  
Survival Time Level of T11 







1 day (n=2) R Y Y N 
 M & C N N/A N/A 
4 days (n=1) R Y Y N 
 M & C N N/A N/A 
7 days (n=1) R Y Y N 
 M & C N N/A N/A 
0.01 ng/µl 
  14 days  (n=2) R, M & C N N/A N/A 
1 day    (n=2) R Y Y N 
 M & C N N/A N/A 
4 days (n=1) R Y Y N 
 M & C N N/A N/A 
7 days (n=1) R Y Y N 




R, M & C N N/A N 
1 day (n=3) R, M & C Y Y N 
4 days (n=2) R, M & C Y Y N 
7 days (n=2) R, M & C Y Y N 
1 ng/µl 
14 days (n=3) R Y Y N 
  M & C N N/A N 
1 day (n=3) R Y N Y 
 M & C Y Y N 
4 days (n=2) R Y N Y 
 M & C Y Y N 
7 days (n=2) R Y N Y 
 M & C Y Y N 
   14 days (n=3) R Y N Y 
10 ng/µl 
 M & C Y Y N 
1 day (n=2) R, M & C Y N Y 100 ng/µl 
   14 days (n=2) R, M & C Y N Y 
 
n= number of rat 
 R= Rostral part of T11 
M= Middle part of T11 
C= Caudal part of T11 
Y= Yes 
N= No 
N/A= Not Applicablable 
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FIGURE 5.1: OX18 +ve microglia in the R-DF of T11 following TNF-α or vehicle
injection into the rostral part of T11.
OX18+ve reactive microglia in the R-DF at rostral (A, C, E, G, I, K) and caudal (B, D,
F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11. The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K, L)
after injection of TNF-α or vehicle.  The vehicle injection induced very little
microglial reactivity, as evidenced by minimal OX18 immunostaining that was
confined to the rostral part of T11 at 1 day after injection (I).  Slightly more OX18
immunostaining was seen in the 0.01 ng/µl TNF-α injected rats at the rostral part of
T11 (E) at 1 day after injection and some reactive microglia were also seen in the
caudal part of T11 (F) at this time point.  However, by 14 days after injection of 0.01
ng/µl TNF-α the OX18 immunostaining (G, H) was virtually indistinguishable from
vehicle-injected controls (K, L).  In contrast, the OX18 immunostaining was quite
intense in the rostral part of T11 at 1 day after 1ng/µl of TNF-α injection (A) and the
OX18+ve reactive microglia were still present in both the rostral (C) and caudal (D)
parts of T11 at 14 days after injection.  Scale bar = 400 µm.
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FIGURE 5.2: OX42 +ve microglia in the R-DF of T11 following TNF-α or
vehicle injection into the rostral part of T11.
OX42+ve reactive microglia in the R-DF at rostral (A, C, E, G, I, K) and caudal (B, D,
F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11.  The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K, L)
after injection of TNF-α or vehicle.  The vehicle injection induced very little microglial
reactivity, as evidenced by minimal OX42 immunostaining that was confined to the
rostral part of T11 at 1 day after injection (I).  Slightly more OX42 immunostaining
was seen in the 0.01 ng/µl TNF-α injected rats at the rostral part of T11 (E) at 1 day
after injection and the OX42+ve reactive microglia were barely detectable in the caudal
part of T11 (F) at this time point.  However, by 14 days after injection of 0.01 ng/µl
TNF-α the OX42 immunostaining (G, H) was indistinguishable from vehicle-injected
controls (K, L).  In contrast, the OX42 immunostaining was quite intense in the rostral
part of T11 at 1 day after 1ng/µl of TNF-α injection (A) and the OX42+ve reactive
microglia were still present in both the rostral (C) and caudal (D) parts of T11 at 14
days after injection.  Scale bar = 400 µm.
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FIGURE 5.3: OX35 +ve microglia in the R-DF of T11 following TNF-α or vehicle
injection into the rostral part of T11.
OX35+ve reactive microglia in the R-DF at rostral (A, C, E, G, I, K) and caudal (B,
D, F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11.  The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K,
L) after injection of TNF-α or vehicle.  The vehicle injection induced very little
microglial reactivity, as evidenced by minimal OX35 immunostaining that was
confined to the rostral part of T11 at 1 day after injection (I).  Slightly more OX35
immunostaining was seen in the 0.01 ng/µl TNF-α injected rats at the rostral part of
T11 (E) at 1 day after injection and there were less OX35+ve microglia in the caudal
part of T11 (F) at this time point.  However, by 14 days after injection of 0.01 ng/µl
TNF-α the OX35 immunostaining (G, H) was indistinguishable from vehicle-injected
controls (K, L).  In contrast, the OX35 immunostaining was quite intense in the rostral
part of T11 at 1 day after 1ng/µl of TNF-α injection (A) and the OX35+ve reactive
microglia were still present in both the rostral (C) and caudal (D) parts of T11 at 14
days after injection.  Scale bar = 400 µm.
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FIGURE 5.4: ED1 +ve microglia in the R-DF of T11 following TNF-α or vehicle
injection into the rostral part of T11.
ED1+ve reactive microglia in the R-DF at rostral (A, C, E, G, I, K) and caudal (B, D,
F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11.  The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K,
L) after injection of TNF-α or vehicle.  The vehicle injection induced very little
microglial reactivity, as evidenced by minimal ED1 immunostaining that was confined
to the rostral part of T11 at 1 day (I) and 14 days (L) after injection.  Slightly more
ED1 immunostaining was seen in the 0.01 ng/µl TNF-α injected rats at the rostral (E,
G) and caudal (F, H) parts of T11 at 1 and 14 days after injection. In contrast, the ED1
immunostaining was more intense in both the rostral (A) and caudal (B) parts of T11
at 1 day after 1ng/µl of TNF-α injection (A) and the ED1+ve reactive microglia were
still present in both the rostral (C) and caudal (D) parts of T11 at 14 days after
injection.  Scale bar = 400 µm.
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FIGURE 5.5: GFAP +ve astrocytes in the R-DF of T11 following TNF-α or
vehicle injection into the rostral part of T11.
GFAP+ve astrocytes in the R-DF at rostral (A, C, E, G, I, K) and caudal (B, D, F, H,
J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01
ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of
T11.  The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K, L) after
injection of TNF-α or vehicle.  No detectable astrocyte reactvity was seen in the
caudal parts of T11 following injection of either vehicle (I-L) or of 0.01 ng/µl TNF-α
(E-H). In contrast, the GFAP immunostaining showed prominent astrocyte reactivity
in the rostral (A) part of T11 at 1 day after 1ng/µl of TNF-α injection, but the GFAP
immunostaining was indistinguishable from controls by 14 days after injection (C, D).
Scale bar = 400 µm.
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FIGURE 5.6: Vimentin+ve astrocytes in the R-DF of T11 following TNF-α or
vehicle injection into the rostral part of T11.
Vimentin immunostaining of the R-DF at rostral (A, C, E, G, I, K) and caudal (B, D,
F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11.  The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K, L)
after injection of TNF-α or vehicle. The vehicle injection induced very little astrocyte
reactivity, as evidenced by minimal vimentin immunostaining that was confined to the
rostral part of T11 at 1 day (I) but not at 14 days (K) after injection.  Slightly more
vimentin immunostaining was seen in the 0.01 ng/µl TNF-α injected rats at the rostral
part of T11 at 1 day (E) but not at 14 days (G) after injection.  In contrast, the vimentin
immunostaining was more intense in both the rostral (A) and caudal (B) parts of T11 at
1 day after 1ng/µl of TNF-α injection and small number of vimentin+ve reactive
astrocytes were still present in the rostral (C) part of T11 but not in the caudal (D) part
at 14 days after injection.  Scale bar = 400 µm.
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FIGURE 5.7: Nestin+ve astrocytes in the R-DF of T11 following TNF-α or vehicle
injection into the rostral part of T11.
Nestin immunostaining of the R-DF at rostral (A, C, E, G, I, K) and caudal (B, D, F,
H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01
ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of
T11.  The rats were killed 1 day (A, B, E, F, I, J) or 14 days (C, D, G, H, K, L) after
injection of TNF-α or vehicle. The vehicle (I) and the 0.01 ng/µl TNF-α (E) injections
induced some astrocyte reactivity, as evidenced by nestin immunostaining that was
confined to the rostral part of T11 at 1 day after injection; no nestin immunostaining
was seen in either the rostral (G, K) or caudal (H, L) parts of T11 for either group of
rats by 14 days after injection.  Comparable levels of nestin immunostaining was seen
in the R-DF in the rostral (A) part of T11 at 1 day after 1ng/µl of TNF-α injection and a
small number of nestin+ve reactive astrocytes were still present in the rostral (C) part
of T11 but not in the caudal (D) part at 14 days after injection.  Scale bar = 400 µm.
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5.3.2 Experimental Design 
To address Specific Aim 4 a focal injection of vehicle (0.03 M PBS), 0.01 ng/µl 
TNF-α, or 1 ng/µl TNF-α was made into the rostral part of the dorsal funiculus of T11.  
This experiment tested the hypothesis that a focal injection of TNF-α gives rise to a 
migratory signal inducing OECs to migrate towards the cytokine injection.  Based on the 
pilot study, 1 ng/µl of TNF-α was determined to be a concentration that induced glial 
reactivity confined ipsilaterally to the entire length of the T11 spinal cord segment (~5 
mm) and 0.01 ng/µl TNF-α was a concentration for which the cytokine-induced 
microglial and astrocytic reactivity would be confined to the vicinity of the injection site 
(i.e., the rostral part of T11).  
A total of 24 female adult rats were assigned to one of six groups, with Group 5 
and 6 rats receiving an injection of 1 ng/µl of TNF-α, Group 7 and 8 rats receiving 0.01 
ng/µl TNF-α, and Group 9 and 10 rats receiving an injection of vehicle (0.03 M PBS).  
The injections were made stereotactically directly into the right dorsal funiculus of T11, 
followed immediately by a stereotactic injection of DiI+ve OECs into the ipsilateral 
dorsal funiculus 5 mm caudal to the TNF-α or vehicle injection. Systemically 
administered minocycline was used to reduce the activation of microglia both at the site  
of TNF-α or vehicle injection and along the 5 mm length of white matter extending 
caudally from this injection site (Groups 6, 8 and 10). Rats in the remaining three groups 
(Groups 5, 7 and 9) received systemic injections of saline.  The minocycline (45 mg/kg in 
0.9% saline) and vehicle (i.e. 0.9% saline) were injected IP on a daily basis for the first 
four weeks after the TNF-α/vehicle injections and OEC grafts into the spinal cord (Fig. 
5.8).  All rats were killed 8 weeks after cell grafting for quantification of the numbers of 
DiI+ve OECs located in the dorsal funiculus that had migrated rostral and caudal to the 
cell grafts. 
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FIGURE 5.8:     Summary of experimental design 
Adult female Wistar rats (230- 260 g) received a 2 µl injection of either 1 ng/µl 
(Groups 5 and 6) or 0.01 ng/µl (Groups 7 and 8) of TNF-α or an equal volume of vehicle 
(Groups 9 and 10) into the right DF in the most rostral part of T11 (n = 4 per group).  
Immediately after injecting the TNF-α or the vehicle into the rostral part of the DF of 
T11, DiI labeled OECs were grafted into the right DF exactly 5 mm caudally.  All rats 
received daily i.p. injections of either saline (Groups 5, 7 and 9) or minocycline (Groups 
6, 8 and 10), with the daily treatments continuing for the first 4 weeks after the OECs 
were grafted. All rats were killed 8 weeks after cell grafting. 
Group 10
PBS  injected  into  T11/OEC
grafted into T12
Group 9
PBS  injected  into T11/OEC grafted
into T12
Group 8
TNF-α (0.01µl) injected into
T11/OEC grafted into T12
Group 7
TNF-α (0.01µl) injected into
T11/OEC grafted into T12
Group 6
TNF-α (1ng/µl) injected into
T11/OEC grafted into T12
Group 5
TNF-α (1ng/µl) injected into
T11/OEC grafted into T12
 TNF-α or PBS injected into T11
DiI labeled OECs grafted into T12
Minocycline/Saline IP injection
            the first 4 weeks
   TNF- α/ PBS injected into T11
  DiI labeled OEC grafted in T12
 Perfusion 8 weeks after
             cell graft
0




5.3.3 Microglial and astrocytic reactivity: Effectiveness of minocycline   treatment 
 The spinal cord tissues of Groups 5-10 rats were stained with antibodies that 
identified reactive microglia (OX18, OX42, OX35 and ED1 monoclonal antibodies) and 
reactive astrocytes (GFAP, Vim and nestin monoclonal antibodies) to confirm that the 
minocycline treatment had been effective in preventing the activation of microglia and in 
assessing the treatment’s effect on astrogliosis.  In the saline-treated rats that had received 
an injection of TNF-α into the rostral part of T11 and a cell graft of DiI+ve OECs 5 mm 
caudally (Groups 5 and 7), OX18+ve (Fig. 5.9), OX42+ve (Fig.5.10), OX35+ve (Fig. 
5.11) and ED1+ve (Fig. 5.12) reactive microglia were present in the right dorsal funiculus 
at the rostral and middle levels of T11 at 8 weeks after TNF-α injection and OEC 
grafting. Although no cell counts of microglia or other tests to determine the level of 
OX42, OX18, OX35 and ED1 expression were performed on spinal cord tissue of Group 
5-10 rats, the immunostaining of the reactive microglia appeared to be more intense 
especially in the rostral part of T11 in Group 5 rats (i.e. after injection of 1 ng/µl TNF-α) 
than in the Group 7 rats (i.e. after injection of 0.01 ng /µl TNF-α) (Fig 5.9-5.12). In the 
saline-treated control rats of Group 9 (i.e. 0.03 M PBS injected into dorsal funiculus) 
there was no detectable OX18+ve (Fig. 5.9), OX35+ve (Fig. 5.11) or ED1+ve (Fig. 5.12) 
immunostaining in the right dorsal funiculus of T11.  In the saline-treated rats of Groups 
5, 7 and 9, GFAP+ve (Fig. 5.13), Vim+ve (Fig. 5.14) and nestin+ve (Fig. 5.15) reactive 
astrocytes were seen only in the rostral part of T11 and only after injection of 1 ng/µl of 
TNF-α (Group 5). There was no detectable astrocyte reactivity in either the rostral or 
middle parts of T11 following injection of vehicle (Group 9; Fig. 5.13-5.15). 
 In the minocycline-treated rats that had received an injection of TNF-α into the 
rostral part of T11 and a cell graft of DiI+ve OECs 5 mm caudally (Groups 6 and 8), 
OX18+ve (Fig. 5.9), OX42+ve (Fig. 5.10), OX35+ve (Fig. 5.11) and ED1+ve (Fig. 5.12) 
reactive microglia appeared to be less intensely immunostained in both the rostral and 
middle parts of T11 in the Group 6 rats (i.e. after injection of 1 ng/µl TNF-α) than in the 
Group 8 rats (i.e. after injection of 0.01 ng/µl TNF-α) (Fig 5.9-5.12). In the minocycline-
treated control rats of Group 10 (i.e. 0.03 M PBS injected into dorsal funiculus) there was 
no detectable OX18+ve (Fig.5.9), OX35+ve (Fig. 5.11) or ED1+ve (Fig. 5.12) 
immunostaining in the right dorsal funiculus of T11.  In the minocycline-treated rats of 
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Groups 6, 8 and 10, reactive astrocytes were seen only in Group 6 rats (i.e. after injection 
of 1 ng/µl of TNF-α) and only in the rostral part of T11 (Fig. 5.13-5.15). 
 
5.3.4 Quantification of DiI+ve cells: Right dorsal funiculus (R-DF) of T11 
 We found that OECs migrated into the R-DF of T11 in response to TNF-α 
induced microglial reactivity within the R-DF following an injection of DiI+ve OECs 
into the R-DF exactly 5 mm caudal to an injection of TNF-α. A two-factor analysis of 
variance (ANOVA) was applied to the data with the data for the rostral (A), middle (B) 
and caudal (C) thirds of T11 being analyzed separately for statistical significance.  
Multiple post hoc comparisons were performed with Bonferonni’s multiple comparison 
post-test. The two-factor ANOVA showed a significant main effect of the TNF-α 
injection at all levels of the T11 spinal cord segment; F (2,18)= 681.2, p <0.0001 (A), F 
(2,18) = 520.6, p <0.0001 (B), F (2, 18) = 821.4, p <0.0001 (C).  There was also a 
significant main effect of the minocycline treatment at all levels of T11; F (1,18) = 543.9, 
p<0.0001 (A), F (1, 18) = 465.2, p<0.0001 (B), and F (1, 18) = 235.5, p<0.0001 (C). The 
two-factor ANOVA revealed a significant interaction between the TNF-α/vehicle and 
minocycline/saline variables in the right DF at all levels of T11 spinal cord segment; F 
(2,18) = 208.1, p <0.0001 (A), F (2,18) = 154.8, p <0.0001 (B), F (2,18) = 47.8, p 
<0.0001 (C).  Bonferonni’s post-test revealed the number of DiI+ve cells in the right DF 
was significantly higher (p<0.05; brackets) in the 1 ng/µl TNF-α than either 0.01 ng/µl 
TNF-α or vehicle groups at the rostral (A), middle (B) and caudal (C) levels of T11.  In 
addition, Bonferonni’s post-test revealed the number of DiI+ve cells in the right DF was 
significantly higher in the 0.01 ng/µl TNF-α than vehicle groups at the rostral (A), 
middle (B) and caudal (C) levels of T11.  The post-test also revealed a significant 
reduction in the number of DiI+ve cells in the right DF in minocycline treated rats both in 
the 1 ng/µl TNF-α and the 0.01 ng/µl TNF-α groups (Groups 6 and 8) compared with the 
saline treated groups (Groups 5 and 7) at all levels of T11.  The post-test also revealed a 
significant reduction in the number of DiI+ve cells in the right DF in the minocycline 
treated rats injected with vehicle (Group 10) compared to the saline treated rats (Group 
9), but only at the rostral (A) and middle (B) levels of T11 (Fig 5.16). In the saline-
treated rats that had received an injection of 1 ng/µl TNF-α into the rostral part of T11 
 146 
and a cell graft of DiI+ve OECs 5 mm caudally (Group 5), the average number of DiI+ve 
cells in the rostral, middle and caudal portion of T11 was 29.25 +/- 0.71, 44.21 +/- 0.68 
and 60.12 +/- 0.68 cells per 40 µm tissue section, respectively. In contrast, the average 
number of DiI+ve cells in the corresponding portions of T11 varied from 9.43 +/- 0.54 
(rostral), 18.56 +/- 0.56 (middle), and 32.87 +/- 0.88 (caudal) cells for the Group 7 (0.01 
ng/µl TNF-α) rats, and from 6.06 +/- 0.29 (rostral), 14.93 +/- 0.32 (middle), and 24.18 
+/- 0.57 (caudal) cells in Group 9 (vehicle control) rats. In the minocycline-treated rats 
that had received an injection of 1 ng/µl TNF-α into the rostral part of T11 and a cell 
graft of DiI+ve OECs 5 mm caudally (Group 6), the average number of DiI+ve cells in 
the rostral, middle and caudal portion of T11 was 10.56 +/- 0.23, 19.81 +/- 0.31 and 
43.43 +/-0.94 per 40 µm tissue section, respectively.  In contrast, the average number of 
DiI+ve cells in the corresponding portions of T11 varied from 6.06 +/- 0.37 (rostral), 
14.50 +/- 1.23 (middle), and 23.12 +/-0.59 (caudal) cells for the Group 8 (0.01 ng/µl 
TNF-α) rats, and from 3.06 +/- 0.25 (rostral), 9.12 +/- 0.29 (middle), and 22.25 +/- 0.77 
(caudal) cells for the Group 9 (vehicle control) rats. 
 
  5.3.5 Quantification of DiI+ve cells: Left dorsal funiculus (L-DF) of T11 
We also found that some OECs migrated into the L-DF of T11 following an injection of 
DiI+ve OECs into the R-DF exactly 5 mm caudal to an injection of TNF-α. A two-factor 
analysis of variance (ANOVA) was applied to the data with the data for the rostral (A), 
middle (B) and caudal (C) thirds of T11 being analyzed separately for statistical 
significance. Multiple post hoc comparisons were performed with Bonferonni’s multiple 
comparison post-test (Fig. 5.17).The two-factor ANOVA showed a significant main 
effect of the TNF-α injection at all levels of the T11 segment; F(2,18)= 119.6, p <0.0001 
(A), F(2,18) = 148.3, p <0.0001 (B), F(2, 18)= 408.6, p <0.0001 (C). There was also a 
significant main effect of the minocycline treatment at all levels of T11; F(1,18) = 103.8, 
p<0.0001 (A), F(1, 18) = 109.1, p<0.0001 (B), and F(1,18) = 51.95, p<0.0001 (C).  The 
two-factor ANOVA revealed a significant interaction between the TNF-α/vehicle and 
minocycline/saline variables in the left DF only at the rostral and middle thirds of T11; F 
(2, 18)= 67.04, p <0.0001 (A), F (2,18)= 37.2, p <0.0001 (B).  Bonferonni’s post-test 
revealed the mean number of DiI+ve cells in the left DF was significantly higher 
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(p<0.05) in the 1 ng/µl TNF-α than either 0.01 ng/µl TNF-α or vehicle groups at the 
rostral, middle and caudal levels of T11 (Fig. 5.17). In addition, Bonferonni’s post-test 
revealed the mean number of DiI+ve cells in the left DF was significantly higher 
(p<0.05) in the 0.01 ng/µl TNF-α than vehicle groups at only the caudal level of the T11 
segment (Fig. 5.17C). The post-test also revealed a significant reduction in the number of 
DiI+ve cells in the left DF (p<0.05) in the minocycline treated 1 ng/µl TNF-α animal 
group (Group 6) compared to saline treated ones (Group 5) at all levels of T11 (Fig. 
5.17).  However, the post-test also revealed a significant reduction in the average number 
of DiI+ve cells in the left DF (p<0.05; brackets) in minocycline treated 0.01 ng/µl TNF-α 
rats (Group 8) compared to saline treated ones (Group 7) only at the caudal part of T11 
(Fig. 5.17C). The post-test also revealed a significant reduction in the mean number of 
DiI+ve cells in the left DF (p<0.05) in minocycline treated rats who received a vehicle 
injection (Group 10) compared to saline treated ones (Group 9) only at the middle and 
caudal part of T11 (Fig 5.17B & C). In the saline-treated rats that had received an 
injection of 1 ng/µl TNF-α into the rostral part of T11 and a cell graft of DiI+ve OECs 5 
mm caudally (Group 5), the average number of DiI+ve cells in the rostral, middle, and 
caudal portion of T11 was 14.06 +/- 1.08, 20.43 +/- 0.92 and 22.68 +/- 0.63 cells per 40 
µm tissue section, respectively (Fig. 5.17).  In contrast, the average number of DiI+ve 
cells in the corresponding portions of T11 for the Group 7 (0.01 ng/µl TNF-α) and 9 
(vehicle control) rats varied from 2.62 +/- 0.52, 6.87 +/- 0.92, and 12.75 +/- 0.36, and 
from 1.50 +/- 0.10, 5.68 +/- 0.41, 9.43 +/- 0.31, respectively (Fig. 5.17 and Fig. 5.19). In 
the minocycline-treated rats that had received an injection of 1 ng/µl TNF-α into the 
rostral part of T11 and a cell graft of DiI+ve OECs 5 mm caudally (Group 6), the average 
number of DiI+ve cells in the rostral, middle, and caudal portion of T11 was 2.87 +/- 
0.33, 8.62 +/- 0.26, and 19.31 +/-0.44 cells per 40 µm tissue section, respectively (Fig. 
5.17).  In contrast, the average number of DiI+ve cells in the corresponding portions of 
T11 for the Group 8 (0.01 ng/µl TNF-α) and 9 (vehicle control) rats varied from 1.87 +/- 
0.12 (rostral), 5.56 +/- 0.60 (middle), 10.06 +/- 0.57 (caudal), and from 0.56 +/- 0.12 
(rostral),  2.31 +/-0.42 (middle), and 7.37 +/- 0.33 (caudal), respectively (Fig. 5.17). 
 
FIGURE 5.9: OX18 +ve microglia in the dorsal funiculus of T11 in Groups 5-10.
OX18+ve reactive microglia in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D,
F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11.  The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or
minocycline (C, D, G, H, K, L), with the daily treatments continuing for the first 4
weeks after the OECs were grafted.  OX18+ve reactive microglia were still present in
the R-DF at the rostral and middle levels of T11 at 8 weeks after the TNF-α injections
(A, B, E, F) in rats treated with saline daily for the first 4 weeks, but there was very
little microglial reactivity in TNF-a injected rats treated with minocycline (C, D, G, H).
No detectable OX18 immunostaining (I-L) was seen in the R-DF of the rats in which
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FIGURE 5.10: OX42 +ve microglia in the dorsal funiculus of T11 in Groups 5-10.
OX42+ve microglia in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D, F, H,
J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01
ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of
T11.  The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or
minocycline (C, D, G, H, K, L), with the daily treatments continuing for the first 4
weeks after the OECs were grafted.  OX42+ve reactive microglia were still present in
the R-DF at the rostral and middle levels of T11 at 8 weeks after the TNF-α injections
(A, B, E, F) in rats treated with saline daily for the first 4 weeks, but there was very
little OX42 immunostaining in TNF-α injected rats treated with minocycline (C, D, G,
H).  In the Group 9 and 10 rats (i.e. vehicle injections in rostral T11) there was a small
area in the R-DF in the rostral part of T11 that contained OX42+ve reactive microglia
in the saline treated rats (I), but otherwise the OX42 immunostaining revealed no
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FIGURE 5.11: OX35 +ve microglia in the dorsal funiculus of T11 in Groups 5-10.
OX35+ve microglia in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D, F, H,
J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01
ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of
T11.  The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or
minocycline (C, D, G, H, K, L), with the daily treatments continuing for the first 4
weeks after the OECs were grafted.  OX35+ve reactive microglia were still present in
the R-DF at the rostral and middle levels of T11 at 8 weeks after the TNF-α injections
(A, B, E, F) in rats treated with saline daily for the first 4 weeks, but there was very
little OX35 immunostaining in TNF-α injected rats treated with minocycline (C, D, G,
H).  In the Group 9 and 10 rats (i.e. vehicle injections in rostral T11) there was no





FIGURE 5.12: ED1 +ve microglia in the dorsal funiculus of T11 in Groups 5-10.
ED1+ve microglia in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D, F, H, J,
L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01 ng/µl
(E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of T11.
The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or minocycline
(C, D, G, H, K, L), with the daily treatments continuing for the first 4 weeks after the
OECs were grafted.  ED1+ve reactive microglia were still present in the R-DF at the
rostral levels of T11 at 8 weeks after the TNF-α injections (A, E) in rats treated with
saline daily for the first 4 weeks, and this immunostaining was most noticeably
reduced in the 0.01 ng/µl TNF-α Group 8 rats that were treated with minocycline.
Some ED1 immunostaining was also seen in the R-DF at the caudal level of T11 of the
TNF-α injected rats treated with saline (C, G), but there were no ED1+ve microglia at
the caudal level of T11 following minocycline treatment (D, H).  In the Group 9 and 10
rats (i.e. vehicle injections in rostral T11) there was no ED1 immunostaining in the
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FIGURE 5.13: GFAP +ve astrocytes in the dorsal funiculus of T11 in Groups 5-10.
GFAP+ve astrocytes in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D, F, H,
J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01
ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of
T11.  The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or
minocycline (C, D, G, H, K, L), with the daily treatments continuing for the first 4
weeks after the OECs were grafted.  No detectable astrocyte reactvity was seen in
either the rostral or middle parts of T11 following injection of either vehicle (I-L) or
of 0.01 ng/µl TNF-α (E-H). In contrast, the GFAP immunostaining showed a small
amount of astrocyte reactivity in the rostral part of T11 after 1ng/µl of TNF-α
injection in both the saline treated (A) and the minocycline treated (C) groups.  Scale
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FIGURE 5.14: Vimentin +ve astrocytes in the dorsal funiculus of T11 in Groups 5-10.
Vimentin immunostaining in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D,
F, H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or
0.01 ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral
part of T11.  The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or
minocycline (C, D, G, H, K, L), with the daily treatments continuing for the first 4
weeks after the OECs were grafted.  The only vimentin+ve reactive astrocytes seen
were in the R-DF of the rostral part of T11 in the TNF-α injected rats treated with




























FIGURE 5.15: Nestin +ve astrocyte in the dorsal funiculus of T11 in Groups 5-10.
Nestin immunostaining in the R-DF at rostral (A, C, E, G, I, K) and middle (B, D, F,
H, J, L) levels of T11 in rats receiving a 2 µl injection of either 1 ng/µl (A-D) or 0.01
ng/µl (E-H) of TNF-α or an equal volume of vehicle (I-L) into the most rostral part of
T11.  The rats received daily i.p. injections of either saline (A, B, E, F, I, J) or
minocycline (C, D, G, H, K, L), with the daily treatments continuing for the first 4
weeks after the OECs were grafted.  The only nestin+ve reactive astrocytes seen were
in the R-DF of the rostral part of T11 in the TNF-α injected rats treated with saline (A,
E) or with minocycline (C, G).  Scale bar = 400 µm.
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5.3.6  Preferential Migration of OECs towards T11 vs. T12-T13  
We found that OECs migrated preferentially in the rostral direction towards the 
TNF- α injection site and through the TNF-α induced microglial reactivity in the R-DF of 
T11, in comparison to the corresponding part of the DF that extended caudally from the 
cell graft into T12 and part of T13. A two-factor analysis of variance (ANOVA) was 
applied to the data with the data for the right and left DF being analyzed separately for 
statistical significance.  Multiple post hoc comparisons were performed with 
Bonferonni’s multiple comparison post-test (Fig. 5.18). The two-factor ANOVA showed 
a significant main effect of TNF-α injection in both the right and left DF (Fig. 5.18 & 
5.19); F (2,18)= 60.6, p <0.0001(A) (right DF), F (2,18) = 10.7, p <0.0004 (B) (left DF). 
There was also a significant main effect of T11 (i.e., rostral, middle and caudal) in both 
the right and left DF; F(2,18) = 27.4, p<0.0001 (right DF), F(2, 18) = 20.3, p<0.0001 (left 
DF). The two-factor ANOVA revealed a significant interaction between the TNF-
α/vehicle and rostral/middle/caudal variables in the right and left DF; F (4,18)= 8.21, p 
<0.0002  (A) (right DF), F (4,18)= 3.4, p <0.0216 (B) (left DF). Bonferonni’s post-test 
revealed the ratio of DiI+ve cells was significantly different (p<0.05) between the 




FIGURE 5.16:     Number of DiI+ve OECs in the right dorsal funiculus of T11 in   
       Groups 5-10 
Histograms depicting the mean number (+/- SEM) of DiI+ve OECs (Y-axis) in the right 
DF of the rostral (A), middle (B) and caudal (C) third of the T11 spinal cord segment at 8 
weeks after either TNF-α (Groups 5-8) or vehicle (Groups 9-10) injection into the R-DF 
of the rostral part of T11 and OECs grafted 5 mm caudally. The rats received daily i.p. 
injections of either saline (Groups 5, 7 and 9) or minocycline (Groups 6, 8 and 10), with 
the daily treatments continuing for the first 4 weeks after the OECs were grafted.   A two-
factor analysis of variance (ANOVA) was applied to the data with the data for the rostral 
(A), middle (B) and caudal (C) thirds of T11 being analyzed separately for statistical 
significance (see Section 5.2.6).  Multiple post hoc comparisons were performed with 
Bonferonni’s multiple comparison post-test. Bonferonni’s post-test revealed the density 
of DiI+ve cells in the right DF was significantly higher (p<0.05; brackets) in the 1 ng/µl 
TNF-α than either 0.01 ng/µl TNF-α or vehicle groups at the rostral (A), middle (B) and 
caudal (C) levels of T11.  In addition, Bonferonni’s post-test revealed the number of 
DiI+ve cells in the right DF was significantly higher (p<0.05; brackets) in the 0.01 ng/µl 
TNF-α than vehicle groups at the rostral (A), middle (B) and caudal (C) levels of T11.  
The post-test also revealed a significant reduction in the number of DiI+ve cells in the 
right DF (p<0.05; brackets) in minocycline treated rats both in the 1 ng/µl TNF-α and the 
0.01 ng/µl TNF-α groups (Groups 6 and 8) compared with the saline treated groups 
(Groups 5 and 7) at all levels of T11.  The post-test also revealed a significant reduction 
in the number of DiI+ve cells in the right DF (p<0.05; brackets) in the minocycline 
treated rats injected with vehicle (Group 10) compared to the saline treated rats (Group 9) 
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FIGURE 5.17:     Number of DiI+ve OECs in the left dorsal funiculus of T11  in 
Groups 5-10 
Histograms depicting the mean number (+/- SEM) of DiI+ve OECs (Y-axis) in the left 
DF of the rostral (A), middle (B) and caudal (C) third of the T11 spinal cord segment at 8 
weeks after either TNF-α (Groups 5-8) or vehicle (Groups 9-10) injection into the R-DF 
of the rostral part of T11 and OECs grafted 5 mm caudally. The rats received daily i.p. 
injections of either saline (Groups 5, 7 and 9) or minocycline (Groups 6, 8 and 10), with 
the daily treatments continuing for the first 4 weeks after the OECs were grafted.   A two-
factor analysis of variance (ANOVA) was applied to the data with the data for the rostral 
(A), middle (B) and caudal (C) thirds of T11 being analyzed separately for statistical 
significance.  Multiple post hoc comparisons were performed with Bonferonni’s multiple 
comparison post-test. Bonferonni’s post-test revealed the number of DiI+ve cells in the 
left DF was significantly higher (p<0.05; brackets) in the 1 ng/µl TNF-α than either 0.01 
ng/µl TNF-α or vehicle groups at the rostral (A), middle (B) and caudal (C) levels of 
T11. In addition, Bonferonni’s post-test revealed the number of DiI+ve cells in the left 
DF was significantly higher (p<0.05; brackets) in the 0.01 ng/µl TNF-α than vehicle 
groups at only the caudal (C) level of the T11 segment. The post-test also revealed a 
significant reduction in the number of DiI+ve cells in the left DF (p<0.05; brackets) in 
the minocycline treated 1 ng/µl TNF-α animal group (Group 6) compared to saline 
treated ones (Group 5) at all levels of T11.  However, the post-test also revealed a 
significant reduction in the number of DiI+ve cells in the left DF (p<0.05; brackets) in 
minocycline treated 0.01 ng/µl TNF-α rats (Group 8) compared to saline treated ones 
(Group 7) only at the caudal (C) part of T11. The post-test also revealed a significant 
reduction in the number of DiI+ve cells in the left DF (p<0.05; brackets) in minocycline 
treated rats who received a vehicle injection (Group 10) compared to saline treated ones 




































FIGURE 5.18:    Ratio of DiI+ve OECs in the dorsal funiculus of T11 vs. T12/13 in    
        Groups 5-10 
Histograms depicting the mean ratio (+/- SEM) of DiI+ve OECs (Y-axis) in the right (A) 
and left (B) DF of the rostral, middle and caudal third of the T11 spinal cord segment at 8 
weeks after either TNF-α (Groups 5 and 7) or vehicle (Group 9) injection into the R-DF 
of the rostral part of T11 and OECs grafted 5 mm caudally. All rats received daily i.p. 
injections of saline, with the daily treatments continuing for the first 4 weeks after the 
OECs were grafted. A two-factor analysis of variance (ANOVA) was applied to the data 
with the data for the right (A) and left (B) DF being analyzed separately for statistical 
significance.  Multiple post hoc comparisons were performed with Bonferonni’s multiple 
comparison post-test. Bonferonni’s post-test revealed the ratio of DiI+ve cells was 
significantly different (p<0.05) between the comparisons indicated by the brackets in ‘A’ 
and ‘B’. 
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FIGURE 5.19:     DiI+ve cells in the dorsal funiculus of T11 in Group 5, 7 and 9 
A, C, E show low power fluorescent image of the DF of the T11 spinal cord segment of a 
rat from Group 5, 7, and 9 respectively that were injected with a 2 µl volume of 1 ng/µl 
of TNF-α  (group 5), 0.01 ng/µl of TNF-α (group 7), vehicle 0.03M PBS (group 9) in the 
R-DF of the rostral part of T11 and received an OEC graft 5 mm caudally.  The part of 
the R-DF enclosed in the white rectangle is shown at higher power in ‘B,D,F’; Higher 
power view of part of the R-DF showing a single DiI+ve cell (red arrowhead) (B) and its 
blue Hoechst-stained nucleus (white arrow), three DiI+ve cells (red arrowheads) and their 
blue Hoechst-stained nuclei (white arrows) (D), four DiI+ve cells (red arrowheads) and 
their blue Hoechst-stained nuclei (white arrows) (F). 
Scale `Bar = 400 µm for ‘A,C, and E ’  










5.4 Discussion  
5.4.1 Focal Injection of TNF-α  as a Tool for Restricting Cytokine-Induced Glial 
Reactivity to Specific Parts of Spinal Cord White Matter 
The findings of the experiment reported in Chapter 4 linked the presence of a 
migratory signal(s) both spatially and temporally with WD-induced microglial reactivity.   
The purpose of the experiment reported in Chapter 5 was to determine whether cytokine-
induced microglial reactivity would also be associated with the presence of migratory 
signal(s) and whether this microglial reactivity must extend at least as far as the OEC 
graft for any migratory signal(s) to be effective. TNF-α was chosen for use in this 
experiment because it is one of the proinflammatory cytokines for which both microglia 
and astrocytes have receptors on the cell surface (see Section 1.5.1).  Injections of small 
quantities of a proinflammatory cytokine into neural tissue to induce inflammation has 
been used by other scientists (Claudio et al., 1994; Schnell et al., 1999; Simmon and 
Willenborg, 1990), but this is the first instance in which such an injection was used for 
the specific purpose of studying the contribution of reactive microglia to the generation 
of a migratory signal(s).   
For example, intracerebral injections of TNF-α have been shown to induce 
inflammatory reactions in murine brain as indicated by immunohistochemical analysis for 
mononuclear infiltrated cells.  However, ultrastructural examinations 2 months after 
TNF-α injection showed no apparent pathological changes in glial and endothelial cells 
(Yamasaki et al., 1992).  Claudio et al. (1994) studied the role of inflammatory cytokines 
(TNF-α and Il-1ß) in induction of inflammation, with the retina system having been used 
as a model for the cytokine injections. Their study showed the inflammatory response is 
characterized by the presence of polymorphonuclear and mononuclear cells. In the CNS 
the effect of cytokine injection appears to be site specific. For reasons that are poorly 
understood, significantly different inflammatory responses occur in brain and spinal cord 
following cytokine injections. Schnell et al. (1990) demonstrated that the injection of 
TNF-α into the striatum of Wistar rats failed to break down the BBB or to recruit 
leukocytes, whereas in the spinal cord injection of TNF-α resulted in marked BBB 
breakdown and leukocyte recruitment. It was also reported that there was an 
inflammatory response similar in pattern to that observed during EAE following a single 
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injection of TNF-α into the lumbosacral spinal cord of rats, with the appearance of 
mononuclear cuffs within the  spinal cord (Simmons and Willenborg, 1990).  
The TNF-α Pilot Study (see Section 5.3.1) determined that a concentration of 1 
ng/µl TNF-α injected into the dorsal funiculus of the T11 spinal cord segment induced 
glial reactivity that extended the entire 5 mm distance between T11 and T12 whereas 
0.01 ng/µl TNF-α only induced a localized glial response confined to the vicinity of the 
injection site. Whether this cytokine-induced glial reactivity as a result of a focal 
injection of TNF-α was due to diffusion of the cytokine over this 5 mm distance cannot 
be ruled out, though it seems unlikely. In support of this idea, Felts et al. (1997, 2005) 
found that a lesion induced by an intraspinal injection of 1-2 µl of ethidium bromide or 
lipopolysaccharide (LPS) is typically only a few millimeters (1-2 mm) in longitudinal 
extent, indicating limited spread of the cytotoxin within the spinal cord white matter. It is 
more likely that microglia situated close to the injection site were activated as a 
consequence of the TNF-α injection. These cytokine-activated microglia, through the 
secretion of proinflammatory cytokines that include TNF-α, may result in the sequential 
activation of additional microglia in a paracrine manner that could extend as far away as 
5 mm from the TNF-α injection site.  
The results of the pilot study are summarized in Tables 5.1 and 5.2. These data 
showed that a single injection of TNF-α (either 1 ng/µl or 0.01 ng/µl) into the dorsal 
funiculus of the spinal cord was well tolerated in adult rats. These doses of TNF-α 
triggered a pronounced microglial reactivity, based on immunostaining with the OX18, 
OX35, OX42 and ED1 monoclonoal antibodies, as well as astrocyte reactivity, based on 
immunostaining with antibodies to GFAP, Vim and nestin.  These results support a key 
role for TNF-α as a mediator of the microglial and astrocytic responses within the white 
matter of the adult rat spinal cord. Based on the results of the pilot study the 
concentrations of 1 ng/µl and 0.01 ng/µl of TNF-α were identified as optimal 
concentrations to test our hypothesis.  
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5.4.2 TNF-α  Induced Glial Reactivity: Microglial Contribution to Generation of a   
  Migratory Signal 
The early release of TNF-α after CNS injury is essential for a proper microglial 
response that can effectively resolve and phagocytose the initial damage and act to 
prevent, or at least limit, subsequent secondary damage (Blais and Rivest, 2004); the 
absence of TNF-α delays activation of microglial cells, which leads subsequently to an 
exaggerated activation of  microglia in response to the accumulation of necrotic debris 
(Blais and Rivest, 2004). Interestingly, the priming of microglial cells by innate immunity 
is TNF-α specific because these effects do not extend to other proinflammatory cytokines 
such as IL-1ß (Blais and Rivest, 2004). The results of the experiments reported in this 
chapter support the presence of a rapid, well regulated microglial reaction in response to 
direct TNF-α injection into the dorsal funiculus of the spinal cord.  
In the current study, a focal injection of TNF-α into the dorsal funiculus of T11 
was used as a tool to induce microglial reactivity; the concentrations of TNF-α used were 
pharmacological doses (Anderson et al., 1992; Glabinski et al., 1998). Thus, a possible 
gliotoxic effect of TNF-α injection might lead to cell apoptosis, particularly of 
oligodendrocytes. Although no test was employed to verify this possible gliotoxic effect, 
phagocytic microglia (paricularly OX42+ve microglia) (see Section 5.3.3) were detected 
in the rostral part of T11 close to the site of TNF-α injection in Groups 5 and 7 rats, 
which had received a focal injection of TNF-α.  A less intense immunostaining of 
microglia with the OX42 antibody in tissue sections from Group 7 rats (i.e. focal 
injection of 0.01 ng /µl of TNF-α) as compared to Group 5 rats (i.e. focal injection of 1 
ng/µl of TNF-α) (see Section 5.3.3) suggests a dose-dependent effect of TNF-α on the 
expression of CR3 (the receptor that binds the OX42 antibody). Furthermore, there was 
no phagocytic phenotype of microglia seen in the vicinity of the vehicle injection 
(Groups 9 and 10).   
Due to the large number of factors, which include cytokines, chemokines, and 
enzymes, that will be released by activated microglia (Kim and Vellis, 2005; Kreutzberg, 
1996; Thomas et al., 2006), it is hard to judge microglial functions by assessment of the 
effects of only a few isolated microglial factors while neglecting many others. Based on 
microarray data, the upregulation or downregulation of such factors produced by LPS-
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activated microglia ranges from two to at least a thousand fold change in expression 
levels (Thomas et al., 2006), suggesting that the amounts of the corresponding proteins 
may change accordingly. The current study used several selected markers known to be 
upregulated during microglial activation and confirmed that the TNF-α activated 
microglia upregulated their expression of complement receptor 3 (OX42), MHC class I 
(OX18), CD4 (OX35), and the lysosomal antigenic epitope recognized by the ED1 
monoclonal antibody. This microglial reactivity extended the entire length of the T11 
segment (approximately 5 mm) in response to a focal injection of 1 ng/µl of TNF-α, 
whereas the reactive microglia were confined mostly to the rostral part of T11 in response 
to an injection of 0.01 ng/µl TNF-α. 
In many injury and disease models microglial activation gradually increases from 
mild to intense. For instance, CR3 expression (OX42 monoclonal antibody), which is the 
most commonly used microglial marker, has been reported to be only slightly 
upregulated on day 1 but drastically upregulated on day 5 in the vicinity of axotomized 
motor neurons (He et al., 1997). In the pilot study, the intensity of immunostaining of 
microglia with the OX42 monoclonal antibody was most intense in the rostral portion of 
T11 at 1 and 4 days after TNF-α injection; the intensity of OX42 immunostaining was 
reduced dramatically by 14 days after cytokine injection, irrespective of the concentration 
of TNF-α which had been used. However, in rats that had received both a focal injection 
of TNF-α and an OEC graft and were treated with daily IP injections of vehicle (i.e. 
Group 5 rats) there was intense OX42 immunostaining of the microglia suggestive of 
their reactivation or of the microglial reaction being prolonged when the cytokine 
injection at T11 was coupled with an OEC graft 5 mm caudally. The reason for such 
fluctuation in microglia reactivity will require more study.  
Minocycline is a tetracycline derivative that exerts anti-inflammatory effects and 
inhibits microglial activation by decreasing IL-1β (Vincet and Mohr, 2007), nitric oxide 
release (Tikka and Koistinaho, 2001) and TNF-α secretion (Fan et al., 2007). The data 
presented in this chapter demonstrate that daily treatment of adult rats with minocycline 
over a 4 week time period after a focal injection of TNF-α into the dorsal funiculus of the 
spinal cord resulted in a marked reduction in the cytokine-induced microglial reactivity in 
comparison to vehicle-treated controls. This reduction in microglial activation in 
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response to minocycline treatment occurred in the absence of any demonstrable change in 
the immunophenotype or morphology of reactive astrocytes since the immunostaining 
intensity for GFAP, Vim, and nestin and the morphology of the astrocytyes was not 
noticeably different from the vehicle controls (see Section 5.3.3). Furthermore, the 
reduction in microglial activation was accompanied by a significant reduction in the 
number of DiI+ve OECs that were seen in the dorsal funiculus of T11.  In other words, 
the decreased cell number of migrated OECs in the minocycline-treated rats was 
associated with a dampening of the microglial reactivity as indicated by immunostaining 
the microglia with the OX42, OX18, OX35 and ED1 monoclonal antibodies (see Sections 
5.3.3 and 5.3.4). These findings support the hypothesis that microglial reactivity plays a 
role in the generation of a migratory signal(s) inducing OECs to migrate towards the 
source of a focal injection of TNF-α.  
 
5.4.3 TNF-α  Induced Glial Reactivity: Potential Migratory Signals Inducing 
OECs to Migrate 
TNF-α by itself activates microglia (John et al., 2003) and activated microglia 
release numerous neuroinflammatory substances, which include prostanoids, proteases, 
nitric oxide (NO), superoxide, and the proinflammatory cytokines TNF-α and IL-1β, that 
potentially can break down the BBB (Dringen, 2005; Tsao et al., 2001; and Yenari et al., 
2006). Could some of these factors play a role either directly or indirectly in the 
migration of OECs? TNF-α certainly could since it causes a redistribution of cadherin 
and of the junctional adhesion molecule (JAM) leading to a rearrangement of 
microfilaments and a down-regulation of occludin expression in endothelial cells, 
increases BBB permeability, and allows the infiltration of immune cells giving rise to a 
more complex cellular environment in the area containing elevated levels of TNF-α 
(Petrache et al., 2003; Mankertz et al., 2000). We cannot at this time, however, verify or 
reject a direct role for TNF-α in the generation of a migratory signal(s) and it remains to 
be determined whether OECs even express the TNF-α receptor.  However, the data do 
indicate OECs preferentially migrated towards the source of the TNF-α injection, and 
that this migration occurred only when the TNF-α induced microglial reactivity extended 
the full distance between the cell graft and the cytokine injection (see Section 5.3.4). 
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Microinjection of the chemokines MCP-1 and MIP-1α into the normal, unlesioned 
spinal cord induced slightly increased expression of IL-1ß, TNF-α, IL-10 and RANTES 
and injection of IL-1ß induced a marked increase in MCP-1 and MIP-1α expression as 
well as that of other cytokines (Perrin et al., 2005). Furthermore, MCP-1, MIP-1α and IL-
1ß also induced expression of the anti-inflammatory cytokines IL-10 and TGF-ß (Perrin 
et al., 2005). The latter response may in part underlie the protective effects noted after 
injection of proinflammatory cytokines, including IL-1ß, into spinal cord lesions 
(Klusman and Schwab, 1997). There is also likely a dynamic interaction between various 
chemokines and cytokines in which the expression of one regulates the expression of 
others and vice versa.  The expression profile of members of this cytokine/chemokine 
network may be crucial for the effective recruitment and activation of 
microglia/macrophages and also for shutting down the immune response to prevent 
abnormal inflammation and tissue damage.   
Whether this expression profile also contributes to the migratory signal(s) that 
induces OECs to migrate along the path of microglial reactivity towards the source of the 
TNF-α injection is a question to be addressed by future studies. However, it is possible to 
speculate based on the findings of other studies that support chemotactic roles for some 
of these factors.  Previous studies have shown that microglia release a large number of 
bioactive factors and each individual factor could exert protective/trophic or 
destructive/toxic effects on cells within the area of microglial reactivity (Giulian and 
Robertson, 1990). The goal of the present study was not to show the type and amounts of 
potential chemotactic factors released from activated microglia, although the data do 
suggest that the strength of the migratory signal(s) might be determined, in part, by the 
intensity of the microglial reactivity and its distribution in the dorsal funiculus of T11 
with respect to the OEC graft.  
The fact that activated microglia resemble peripheral macrophages (Raivich and 
Banati, 2004) is the reason why the exact role that microglia play in immunologic 
functions in the CNS has been difficult to study. It was long believed that the CNS had a 
poor ability to tolerate activity of intrinsic immune cells like microglia. According to this 
view, activation of these cells would always be detrimental to the CNS, causing death of 
neurons and oligodendrocytes, and interfering with repair processes. However, more 
 170 
recent studies showed that a local immune response that is properly controlled can 
support survival, promote remyelination, and facilitate recovery (Schwartz et al., 2003). 
When microglia are activated, they start secreting a broad range of cytokines, trophic 
factors and toxic mediators that could mediate a protective or damaging effect on 
surrounding cells. One of the most remarkable properties of microglia is their ability to 
respond to internal signals (e.g., from cells of the body that are damaged or stressed) or to 
signals that arise from outside the body (e.g. from pathogens); the microglial response is 
directed for purposes of tissue repair or induction of an immune response (Aloisi, 2001). 
When activated in vitro, microglia undergo morphological changes including shortening 
of cellular processes and enlargement of their soma and become phenotypically and 
morphologically similar to peripheral macrophages. Reactive microglia upregulate the 
expression of several molecules, which include CD4, MHC-I, CR3 and ED1 antigenic 
epitope. The opposite can also happen; when macrophages from the blood stream enter 
the CNS environment, they will gradually transform into ramified microglia (Raivich and 
banati, 2004). Microglia have also been shown to differentiate in vitro into cells that 
resemble dendritic cells. As stated before, microglia upregulate a number of molecules 
when they are activated, including CD11b, which is a dendritic cell marker (Fischer and 
Reichmann, 2001). Microglia can express a large array of receptors, which are either 
constitutively expressed or induced by certain signals. This variety of receptors enables 
microglia to response differently to various signals (Aloisi, 2001).  Both activated 
microglia and macrophages express all of the markers that were used in the experiments 
described in this thesis; therefore, it would be impossible to distinguish microglia from 
infiltrated macrophages in the inflamed environment of spinal cord created through the 
TNF-α injection.  
A common problem encountered with cell-based therapy is exposure of 
transplanted cells to host cytokines such as TNF-α which results in donor cell damage. 
The initial damage may then trigger a secondary phase of damage causing substantial 
destruction of the spinal cord. OEC grafting has been introduced as one of the prominent 
candidates to assist CNS axon regeneration and remyelination in several animal models 
of SCI (Li et al., 1997; Ramon-Cueto et al., 2000). Since OECs are able to modify the 
behavior of host glial cells (Lakatos et al., 2000) they are candidates for cell-based 
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therapy, and initial experimental studies in rats demonstrated neuroprotection by reducing 
astrocystic gliosis and cystic cavitation (Verdu et al., 2001). We used an in vivo animal 
model in which OECs were grafted into the right dorsal funiculus of T12 in adult rats; in 
one group of rats, the cells were injected into an area of white matter containing activated 
microglia that were participating in an inflammatory response due to the focal injection 
of 1 ng/µl TNF-α exactly 5 mm rostral to the graft.  Several immunohistochemical 
markers, including immunstaining with the antibodies recognizing CR3, MHC-I, CD4, 
and ED1 (CD68) antigenic epitopes confirmed that the focal injection of TNF-α resulted 
in the activation of microglia (Fig 5.1, 5.2, 5.3, 5.4), and a lesser activation of astrocytes 
(Fig 5.5, 5.6, 5.7). Significant more OECs migrated towards the TNF injection site in the 
rostral portion of T11 when reactive microglia were present than in their absence, which 
demonstrated the ability of OECs to enter areas undergoing an inflammatory reaction 
(5.10, 5.17 and 5.18).  
It was reported that microglia-derived TNF-α acts in an autocrine manner to 
regulate the secretion of inflammatory mediators including TNF-α (Kuno et al., 2005). It 
was proposed that microglial autocrine responses contribute to the persistent activation of 
microglia in chronic inflammatory diseases (Kuno et al., 2005). Production of TNF-α 
within the CNS is induced after injury (Fan et al., 1996). The limited entry of TNF-α 
from the periphery to regions distant from the site of injury might not only provide a 
feedback signal to restrict local production but may also serve as a mediator for 
neuroregeneration. An adequate concentration of TNF-α seems to be essential for 
homeostasis in the CNS. TNF-α also induces the secretion of nerve trophic factors 
including NGF and GDNF (Appel et al., 1997; Brodie, 1996; Hattori et al., 1996) that 
might contribute to OEC migration. Indeed, it was shown that GDNF significantly 
promoted OEC migration in vitro and in vivo (Cao et al., 2006).  GDNF has raised great 
expectations as a potential therapeutic agent for the treatment of neurodegenerative 
diseases (Lapchak, 1996). The transplantation of OECs genetically modified to secrete 
high levels of GDNF significantly improved neural repair after SCI (Cao, et al., 2004). 
The underlying mechanisms are not fully understood. It was likely that the OEC-secreted 
GDNF had not only promoted neural repair, but also had some effects on OECs 
themselves such that GDNF might be a an important regulator of OEC migration during 
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nerve regeneration after SCI in a paracrine and/or autocrine fashion (Cao et al., 2006).  
Interestingly, an in vitro study (Lai and Todd, 2006) showed that minocycline has no 
effect on GDNF expression by microglia; whether minocycline’s effect on microglia is 
the same in vivo remains to be determined. Our data showed that minocyline treatment 
substantially reduced microglial reactivity after TNF-α injection and to a significant 
decrease in the number of OECs that had migrated along the right DF of T11. If GDNF is 
a potent migratory signal for OECs, then the minocycline treatment in our in vivo animal 
model must act differently from that reported previously by Lai and Todd (2006) in their 
in vitro study. 
Exogenous microglia directly applied to hippocampal slice cultures could save 
more neurons after deprivation of oxygen and glucose (Neumann et al., 2006). 
Transplanted microglial cells were found to facilitate neuronal growth in the injured site 
in the CNS (Kitamura et al., 2004). Activated microglia could also secrete some 
neurotrophic factors such as NGF, NT-3, GDNF and BNDF, which have been 
demonstrated to be neuroprotective (Nakajima et al., 2001). On the other hand, TNF-α 
released from LPS-activated microglia could not only lead to a significant loss of 
motoneurons in vitro (He et al., 2002), but also be directly cytotoxic to oligodendrocytes 
in vitro and induce significant demyelination in vivo (Probert et al., 1995). Therefore, the 
inhibition of microglial activation may possibly attenuate neuronal degeneration induced 
either by ischemia (Giulian and Robertson, 1990) or by excitatory neurotoxin (Coffey et 
al., 1990). However, it is difficult to predict which function activated microglia would 
predominantly execute in various pathological conditions of the CNS. The balance 
between co- and counter-effects of various microglial factors might determine the role of 
microglia after neural injury or in neurodegeneation diseases.  
In most neurodegenerative diseases, post-mortem analysis found the clustering of 
activated microglia in and around the brain regions affected by the pathology (Dickson et 
al., 1993). The increased numbers of microglia in such regions has been claimed to be a 
result of microglial proliferation and migration. An increase in the number of activated 
microglia may correspondingly increase the concentration of factors released from 
reactive microglia and these factors may play a role in inducing OEC migration. In fact 
the results of this research project demonstrated that the higher concentration of TNF-α, 
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in comparison to the lower concentration of TNF-α, induced a more intense microglial 
activation that spatially extended for at least 5 mm away from the injection site.  This 5 
mm length extent of microglial reactivity may create an environment containing 
migratory signals that induce OEC migration towards the rostral part of T11. Whether 
direct contact between activated microglia and OECs was required for OEC migration 
cannot be answered at present, but as shown in the experiments in Chapter 4 the OECs 
preferentially migrated along a pathway containing reactive microglia.  
Merrill et al. (1993) showed that direct contact between activated microglia and 
oligodendrocytes induced cell death of the latter cells (Merrill et al., 1993). Although this 
microglial toxicity through direct cell–cell contact may involve special molecules, a 
possible immediate effect on OECs from the cell-to-cell proximity of the glial cells 
migrating through areas containing microglial reactivity would be an increase in 
concentrations of migratory signal(s) directly or indirectly released as a consequence of 
the activation of the microglia. Therefore, the duration and spatial effects of microglial 
activation in injured areas of the CNS may indicate dual microglial functions. The type of 
microglia reactivity as induced in the experiments reported in Chapters 4 and 5 of this 
thesis, may contribute to the formation of more inducible environment for OEC 
migration. 
All together, the present results indicate that direct injection of TNF-α into the 
dorsal funiculus of the spinal cord of adult rats is an appropriate animal model with 
which to investigate at the molecular level the mechanisms through which microglial 
activation induce OEC migration. Another substantial result of this experiment is the 
capacity of OECs to intermingle with microglia and astrocytes within an area of white 
matter undergoing an inflammatory reaction. Presumably, some of components of this 
inflammatory response could contribute to the migratory signal(s) that drove the OEC 
migration in these TNF-α experiments. 
 
5.4.4 Conclusion 
The data from this experiment demonstrated that a focal injection of 1 ng/µl of 
TNF-α created a path of reactive microglia that extended caudally as far as the OEC 
graft, gave rise to a migratory signal(s) that induced OECs to migrate, and dampening the 
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microglial reactivity with minocycline also decreased the number of OECs that migrated 
towards the cytokine injection. Therefore, the hypothesis of microglial reactivity 
contributing to the generation of a migratory signal(s) for the OECs was supported. In 
addition, the OEC migration toward the site of the TNF-α injection in the animal model 
used in this chapter should be considered as an important subject of therapeutic relevance 
to any treatment of  SCI or demyelination disorders that involves glial cell 
transplantation. The TNF-α model used in this research project induced less glial 
reactivity and inflammation compared to animal models using chemotoxins such as EtBr. 
Nevertheless, the ultimate effect of the TNF-α induced microglial activation still 
generated migratory signal(s) that were strong enough to induce OECs to migrate. 
It was noted that the expression of all microglial markers used in this experiment 
fluctuated such that there was a remarkable downregulation of expression by 14 days 
after TNF-α injection as compared to 1 day after injection.  However, in the rats who 
received an OEC graft 5 mm caudal to the TNF-α injection then these markers, 
particularly CR3 expression (OX42+ve microglia) (Fig 5.10), appeared to be upregulated 
at the 8 week time point after cell grafting.  The OEC grafting might be the reason for 
what appeared to be microglial reactivation, as opposed to a de novo activation of the 
microglia.  Firstly, the OECs were grafted at T12 some 5 mm away from the TNF-α 
injection site but the most intense microglial reaction was detected in the rostral part of 
T11 far removed from the site of the cell graft.  Secondly, if the microglial reaction at 8 
weeks after injury was due mainly to the cell grafting, then a similar microglial response 
should have been seen in all animal groups, including those receiving the lowest 
concentration of TNF-α or vehicle.  However, the immunohistochemical staining showed 
clear differences in the intensituy of microglial reactivity in different animal groups (Fig. 
5.9, 5.10).  
However, the mechanism of microglia re-activation and how such activation 
might induce OEC migration are two challenging questions that need to be addressed in 
future studies. It seems that the mechanism of microglia activation is dependent on the 
type of signal(s) inducing their reactivity. This re-activation of microglia may create an 
appropriate environment containing robust migratory signals that facilitate the migration 
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of OECs. What microglia do to manipulate the environment to maximize OEC migration 
is another challenging question that needs to be investigated. 
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CHAPTER 6.0     GENERAL CONCLUSION 
Following OEC transplantation into the host parenchyma it is important that the 
grafted cells survive if they are to exert their regenerative effects and to be fully 
functional. The extracellular environment of the injured spinal cord contains some toxic 
and apoptotic factors that can affect glial cell survival (Beatti et al., 2000). Hence, it 
stands to reason that OECs have a better chance of surviving the cell grafting process if 
they are transplanted into intact spinal cord tissue some millimeters away from the lesion 
site. In fact, when grafted into such areas adjacent to tissue injury, OECs were reported to 
have integrated successfully into the host spinal cord (Ramon-Cueto and Avila, 1998; 
Ramon-Cueto et al., 2000; Ramon-Cueto and Nieto Sampedro, 1994). Several studies 
have demonstrated that OECs were able to migrate from the injection sites following 
transplantation into tissue near a spinal cord transection. They crossed the injury region 
and reached the tissue on the opposite side of the transection (Boruch et al., 2001, 
Ramon-Cueto et al., 1998, Ramon-Cueto, and Nieto Sampedro 1994).  
When OECs were grafted into tissue adjacent to a spinal cord transection in 
combination with Schwann cell-filled PAN/PVC guidance channels (Ramon-Cueto et al., 
1998), the OECs freely moved through the glial scar at the border between CNS tissue 
and guidance channel and crossed the astrocyte-Schwann cell interface. Interestingly, 
OECs entered the guidance channel containing Schwann cells and exited the channel at 
the distal end to once again enter the CNS tissue. In contrast, Schwann cells remained 
inside the bridges and did not migrate through spinal cord tissue (Xu, et al., 1997). In the 
presence of astrocytes, Schwann cells have a poor ability to migrate (Franklin and 
Blakemore, 1993; Iwashita, et al., 2000; Lakatos et al., 2000), and this could be related to 
the morphological and biochemical changes induced in astrocytes by Schwann cells (Qiu 
et al., 2000). In contrast, OECs are able to intermingle with astrocytes after 
transplantation into injured spinal cord, with no separate territories being formed (Boruch 
et al., 2001; Li, et al., 1998; Ramon-Cueto et al., 2000; Ramon-Cueto and Nieto 
Sampedro, 1994). Both in vivo and in vitro observations have demonstrated this 
interaction between OECs and astrocytes (Lakatos et al., 2000).  Furthermore, OECs do 
not induce astrocyte hypertrophy or their expression of neurite-inhibitory CSPGs and 
OECs are less adhesive to astrocytic surfaces than other cells used for transplantation. 
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OECs were also reported to migrate through connective tissue and peripheral nerves 
(Ramon-Cueto et al., 2000, Ramon-Cueto et al., 1998).   
The capacity of OECs to migrate within the CNS environment can be at least 
partially explained by the ability of OECs to interact with astrocytes. However, more 
studies are needed to fully understand the molecular mechanisms responsible for 
facilitating OEC migration within the CNS. Some recent data suggest that neuregulins 
might be involved in OEC migration (Boruch, et al., 2001; Meintanis et al., 2001; Pollock 
et al., 1999; Thompson et al., 2000). In addition, OECs produce a number of different 
growth associated factors, and if needed they change their morphology, intermingle with 
reactive CNS glia, and migrate within the CNS. OECs are able to properly integrate 
within the host parenchyma and cross the PNS/CNS boundary. 
The signals responsible for promoting OEC migration toward the site of a SCI are 
unknown. A limited migration of GFP+ OECs was observed by Pearse et al. (2007) after a 
contusion injury of the spinal cord. In the study by Pearse et al. (2007), GFP+ OECs were 
not observed within regions of normal appearing white or gray matter. Furthermore, even 
when the OECs were grafted rostral and caudal to the contusion injury, where the OECs 
exhibited higher cell survival, they failed to migrate from the site of grafting into 
surrounding host tissue. However, Ramon-Cueto et al. (2000) reported that OECs did 
migrate away from a complete spinal cord transection in adult rats. OEC migration over 
an approximately 20 mm distance towards the site of injury was demonstrated by Skihar 
(2004) using ethidium bromide to induce a focal demyelination in the adult rat spinal 
cord. These discrepancies of whether or not OECs will or will not migrate away from the 
site of grafting may be due either to the different injury paradigms that were used or to 
the different sources or cell culture techniques that were used.  For example, differences 
in the presence or absence of migration might be due to the use of cells from different 
passages (e.g. primary vs. secondary cell cultures) or from different tissue sources (e.g. 
OB vs. lamina propria). The timing of implantation also may play a significant role in the 
ability of grafted OECs to migrate from their original site of deposition. The implantation 
of cells immediately after injury, before the formation of a glial scar around the lesion 
site (Silver and Miller, 2004), may enable the cells to migrate out from the injection site 
(Li et al., 2003; Ramon-Cueto et al., 1998, 2000; Richter et al., 2005). At later times, 
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such as after a delay of some days or weeks the formation of the glial boundary within 
the injured spinal cord may restrict the ability of implanted glia to migrate into normal 
host cord tissue (Barakat et al., 2005; Pearse et al., 2004) due to the presence of various 
inhibitory components of the ECM (Faissner, 1997; Kapfhammer and Schwab, 1992), 
such as CSPG and tenascin, to soluble chemorepellant molecules (Barallobre et al., 
2005), or even to physical interactions with the astrocytic-meningeal fibroblast network 
(Fawcett, 1997).  A study by Plant et al. (2003), however, showed there was little 
migration of OECs into the surrounding host cord tissue after transplantation into a spinal 
contusion injury in rats at two different time points after injury, namely at 0 and 7 days. 
Additionally, the lesion environment may play a role in altering the ability of implanted 
glia to migrate outward into the host cord as OECs have been reported to exhibit an 
extensive migratory capacity in models of spinal cord hemisection (Deng et al., 2006; Li 
et al., 2003) but not after contusion injury (Barakat et al., 2005; Collazos-Castro et al., 
2005; Pearse et al., 2004; Plant et al., 2003). Besides, when OECs are transplanted 
directly into the lesion site the cells may be induced to stay in place within the lesion to 
assist host cells in neural repair, rather than migrate away from the site of injury. 
Microglia rapidly respond to microenvironmental changes within the CNS (Streit, 
2004). They are thus one of the most important cells in directing the repair of the CNS. 
Despite the clear association between reactive microglia and disease processes, the 
precise consequence of microglia activation on OEC survival and migration in vivo 
remain uncertain. In vitro, activated microglia produce cytotoxins such as free radicals, 
excitory amino acids, and inflammatory cytokines, as well as trophic factors, suggesting 
that activated microglia play dual roles (Streit, 2004). The outcome is likely the 
combined effect of both detrimental and beneficial effects. The experiments reported in 
Chapters 4 and 5 of this thesis demonstrate that OEC migration is enhanced when it 
occurs in the presence of micoglial reactivity. The two different animal models used in 
this study implicate microglia as playing an important role in generating migratory 
signal(s) that induce OECs to migrate. Thus, defining the role of reactive microglia and 
identifying ways to modulate activated microglia in vivo will be instrumental to the 
design of treatments that permit the beneficial effects of microglial reactivity to occur 
without dampening its contribution to generation of migratory signal(s). 
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The potential advantages of OEC transplantation for neural repair are several.  
Firstly, is the ability of the OECs to integrate properly within the CNS after 
transplantation (Ramon-Cueto and Nieto-sampedro, 1994).  Secondly, although the glial 
scar, which is formed predominantly by reactive astrocytes and microglia, is a major 
obstacle to the migration of myelin-forming glia in the CNS after damage (Fernaud-
Espinosa et al., 1993; Hatten et al., 1991), OECs allow the regenerating axons to grow 
through known growth inhibitory substrates such as this gliotic tissue (Ramon-Cueto and 
Nieto-sampedro, 1994). Thus, the OECs might also be able to navigate glial scars and 
remyelinate axons in the damaged CNS (Ramon-Cueto and Nieto-sampedro, 1994). 
Thirdly, OECs are a source of neurotrophic factors, such as nerve growth factor (NGF), 
platelet-derived growth factor (PDGF) and neuropeptide Y (Knott et al., 1994; Ubink et 
al., 1994; Williams and Rush 1988). Thus, trophic factor production by OECs might 
enhance the survival of neurons whose axons have been damaged. Fourthly, OECs may 
also remyelinate demyelinated CNS axons based on reports that have appeared of their 
remyelination of CNS axons in vivo after transplantation of either rodent or human OECs 
(Barnett et al., 2000; Kato et al., 2000) (Barnett et al., 2000; Imaizumi et al., 1998 ;  Kato 
et al., 2000).  A fifth advantage is that OECs respond to migratory signals arising as a 
result of WD and migrate towards the area containing the degenerating axons (e.g. the 
right dCST), as described in this research project. Finally, OECs can respond to 
migratory signals arising as a result of a single direct injection of TNF-α into the spinal 
cord.  This latter finding suggests that the more prolonged production of proinflammatory 
cytokines that occurs after SCI or in areas of white matter undergoing demyelination is 
likely to provide, directly and/or indirectly, a more constant source of migratory signals 
than would arise from a single intraparenchymal injection. 
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CHAPTER 7.0      FUTURE DIRECTIONS 
Identifying migratory signals is an important issue in the design of any therapeutic 
approach that involves glial cell transplantation. Scattered lesions in the CNS white 
matter, as occurs for example in MS, presents the challenge of delivering the myelinating 
glia directly to multiple plaques containing the demyelinated axons. Thus, understanding 
the endogenous host glial cell response to the exogenous grafted OECs as well as the 
molecular interactions among these cells that create a migratory path for the OECs is a 
new avenue for future studies that involve cell transplantation into areas of CNS adjacent 
to or remote from areas of injury.  
Microglia respond to microenvironment changes within the CNS rapidly. 
Therefore, they are one of the most essential cells in directing neural repair in the CNS. 
The precise consequence of microglial activation on OEC migration in vivo remains 
uncertain. In vitro, stimulated microglia produce cytotoxins such as free radicals, 
excitatory amino acids, and proinflammatory cytokines as well as trophic factors, which 
collectively suggests that activated microglia play dual roles. The outcome is likely the 
combined effect of both detrimental and beneficial effects. Thus defining the role of 
reactive microglia and identifying ways to modulate activated microglia in vivo will be 
instrumental to the design of therapeutic approaches to treating neurological disorders. 
Two different animal models used in my thesis research have provided some 
important insights into the key role of reactive microglia in the generation of migratory 
signals that induce OECs to migrate. All of my experiments were performed in vivo, 
leaving plenty of opportunity now to use an in vitro approach to see whether molecules 
directly released by activated microglia are chemotactic for OECs.  Thus, in spite of 
several benefits of using in vivo animal models to study OEC migration, due to the 
complexity of these in vivo models it is a huge challenge to determine the underlying 
molecular mechanisms. The in vitro approach would allow for the identification of 
putative chemotactic molecules, which could then be tested using, for example, the 
animal model used in Chapter 5.   
I demonstrated that OEC migration occurred along a migratory path containing 
reactive microglia and that minocycline treatment for 4-6 weeks not only dampened the 
microglia reactivity but also resulted in a significant reduction in the number of OECs 
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that migrated into the T11 segment.  It was shown by Kotter et al. (2001) that an early 
treatment of animals with clodronate caused depletion of microglia in lysolecithin-
induced demyelinated areas in the CNS of adult rats and also resulted in a decreased 
remylination by oligodendrocytes.  However, late treatment with clodronate had no effect 
on this neural repair although it was still effective in reducing the number of reactive 
microglia (Kotter et al., 2001). Preliminary data from our lab also showed that early 
minocycline treatment (i.e. during the first 2 weeks after injury) caused a remarkable 
reduction in microglial reactivity and a significant decrease in the number of OECs that 
migrated towards an EtBr-induced demyelination in the adult rat spinal.  To work out the 
timing of the relationship between the micoglial reaction and the generation of a 
migratory signal(s) it is important to know whether delaying the minocycline treatment 
until, for example, weeks 3-4 after TNF-α injection, would have any impact on OEC 
migration.  A similar delayed treatment with minocycline could also be used with the 
WD animal model I used in Chapter 4.  Knowing the critical time frame is important for 
designing experiments to identify the molecules comprising the migratory signals.  
Indeed, once the time frame over which the microglial response contributes to the 
generation of the migratory signal(s), it may be possible to predict whether early vs. late 
proinflammatory cytokines contribute to migratory signal(s).   
In my second animal model, TNF-α was used as a tool to activate microglia and I 
have not tested whether TNF-α itself is a migratory factor that induced OECs to migrate.  
In addition, whether other proinflammatory cytokines (e.g., IL-6) will have the same 
effect on microglial activation should also be addressed in future studies. The next step 
then would be to determine whether OECs migrate in response to such microglial cell 
activation. It can be also hypothesized that anti-inflammatory cytokines will attenuate 
microglial activation and thus should not induce OEC migration.  Thus, an additional set 
of experiments should test the effect of anti-inflammatory cytokines on microglial 
reactivity and on OEC migration.  
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